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CHEMOPREVENTIVE AND CHEMOTHERAPEUTIC ACTIVITIES OF 
DRACAENA CINNABARI BALF.F AGAINST ORAL CANCER IN VIVO 
ABSTRACT 
Dracaena cinnabari (DC) is a perennial tree possesses various pharmacological 
properties but its anticancer properties have not been clarified. Aims: To evaluate the 
toxicity, anticancer activity (chemopreventive and chemotherapeutic) and metastasis 
obstruction of the DC resin methanol extract on 4-nitroquinoline-1-oxide (4NQO)-
induced oral cancer in rats. Materials and Methods: The powder of DC resin was 
extracted with methanol using the maceration extraction method. The toxicity profile of 
DC extract was investigated in Sprague Dawley (SD) rats using acute and sub-acute oral 
toxicity tests. In general, the chemopreventive study involves administration of 4NQO 
solution (cancer induction) to SD rats for 8 weeks alone or with DC extract at 100, 500 
and 1000 mg/kg that started one week before the exposure until one week after the 
cessation of the carcinogen exposure. In the chemotherapeutic study, SD rats were given 
4NQO (20 ppm) for 8 weeks followed by administration of DC extract at 100, 500 and 
1000 mg/kg for another 10 weeks with or without Cisplatin (3 mg/kg I.P for every 3 
weeks). All rats from both studies were sacrificed after 22 weeks, and histological 
analysis was performed to assess any incidence of pathological changes. 
Immunohistochemical expressions of selected tumour marker antibodies were analysed 
using an image analyser computer system, and the expression of selected genes involved 
in apoptosis and proliferative mechanism related to oral cancer were evaluated using RT2-
PCR. Result: Acute oral toxicity revealed that the DC extract could be well tolerated up 
to the dose of 2000 mg/kg and at the dose of 1500 mg/kg, the sub-acute test revealed no 
evidence of any treatment-related changes of the animals used in this study. In the 
chemopreventive study, the incidence of OSCC decreased with the administration of DC 
extract at 100, 500 and 1000 mg/kg compared to the induced cancer and vehicle groups. 
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In the chemotherapeutic study, there was no incidence of OSCC (0%) with the 
administration of DC 1000 mg/kg and Cisplatin. For both chemopreventive and 
chemotherapeutic studies, the survival rate increased to 100% for DC doses of 500 and 
1000 mg/kg. The developed tumour was also observed to be smaller, and lymph node 
metastasis was inhibited in all DC treated groups with or without Cisplatin when 
compared to the induced cancer and vehicle groups. The DC 1000 mg/kg group inhibit 
the expression of Cyclin D1, Ki-67, Bcl-2 and p53 genes responsible for decreasing the 
transformation and the aggressiveness of the cancer tissue while a slight increase in the 
expression of β-catenin and E-cadherin genes that decrease the proliferation of cancer 
cells while maintaining epithelial polarity was observed. It was also observed that DC 
1000 mg/kg induced apoptosis by upregulation of Bax and Casp3 genes and down-
regulation of Tp53, Bcl-2, Cox-2, Cyclin D1 and EGFR genes when compared to the 
induced cancer group. Conclusion: This study provides scientific validation for the safety 
of DC extract up to the highest dose level used in this study. Furthermore, the data 
indicated that systemic administration of the DC extract has anticarcinogenic potency on 
oral carcinogenesis.  
Keywords: Dracaena cinnabari, Oral toxicity tests, Chemoprevention, 
Chemotherapeutic, Oral squamous cell carcinoma. 
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CHEMOPREVENTIVE AND CHEMOTHERAPEUTIC ACTIVITIES OF 
DRACAENA CINNABARI BALF.F AGAINST ORAL CANCER IN VIVO 
ABSTRAK 
Dracaena cinnabari (DC) adalah pokok saka yang mempunyai pelbagai sifat 
farmakologi tetapi sifat antikansernya tidak dijelaskan. Tujuan: untuk menilai keracunan, 
aktiviti antikanser (kemopencegahan dan kemoterapeutik) dan halangan metastasis 
ekstrak metanol resin DC pada tikus yang diaruh kanser mulut oleh 4-nitroquinoline-1-
oksida (4NQO). Bahan dan Kaedah: Serbuk resin DC diekstrak dengan metanol dengan 
menggunakan kaedah pengekstrakan makerasi. Profil toksisiti ekstrak DC disiasat dalam 
tikus Sprague Dawley (SD) yang menggunakan ujian ketoksikan akut dan sub-akut. 
Secara umumnya, kajian kemopencegahan melibatkan penggunaan 4NQO (aruh kanser) 
kepada tikus SD selama 8 minggu sahaja atau dengan ekstrak DC pada 100, 500 dan 1000 
mg/kg yang bermula seminggu sebelum pendedahan sehingga satu minggu selepas 
pemberhentian pendedahan karsinogen. Dalam kajian kemoterapeutik, tikus SD diberikan 
4NQO (20 ppm) selama 8 minggu diikuti dengan pemberian ekstrak DC pada 100, 500 
dan 1000 mg/kg selama 10 minggu lagi dengan atau tanpa Cisplatin (3 mg / kg IP untuk 
setiap 3 minggu). Semua tikus dari kedua-dua kajian dikorbankan selepas 22 minggu, dan 
analisis histologi dilakukan untuk menilai sebarang kejadian perubahan patologi. 
Ekspresi imunohistokimia antibodi penanda tumor yang dipilih dianalisis menggunakan 
sistem komputer penganalisis imej, dan ungkapan gen terpilih yang terlibat dalam 
apoptosis dan mekanisme proliferatif yang berkaitan dengan kanser mulut dinilai 
menggunakan RT2-PCR. Keputusan: Ketoksikan oral akut mendedahkan bahawa ekstrak 
DC boleh diterima dengan baik sehingga dos 2000 mg/kg dan pada dos 1500 mg/kg, ujian 
sub-akut tidak menunjukkan bukti sebarang perubahan berkaitan dengan haiwan 
digunakan dalam kajian ini. Dalam kajian kemopencegahan, kejadian OSCC menurun 
dengan penggunaan ekstrak DC pada 100, 500 dan 1000 mg/kg berbanding dengan 
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kumpulan yang diaruh kanser dan vehicle. Dalam kajian kemoterapeutik, tidak terdapat 
kejadian OSCC (0%) dengan pentadbiran DC 1000 mg/kg dan Cisplatin. Untuk kedua-
dua kajian kemopencegahan dan kemoterapeutik, kadar survival meningkat kepada 100% 
untuk dos DC 500 dan 1000 mg/kg. Pertumbuhan tumor juga diperhatikan lebih kecil, 
dan metastasis nodus limfa dihalang dalam semua kumpulan rawatan DC dengan atau 
tanpa Cisplatin jika dibandingkan dengan kumpulan yang diaruh kanser dan kumpulan 
vehicle. Kumpulan DC 1000 mg/kg menghalang ekspresi Cyclin D1, Ki-67, Bcl-2 dan 
p53 gen yang bertanggungjawab untuk mengurangkan transformasi dan agresif tisu 
kanser sementara sedikit peningkatan dalam ungkapan β-catenin dan E- cadherin gen 
yang mengurangkan sel-sel kanser disamping mengekalkan polaritas epitel dapat 
diperhatikan. Ia juga diperhatikan bahawa DC 1000 mg/kg menyebabkan apoptosis 
dengan peningkatan gen Bax dan Casp3 dan penurunan gen Tp53, Bcl-2, Cox-2, Cyclin 
D1 dan EGFR berbanding dengan kumpulan yang diaruh kanser. Kesimpulan: Kajian ini 
menyediakan pengesahan saintifik untuk keselamatan ekstrak DC hingga tahap dos 
tertinggi yang digunakan dalam kajian ini. Selain itu, data menunjukkan bahawa 
penggunaan ekstrak DC mempunyai potensi antikarsinogenik pada karsinogenesis mulut. 
Kata kunci: Dracaena cinnabari, Ujian ketoksikan oral, Kemopencegahan, 
Kemoterapeutik, Karsinoma sel skuamosa mulut 
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1.1 Introduction 
Cancer is a group of diseases characterised by uncontrolled growth and spread of 
abnormal cells. Cancer may spread in an uncontrolled manner and can cause death. The 
cause of cancer can be attributed to both external factors (tobacco, chemicals, radiation, 
and infectious organisms) and internal factors (inherited mutations, hormones, immune 
conditions, and mutations that occur from metabolism). These factors may act together or 
in sequence to initiate or promote carcinogenesis (Srinivasan et al., 2008). 
Among the ten most common cancer sites, oral cancer has been ranked as the sixth 
most common cancer worldwide and third in the developing countries (Ogbureke & 
Bingham, 2012). Depending on the type of tissues that are affected, the development of 
cancer involves several phases; dysplasia, cancer in situ, localised invasive cancer, 
regional lymph node involvement, and distant metastases (WHO, 2002). The six hallmark 
features of cancer cells that provide a logical framework for understanding the cell 
biology and survival of cancer cells are: self-sufficiency in growth signals, insensitivity 
to growth-inhibitory (antigrowth) signals, evasion of programmed cell death (apoptosis), 
limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis 
(Hanahan & Weinberg, 2000). 
Oral squamous cell carcinoma (OSCC) has been considered as one of the most 
common malignancies of the oral cavity. The most important predisposing risk factors of 
OSCC include tobacco use and excessive alcohol consumption while other factors such 
as viral infections (e.g. human papillomavirus and herpes simplex viruses) and diet 
deficient in antioxidants have also implicated (Yedida et al., 2013). Although the 
development of OSCC progresses sequentially from hyperplasia through to dysplasia and 
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CHAPTER 1: INTRODUCTION 
carcinomas, in most cases, patients are often presented with the advanced stage of the 
disease at the time of diagnosis (Yedida et al., 2013). 
The ultimate goal of oral cancer treatment is to eradicate cancer, preserve or restore 
form and function, minimise the complication of treatment and finally to prevent any 
subsequent new primary types of cancer. To achieve these goals, the currently available 
treatment pattern includes surgery, radiotherapy, chemotherapy, combined treatments and 
primary and secondary prevention strategies including lifestyle changes as well as 
chemoprevention (Shah & Gil, 2009). Radical removal of a tumour and surrounding 
tissues results in significant tissue defect. Thus, tissue and organ preservation would be a 
major aim of alternative therapeutic strategies (Kreimann et al., 2001). Cancer treatment 
with radiation therapy can result in oral mucositis and xerostomia due to patients with 
squamous cell carcinoma of the head and neck receiving radiation at the oral and 
pharyngeal regions (Silverman, 2007).  
Recently, chemotherapeutic agents have been clinically used in combined treatments, 
and this has been reported to have a synergistic effect. Although the patient response in 
combined treatments is improved, it is often associated with toxicity, and there is very 
little change in the general survival rate of the patients (Ho & Slevin, 2008; Vermorken 
& Specenier, 2010). Depending on the location of the cancer tissue, the survival rate of 
the patient may vary. The survival rate for 50% of patient with cancers of the tongue is 
about five-years while the survival rate for 90% of patient with cancers of the lip is also 
about five years (Warnakulasuriya, 2009b). There are many complications associated 
with cancer treatments, and very often, patients have to overcome the devastating 
consequences of their treatment where the patient’s appearance and function, e.g. eating, 
drinking, swallowing and speaking may be affected. These residual defects can lead to 
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other issues like depression and nutritional deficiency, and therefore the quality of life in 
this patients is also affected (Warnakulasuriya, 2009b).  
Medicinal plants have played an important role in ancient medicine for preventive and 
curative treatments in many parts of the world population such as the Chinese, Ayurvedic, 
Unani and their secondaries in many Asian countries (Vasisht & Kumar, 2003). These 
medicinal plants have attracted much attention not only for their health benefits and 
disease treatment but also in drug discovery and development (Jiao et al., 2013).  
Dracaena cinnabari (DC) (Agavaceae) is a perennial tree that is native to Socotra 
Island located on the Southern coast of Yemen. The tree produces a deep red resin called 
the Dragon’s blood and is classified under the family of Dracaenaceae, a genus of 
Dracaena and species of cinnabari (Gupta et al., 2008). The dry powdered resin is often 
used in the Arabian Peninsula, as well as in other countries as a herbal remedy for many 
ailments including analgesic, astringent, antiseptic, haemostatic, antiulcer and as an 
abortifacient if taken during the first trimester of pregnancy (Al-Awthan et al., 2010). 
Although DC has been used as a herbal remedy for many ailments, the anticancer activity 
of the DC and its effect on oral cancer is not known. 
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1.2 Significance of the Study 
Cancer of the oral cavity is one of the most common neoplasms worldwide, and the 
increased incidence of oral cancer in many countries is associated with the prevalence of 
risk-associated behaviours (e.g. smoking and alcohol consumption). Oral Squamous cell 
carcinoma (OSCC) represent over 90% of oral cancer which arises in the mucosal lining 
of the oral cavity. Due to the increased incidence of oral cancer worldwide, new 
approaches such as the use of medicinal plants for the treatment of oral cancer have been 
emerging. This study was carried out to investigate the anticancer effect of DC and the 
role of DC as an anticancer drug for the treatment of oral cancer.  
 
1.3 Null Hypothesis  
DC resin methanol extract is not safe to be used on animals and does not have 
anticancer activities towards oral cancer. The extract cannot be developed as a 
chemopreventive or chemotherapeutic agent for oral cancer prevention and treatment.  
 
 
1.4 Purpose of the Study  
1.4.1 Aim of Study  
To evaluate the toxicity of DC resin methanol extract using an animal model, and to 
evaluate the anticancer activity (chemopreventive and chemotherapeutic) and metastasis 
obstruction of DC resin methanol extract on 4NQO-induced oral cancer in rats. 
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1.4.2 Objectives of Study 
1. To evaluate the acute and sub-acute oral toxicities of DC resin methanol extract 
in rats. 
2. To evaluate the chemopreventive and chemotherapeutic effects of DC resin 
methanol extract at different concentrations (100, 500 and 1000 mg) on oral 
carcinogenesis in vivo with respect to food consumption, water intake, body 
weight gain, haematological and biochemical parameters, tongue tumour size and 
histopathological changes in rat tongue epithelium.  
3. To study the effect of DC resin methanol extract on oral cancer regional lymph 
node metastasis.  
4. To investigate the expression of selected tumour markers; Cyclin D1, Ki-67, Bcl-
2, p53, β-catenin and E-cadherin on oral cancer in vivo using 
immunohistochemistry.  
5. To investigate the expression of selected apoptosis and proliferative genes related 
to oral cancer in vivo using RT2-PCR.  
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CHAPTER 2: LITERATURE REVIEW 
2.1 Overview of Cancer  
The aetiology of cancer is multifactorial involving both genetic and environmental 
factors. Cancer cells are associated with abnormal cellular proliferation and exhibit 
prevalent features that distinguish them from normal cells (Stathopoulou et al., 2012). The 
abnormal cellular proliferation interrupts with the normal processes of cell division which 
are controlled by the genetic material (DNA) of the cells (Reddy et al., 2003). Several 
factors that can act together or in sequence to initiate or promote carcinogenesis include 
external factors (chemicals, tobacco, radiation, and infectious organisms) and internal 
factors (hormones, inherited mutations, immune conditions and metabolic mutations) 
(Srinivasan et al., 2008). Cancer can also be associated with improper diet, genetic 
predisposition and environmental factors. Current evaluations from the American Cancer 
Society and the International Union Against Cancer indicate that 12 million cases of 
cancer were diagnosed in the year 2008 with 7 million deaths worldwide. It is predicted 
that these numbers will be doubled by 2030 (27 million cases with 17 million deaths) 
(Bhanot et al., 2011).  
2.2 Oral Cancer  
The oral cavity is lined by a mucous membrane consisting of stratified squamous 
epithelium and lamina propria which is made up of dense connective tissue. The 
squamous epithelium of the hard palate, gingiva and the dorsum of the tongue is entirely 
keratinized with a superficial horny layer, whereas the epithelium of the cheek, lip, 
vestibular fornix, alveolar mucosa, the floor of the mouth and soft palate is non-
keratinized (Syrjänen, 2003).  
Squamous cell carcinoma of the oral cavity is one of the most common human cancers 
in the world. Jafari et al. (2013), stated that the successful treatment of oral cancer could 
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be achieved up to 70% to 90% when the tumours are diagnosed in the early clinical stage. 
However, 60–70% of cancers of the oral cavity are diagnosed only after the tumours have 
become locally progressive (Tang et al., 2014). OSCC represent over 90% of this group 
of oral cancer which arise in the mucosal (epithelium) lining of the oral cavity, pharynx 
and larynx (Ragin & Taioli, 2007; Valente et al., 2016). The World Health Organization 
(WHO) stated that the oral cavity cancer has one of the highest mortality ratios of all 
malignancies because of extensive local invasion and distant metastasis even at the stage 
when initial diagnosis was being made (Koh et al., 2011).  The common site for intraoral 
carcinoma is mostly the tongue, which accounts for around 40% of all cases in the oral 
cavity proper. The tongue cancers frequently occur on the posterior-lateral border and 
ventral surfaces of the tongue. The second most common intraoral location of oral cancer 
is the floor of the mouth. Less common sites of oral cancer include the gingival, buccal 
mucosa, labial mucosa, and hard plate (Tanaka et al., 2011).  
Cancer of the oral cavity is one amongst the most well-known neoplasms worldwide 
with up to 263,900 new cases occurred in 2008 including lip cancer (Jemal et al., 2011). 
It is frightening to note that the estimated number of deaths from oral cancer was 145,000 
in 2012 and this is expected to increase in the next 15 years despite easy accessibility to 
this site of the body for diagnosis (Ferlay et al., 2015). The incidence of oral cancer varies 
worldwide with India and South and Southeast Asia showing the highest rates (Rodrigues 
et al., 2014). The incidence of oral cancer is increasing in many countries mainly because 
of the prevalence of risk-associated behaviours (e.g. varying patterns of use of tobacco 
and alcohol consumption). In many Asian countries including Malaysia, the consumption 
of betel quid chewing plays a vital role in the development of oral cancer (Saleh et al., 
2014). In Malaysia, the incidence of oral cancer has been shown to be the tenth most 
common cancer among both the male and female Indian ethnic group, with the highest 
incidence reported in Indian females (Omar & Ibrahim Tamin, 2011). Furthermore, in 
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Malaysia, oral cancer has been ranked as the second most common cause of cancer-
related deaths among males and this could be partially contributed to the late disease 
presentation as 70% of patients with oral cancer often presented with cancers of stage 
III/IV when initial diagnosis was being made (Saleh et al., 2016). 
2.3 Carcinogenesis 
Oral carcinogenesis is a multistep and complex process related to the serial incidence 
of modifications in genetic structures, promoting inhibitory or excitatory effects of the 
tumour oncogenes and gene suppressors, compromising the histophysiology of the cell 
division, differentiation and cell death (Shah & Kaur, 2014).  
Carcinogenesis involves initiation, promotion and tumour progression in which a 
genetic damage may occur at any point of the disease (Macluskey & Ogden, 2000; 
Oliveira et al., 2007) (Figure 2.1). The first cellular alterations occur at the molecular 
level, such as alterations in the genetic material which are not detectable by conventional 
histopathology (Martínez & Rivera, 2012). Initiation comprises mutational events in 
unknown genes that may be caused by chemical carcinogens, radiation or viruses and is 
thought to be irreversible (Macluskey & Ogden, 2000). During this stage, the initiated 
cells can stay in a latent phase for several weeks, months or years, or they can grow in an 
autonomous and clonal pattern. This initiation process ensures that cellular division 
remains symmetrical by creating two new initiated cells (Trosko, 2003). Cell proliferation 
is essential for this stage, if cellular division occurs before DNA repair systems take place 
then the injury becomes permanent and irreversible (Oliveira et al., 2007). 
 In the later stages of promotion further genetic alterations may occur leading to 
malignancy (Macluskey & Ogden, 2000). Over time, these molecular changes accumulate 
causing massive individual cell changes that may be detected histologically and when the 
number of altered cells increases to a substantial amount, it is possible to observe 
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macroscopic changes of the tissues in the affected areas (Martínez & Rivera, 2012). The 
expansion of a malignant clone ultimately leads to local invasion and possible distant 
metastasis (Macluskey & Ogden, 2000). During carcinogenesis, chromosomal damage 
can lead to the activation of cell-cycle checkpoint controls that regulate cell progression 
and proliferation. The progression towards malignancy can range from hyperplasia 
through dysplasia to carcinoma in situ and invasive carcinoma, which are determined by 
the accumulation of sequences in genetic events (Ye et al., 2008).  
Another explanation of carcinogenesis involves the process of initiation, promotion 
and progression that has been described by Surh (2003). Initiation is a rapid and 
irreversible process which involves a chain of extracellular and intracellular events. These 
include the initial uptake of or exposure to a carcinogenic agent, its distribution and 
transport to organs and tissues where metabolic activation and detoxification can occur, 
and the covalent interaction of reactive species with target cell DNA, leading to genotoxic 
damage. In contrast to initiation, tumour promotion is considered to be a relatively lengthy 
and reversible process in which actively proliferating preneoplastic cells accumulate. 
Progression, the final stage of neoplastic transformation, involves the growth of a tumour 
with invasive and metastatic potential. 
 
Figure 2. 1: The process of carcinogenesis involves initiation, promotion and tumour 
progression. Adopted from (Oliveira et al., 2007). 
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2.4 Clinical Characteristics and Histological Appearance of Oral Cancer  
OSCC may appear in any location in the oral cavity. However, there are certain areas 
in which it is more commonly found. The most common locations for oral cancer with 
poor prognosis are the tongue and the floor of the mouth (Brandizzi et al., 2008).  
The clinical presentation for oral cancer may vary as follows (Zain et al., 2002): 
1. White lesion: This lesion may develop as a white area but is indurated. The surface 
may be nodular or ulcerated. There may be fixation if the cancer tissue is located on 
a movable part of the mucosa. 
2. Red lesion: This lesion may develop as a red area with induration. The tissue is firm 
and thickened throughout the lesion or at the margins if ulcerated.  
3. Ulcerated lesion: This lesion is ulcerated with indurations at the ulcer margins. The 
ulcer may have a raised, rolled border and may develop as a white ulcerated mass. It 
should be distinguished from a large solitary major aphthous ulcer, traumatic ulcer or 
infectious ulcer.  
4. Exophytic mucosal swelling: The lesion may appear as a fungating exophytic mass 
which could easily bleed in the later stages. It may also appear as a painless lesion 
with a warty or white nodular surface as in verrucous carcinoma. 
OSSC clinically can be differentiated in the advanced stages because there is usually 
a clear suspicion of malignancy. In contrast, it is relatively possible in the early stages to 
make the wrong diagnosis. Due to the insufficient clinical characteristics, a biopsy and 
histopathological examination will be crucial for the diagnosis of OSCC (Bagan et al., 
2010). 
Although this disease can cause destruction to the oral tissues and spread to regional 
lymph nodes, the metastases at distant sites for oral cancer are relatively small compared 
with other malignancies such as cancers of the stomach, pancreas, lung, breast or kidney. 
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However, when distant metastasizes to other organs occur, the chance for a cure from oral 
cancer becomes very low and the survival rate decreases (Garavello et al., 2006). 
 
OSCC can be defined as a malignant epithelial neoplasm exhibiting squamous 
differentiation as characterised by the formation of keratin and the presence of 
intercellular bridges (Pindborg et al., 1997). Over 90% of OSCC is derived from the 
surface epithelium and extends from the basement membrane which would expand 
upward and laterally to replace the normal epithelium (Nagpal & Das, 2003). Based on 
the histologic resemblance of the cancer lesion to its original normal tissue, the WHO 
grading system (Barnes et al., 2005) classifies OSCC into well, moderately and poorly 
differentiated tumours as follows: 
I. Well-differentiated SCC: The tumour tissue (and individual tumour cells) is similar 
to the squamous epithelial cells of normal oral mucosa. The tumour contains foci of extra- 
or intracellular keratinization. The cells have few mitotic figures and rarely show nuclear 
pleomorphism or variation in cell size and shape. Atypical mitoses are rare or absent. 
II. Moderately-differentiated SCC: Tumour cells are less keratinized, and mitotic 
figures are present. Nuclear pleomorphism or variation of cell size and shape can be 
present. A few atypical mitotic figures may be seen. 
III. Poorly-differentiated SCC: Tumour cells are rarely keratinized, and mitotic figures 
are more frequent. Nuclear pleomorphism and variation in cell size and shape are 
commonly seen. Atypical mitoses are common. 
The presence of dysplasia in the epithelial tissue is believed to be associated with a 
possible progression to cancer. The term dysplasia is applied when a disturbance in its 
architecture is accompanied by cytological atypia (variations in the size and shape of the 
keratinocytes) (Warnakulasuriya et al., 2008). 
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There is evidence that the severity of the dysplasia is related to the progression of 
malignancy. Infrequently, non-dysplastic lesions may also show malignant development 
(Warnakulasuriya et al., 2008). The presence of dysplasia is more important in predicting 
malignant development than its clinical presentation such as leukoplakia, erythroplakia 
or leuko-erythroplakia (Reibel, 2003). Based on the abnormality of cell proliferation and 
disorderly maturation as seen in epithelial tissue, WHO classifies epithelial dysplasia as 
mild, moderate and severe where dysplastic changes are associated with the basal third of 
the epithelium or affecting up to two-thirds of the epithelium or more than two-thirds of 
the epithelium respectively (Barnes et al., 2005). 
2.5 Risk Factors for Oral Cancer 
The main factors attributed to the development of oral cancer are tobacco, 
consumption of alcohol or betel quid usage and that these factors may act separately or 
synergistically (Warnakulasuriya, 2009b). Both tobacco and alcohol have been shown to 
increase the risk of oral cancer by more than 80%. Heavy drinkers and smokers are 38 
times more prone than the abstainers of alcohol and tobacco smoking (Blot et al., 
1988). There are different forms of tobacco smoking such as oral and nasal smokeless 
tobacco and evidence for smokeless tobacco causing oral and pharyngeal cancer have 
been confirmed (Boffetta et al., 2008). Other factors such as HPV infection may also be 
involved in the cancer of the oral cavity and oropharynx (Herrero et al., 2003).  
2.5.1 Alcohol and Tobacco 
The consumption of alcohol and tobacco smoking are lifestyle risk factors which play 
a major role in oral cancer development and are considered as important etiological 
factors. Since the 70’s, there are consistent observational studies which have reported that 
these lifestyle risk factors are significantly associated with oral cancer (IARC, 2004b, 
2010). Factors such as alcohol consumption and tobacco smoking may act separately or 
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synergistically and are associated with an increased risk of various types of cancer, 
including those of the upper aerodigestive tract and liver. Both alcohol and tobacco use 
can increase the danger of cancer of the oral cavity and throat (pharynx), and their 
combined use has an increasing effect on the risk of oral cancer development. Compared 
to other regions, areas of the oral cavity and throat that are directly exposed to alcohol or 
tobacco are more prone towards cancer development (Pelucchi et al., 2008). In studies 
where smoking is controlled, moderate-to-heavy drinkers have been shown to have three 
to nine times greater risk of developing oral cancer (Lewin et al., 1998).  
The risk of developing oral and oropharyngeal cancer has been shown to increase up 
to 30 times among heavy drinkers (more than 100 gm of alcohol per day) (Blot et al., 
1988). As mentioned elsewhere,  the effect of alcohol abuse on other types of carcinogens, 
particularly tobacco, has been shown as in heavy smokers who are also heavy drinkers, 
the risk of oral cancer increases up to 100 times (Andre et al., 1995; Blot et al., 1988). 
Alcohol can directly act on cell membranes and alters the mucosal permeability resulting 
in increasing penetration of carcinogens across the oral mucosa (Wright & Morgan, 
2013). Moreover, during alcohol metabolism, acetaldehyde which is a cytotoxic 
compound is produced which results in the production of free radicals and hydroxylation 
of DNA bases which further causes cellular DNA damage (Scully et al., 2000). As stated 
by Ministry of Health Malaysia in 2006, the prevalence of alcohol users in the Malaysian 
population was around 12.2% where 1.5 million drinkers were between 25-64 years old, 
and when compared to women, men were found to be the most frequent alcohol drinkers 
in Malaysia (Tan et al., 2009).  
The risk of the developing oral cancer has shown to be five to nine times greater in 
smokers compared to non-smokers. This risk may increase to as much as 17 times higher 
for heavy smokers who smoke 80 or more cigarettes per day (Andre et al., 1995; Blot et 
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al., 1988). Tobacco products contain a diverse array of chemicals, including nicotine and 
carcinogens. The effect of tobacco on human health varies depending on the types of 
tobacco products used and the duration of exposure (Xue et al., 2014). Nicotine is the 
principal component of all kinds of tobacco products and smoke. Nicotine is addictive 
and noncarcinogenic (Hukkanen et al., 2005). Most type of carcinogens, when exposed 
to organisms, are enzymatically transformed to other forms of metabolites that are more 
readily excreted by the organisms. The initial steps in this process involve cytochrome 
P450, and if the oxygenated intermediates are formed in these initial reactions, they may 
react with DNA or other macromolecules to form covalent binding products known as 
adducts (IARC, 2004b).  
2.5.2 Betel Quid Use 
In 1996, a consensus from a workshop  held in Kuala Lumpur, Malaysia recommended 
that the term “quid” should be defined as “a substance or mixture of substances, placed 
in the mouth, usually containing one or both of the two basic ingredients, tobacco or areca 
nut, in a raw or manufactured or processed form” which remains in contact with the oral 
mucosa over an extended period (Zain et al., 1999). The composition of the quid can vary 
and in many countries, ready-made, mass-produced packets are available as proprietary 
mixtures known as pan masala or gutka (IARC, 2004a). In Malaysia, the major 
constituents of the quid are areca nut (taken either fresh or dried), betel leaf and slaked 
lime where they are occasionally folded in betel leaves like little parcels and chewed. 
However, the quid from different ethnic groups may also vary, and additional ingredients 
such as tobacco and spices may be added and this may be consumed using different 
chewing methods (Zain et al., 1999).  
Tobacco, when added to the component of the quid, is associated with a significant 
risk of oral cancer. Another component of the quid, the lime, has been shown to release 
14
reactive oxygen species from extracts of areca nut, which might contribute to the 
cytogenetic damage involved in oral cancer (Nair et al., 1992). Sharan et al. (2012) 
performed a systematic review and concluded that betel quid seems to be significantly 
associated with susceptibility to oral and oropharyngeal cancers. Despite the strong 
association between betel quid and human susceptibility to oral cancer, the habit of 
consuming betel quid is still taking place in many parts of the world. 
2.5.3 Human Papillomavirus Infection 
Human papillomavirus (HPV) infection is the most common sexually transmitted viral 
infection worldwide (IARC, 2007). The oral mucosa is lined by a mucous membrane, and 
its histology is similar to that of the uterine cervix or the lower genital tract. The histology 
of the oral mucosa consists of stratified squamous epithelium and lamina propria made 
up of dense connective tissue. Based on these similarities, one can anticipate that both the 
mucosal and cutaneous types of human papillomavirus (HPV) can also be present in the 
different types of squamous cell lesions of the oral mucosa (Syrjänen, 2003).  
According to their clinical behaviour, HPVs are divided into two main groups. Low-
risk HPVs cause wart-like lesions of the skin, anogenital region and the oral mucosa while 
high-risk HPVs are aetiologically associated with cervical and anogenital cancers (IARC, 
2007; Syrjänen et al., 2011). HPVs are epitheliotropic DNA viruses that can induce 
hyperplastic, papillomatous and verrucous squamous cell lesions in the stratified 
squamous epithelia of skin and mucosa (Varnai et al., 2009).  
The most frequently detected oncogenic HPV in OSCC is HPV16 and is present in up 
to 22% of cases, either alone or in combination with other HPV types e.g. HPV18 which 
may be present in up to 14% of cases (Sugerman & Shillitoe, 1997). Recently, HPV 
infection especially HPV16 has been identified as an etiologic agent for a subset of 
OSCC, particularly those that arise from the base of the tongue and tonsil (Gillison et al., 
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2000).  Patients with HPV DNA-positive OSCC have been shown to be younger and are 
less likely to have a history of tobacco or alcohol abuse compared to patients with HPV 
DNA-negative OSCC (Gillison, 2007). Interestingly, it has been shown that patients with 
HPV-positive SCC have a better outcome and were estimated to have up to 80% reduction 
in risk of disease failure compared to HPV-negative patients (Boscolo-Rizzo et al., 2013; 
Goldenberg et al., 2008).  
2.5.4 Poor Diet and Nutritional Deficiencies 
Poor diet, or a diet lacking in fresh fruit and vegetables, has appeared to be a significant 
risk factor for head and neck cancer, independent of tobacco, alcohol, betel nut 
consumption and HPV infection (Bradshaw et al., 2012; Veer & kampmann, 2007). A 
diet high in consumption of fruits and vegetables seems to reduce the risk of oral cancer 
in epidemiologic studies where tobacco and alcohol use are controlled (Pavia et al., 2006; 
Winn et al., 1984). More investigation about this phenomenon has shown that β-carotene 
and vitamin A supplement has significantly lead to regression of some of the oral 
potentially malignant disorders (Stich, Hornby, et al., 1988; Stich, Rosin, et al., 1988).  
An animal study has shown that the occurrence of tumour in iron-deficient animals 
was significantly earlier (mean 183 days) when compared to the controls of non-iron-
deficient animals (mean 229 days) (Prime et al., 1983). The hypothesis for this is that iron 
deficiency may increase one's susceptibility towards oral cancer as the epithelium 
becomes thinner, atrophic and more permeable epithelium towards chemical carcinogens 
(Rennie & MacDonald, 1982; Rennie et al., 1984).  
It has also been reported that drinks and foods should not be consumed when they are 
scalding hot as this may increase the risk for cancers of the oral cavity, pharynx and 
oesophagus (Key et al., 2004). The consumption of meat, especially red and processed 
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meats, may also increase the risk of several types of cancer and that vegetarian diets are 
reported to be a useful strategy in reducing the risk of cancer (Lanou & Svenson, 2011). 
2.5.5 Oral Hygiene and Chronic Inflammation  
Poor oral hygiene and the status of an individual dentition (e.g. faulty restorations, 
sharp teeth, and ill-fitting dentures) have also been associated with oral cancer in a few 
epidemiological type of studies, but it is not clear whether confounding factors such as 
tobacco smoking and alcohol consumption were taken into consideration (Marshall et al., 
1992; Warnakulasuriya, 2009a).  
Periodontal disease has been shown to increase the risk of oral cancer. Periodontitis, 
characterised by epithelial proliferation and migration often results in the chronic release 
of inflammatory cytokines, chemokines, growth factors, prostaglandins and enzymes, all 
of which are associated with cancer development (Rajesh et al., 2013). This may explain 
why poor oral hygiene is linked to oral cancer. Some microorganisms facilitate the 
metabolism of ethanol to acetaldehyde in the oral cavity. Acetaldehyde, a known 
carcinogen, has been considered as a major factor in oral carcinogenesis (Kocaelli et al., 
2014). The production of acetaldehyde by the microbes of the oral cavity, including 
Candida albicans, has been reported (Bakri et al., 2015). Candida albicans have the 
ability to invade the oral epithelium and cause the tissue to undergo dysplastic change 
(Bakri et al., 2014).  
Evidence suggests that other factors such as inflammatory response and secretion of 
nitrosamines as generated by the fungus may also activate proto-oncogenes which are 
related to the development of oral cancer (Scully, 2011). A case-control study from Japan 
reported that frequent tooth brushing could reduce the risk of cancer of the upper 
aerodigestive tract, especially in the high-risk group of heavy tobacco and alcohol 
consumers (Sato et al., 2011). 
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2.5.6 Others 
The predisposition to head and neck SCC in an individual with a family history of 
cancer is thought to be based on or at least in part, on the genetic variability in the 
metabolic activation and detoxification of the environmental procarcinogens, although it 
is noted that there is variability in individual susceptibility to chemically induced 
carcinomas (Bongers et al., 1996). The relative risk of oral cancer was between 1.2% and 
3.8% for those who had a family history (first-degree relative) of head and neck cancer 
when compared with those with no such family history (Radoi & Luce, 2013).  
Other factors such as immunosuppression has been reported to increase the incidence 
of lip cancer following kidney transplantation and is significantly related to use of 
immunosuppressive drugs such as azathioprine and cyclosporine (van Leeuwen et al., 
2009). Other controversial risk factors with limited evidence include HIV infection, 
immunosuppression resulting from HIV infection, cannabis smoking, indoor air pollution 
and alcohol containing mouthwash (Warnakulasuriya, 2009a). The evidence that the use 
of mouthwashes increases the risk of oral cavity cancer remains controversial (Radoi & 
Luce, 2013). An in vitro study performed by McCullough and Farah (2008), reported that 
alcohol-containing mouth-washes have been shown to penetrate the oral microbial 
biofilms efficiently and thus reducing the oral bacterial load. However, as alcohol can be 
converted to acetaldehyde, a pro-carcinogen, by the oral microorganisms, it would be 
wise to restrict the use of an alcoholic mouthwash to short-term therapeutic situations like 
the use of alcohol-free mouth-washes may also be equally effective (McCullough & 
Farah, 2008). Similarly, it has been found that the use of alcohol-free chlorhexidine 
solution has been associated with a lower incidence of adverse events (e.g. staining of 
teeth and tongue, taste disturbances and reversible swelling of the lips) and that this 
mouthwash was better accepted by trial participants than the alcohol-containing 
chlorhexidine mouthwash (Santos et al., 2017).  
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2.6 General Treatment of OSCC 
The goal of oral cancer treatment is to eradicate cancer, preserve or restore form and 
function, minimise the complications of treatment and finally prevent any subsequent new 
primary cancers. To achieve these goals, the currently available treatment modalities 
include surgery, radiotherapy, chemotherapy, combined modality treatments and primary 
and secondary prevention strategies including lifestyle changes as well as 
chemoprevention (Shah & Gil, 2009). The selection of treatment modalities depends on 
a wide range of factors including the site and stage of the lesion, preservation of the 
underlying anatomical structures and their function, patient and institutional preference, 
patient age, general health condition and risk of tumour recurrence (second primary 
tumour) (Fung & Grandis, 2010). 
2.6.1 Surgery and /or Radiation Therapy 
Surgery has been considered as one of the most well established primary treatment for 
oral cancers (Shah & Gil, 2009). Generally, in the early-stages of head and neck SCC 
(stage I and II), the treatment could consist of a single modality treatment of either surgery 
or radiation or a combination of both types of treatments. The success rate for both types 
of treatment has been reported to be 90% for stage I and 70% for stage II patients (Fung 
& Grandis, 2010). Radiation therapy is usually given as an adjunct treatment following 
surgery to prevent lymph node involvement (Cooper et al., 2004). In the advanced stages 
of SCC, the treatment and management are more complicated, and patients could be 
treated with a combination of chemotherapy, radiation, or surgery (Haddad & Shin, 
2008). 
2.6.2 Chemotherapy  
Cancer continues to be one of the main causes of death in humans, and thus continuous 
efforts are being undertaken to develop cancer treatments (Leaf, 2004). Chemotherapeutic 
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agents can be used either as a single modality intervention or in combination with surgery 
or radiation in patients with recurrent and/or metastatic tumour (Vermorken & Specenier, 
2010). Unfortunately, the commonly used cancer treatment of chemotherapy is 
detrimental to the patient’s health, and moreover, the patients become more susceptible 
to other diseases, and this may often cause the death of the patient as the immune system 
of the patient’s body is weakened (Carelle et al., 2002). In addition, the drug-resistant 
cancer cells that survived the chemotherapy treatment are responsible for the recurrence 
of tumours and is often associated with poor prognosis for the recovery of the cancer 
patients. The occurrence of drug resistance which may occur during treatment may also 
lead to the failure of tumour treatment (Gottesman, 2002). Among the challenges 
associated with chemotherapy treatment are the occurrence of toxicity on the remaining 
healthy cells and development of multi-drug resistance against the chemotherapeutic 
agents. The lack of tumour cell specificity towards chemotherapeutic agents has often 
restricted the strategy of delivering the systemic chemotherapeutic agents at a high dose 
which in turn, can prevent the life-threatening side effects of the chemotherapy agent 
(Carelle et al., 2002).  
The most common component of chemotherapy for the treatment of solid organ 
cancers is Cisplatin that was first described by Michele Peyrone as early as in 1845 (Kim 
et al., 2015). Cisplatin and other platinum drugs are the common drugs in contemporary 
medical oncology and are considered to have a major impact in the management of ovary, 
testes, head and neck and other types of cancers (Kelland, 2007). However, the dose 
toxicities associated with platinum therapy has presented a serious concern as it has been 
shown that Cisplatin can affect certain organs such as the kidneys and also the nervous 
system (Hartmann et al., 1999; Hartmann & Lipp, 2003). Several forms of the 
chemotherapy treatment are targeted at the process of cell division as the proliferation 
rate for cancer cells are more likely to be higher than normal cells. Unfortunately, their 
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mode of action is not specific and are associated with significant toxicity side effects 
(Payne & Miles, 2008). As a result, the search for less toxic platinum compounds and 
treatment regimens or delivery methods that can help improve the anticancer efficacy 
effects of the compounds with minimum side effects still continues to this day (Amin & 
Buratovich, 2009; Cossa et al., 2009). However, chemoradiotherapy treatment which 
involves administration of chemotherapeutic agent with radiation therapy has been used 
in an effort to treat tumours without previous surgical intervention (Haddad & Shin, 
2008).  
2.6.2.1 Mechanisms of Anticancer Drugs 
Currently, chemotherapeutic agents used for cancer treatment consist of around 60% 
small molecule compounds or natural products (Cragg et al., 1997). Small molecule 
compounds play a major role in anti-cancer medicine and are major players in anti-cancer 
drug discovery. The small molecule compounds are involved in several processes such as 
apoptosis, angiogenesis, cell cycle, macromolecule synthesis, mitochondrial respiration, 
mitosis, multidrug efflux and signal transduction (Nagle et al., 2004).  
Most cancer therapeutic approaches, such as radiation and chemotherapy, inhibit 
cancer by activating cancer cell apoptosis (Marsoni & Damia, 2004). The apoptotic 
mechanism by using apoptotic inducers or modulators can be targeted for therapeutic 
benefits through the targeting of protein kinases, phosphatases, and transcription factors 
(Luo et al., 2008). The effective anticancer drug should be able to eliminate cancer cells 
without producing excessive damages to normal cells. However, this ideal situation can 
be reached successfully by inducing apoptosis in cancer cells (Taraphdar et al., 2001).  
The cytotoxic process following exposure to chemotherapeutic agents can be described 
as follow; the chemotherapeutic agents disrupt cellular homeostasis which results in 
dysfunction of the target structures such as DNA, RNA or microtubules. Following the 
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disruption of the target structures, p53, bcl-2 and presumably other types of proteins 
activate the family of cysteine proteases known as caspases. Depending on the severity 
of the injury, the cells will then decide to undergo repair or proceed for apoptotic cell 
death, in which case activation of the caspases are initiated causing cell death (Bold et al., 
1997).  
2.7 Medicinal Plant as Anticancer Drugs 
Although the present chemotherapeutic drugs improved the overall survival rate of 
patients, the outcome of treatment remains poor due to the development of drug resistance 
(Lee et al., 2013) and the presence of severe side effects of chemotherapy and radiation 
therapy (Madhuri & Pandey, 2009). Thus, alternative treatments which are ‘back-to-
nature’ might yield improved treatment possibilities with fewer or no undesirable effects 
(Lee et al., 2013).  
Medicinal plant formed the source of traditional medicine systems that have been used 
for centuries in many countries such as China, Egypt and India (Balandrin et al., 1993). 
However, preventive measures such as abstinence from the use of tobacco products, 
dietary changes, treatment of inflammatory diseases and consumption of nutritional 
supplements that support the immune functions are also being practised. Based on new 
discoveries in cell biology, researchers around the world are still continuing to further 
develop the use of the chemotherapy method for the treatment of cancer with minimum 
toxic side effects (Madhuri & Pandey, 2009).  
On another hand, the term natural products refer to small molecules that are produced 
from biological sources (Krause & Tobin, 2013). Natural products have attracted wide 
attention not only in health promotion and disease treatment but also in drug discovery 
and development. The natural product discovery and development plays a major role in 
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the development of therapeutic agents for many types of diseases as well as for cancer 
treatment (Jiao et al., 2013). 
WHO (2000) has characterised herbs to comprise of crude (rough and ready) plant 
materials such as leaves, flowers, fruits, seeds, stems, wood, barks, root, rhizomes or other 
plant parts which may be in its entire form, fragmented or powdered. Herbal products 
may also consist of herbal preparations made from one or more herbs and may contain 
excipients in addition to the active components (WHO, 2000). Herbal medicine or 
medicinal plants have been defined as the use of crude drugs of plant source to treat 
illnesses or to compliment and support the health system (Archer & Boyle, 2008). In the 
developing countries of Asia, medicinal plants play a major role in preventive and 
curative treatments (Vasisht & Kumar, 2003). The WHO has estimated that 80% of the 
population of the world depend on traditional medicines to help meet their essential health 
care needs (Gopal et al., 2014) and that 60% of the current drugs employed in the 
treatment of cancer are derived from sources found in nature (Gordaliza, 2007). In fact, 
more than 60% of cancer patients use vitamins or herbs in the management and treatment 
of cancer (Madhuri & Pandey, 2008).  
The search for anticancer agents from plant-derived compounds started around the 
1950s with the discovery and development of the vinca alkaloids, vinblastine and 
vincristine and the isolation of the cytotoxic podophyllotoxins. Between the 1960 and 
1982, the National Cancer Institute screened around 114,000 extracts from an estimated 
35,000 plant samples for anticancer activity (Cragg & Newman, 2005). The use of plant 
extracts has provided an option for the search for drugs with cytotoxic activity in 
inhibiting tumour growth (Júnior et al., 2010; Lee et al., 2010).  
There are several steps involved in the discovery and evaluation of plant-derived 
anticancer agents; the initial step is the authentication and extraction of the plant material, 
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followed by the separation and isolation of the components of interest, characterization 
of the isolated compounds and quantitative evaluation (Evans, 2002). 
An example of a plant-derived agent that has been successfully used as an anticancer 
drug is paclitaxel (Taxol®) which was prepared from the bark of the Pacific Yew, Taxus 
brevifolia Nutt. (Taxaceae) (Cragg & Newman, 2005). Other examples are topotecan and 
irinotecan which are semi-synthetic derivatives of camptothecin and are used to treat 
cancer of ovarian and colorectal cancers, respectively (Creemers et al., 1996; Fuchs et al., 
2006).   
2.7.1 Dragon’s Blood  
Dragon’s blood is a term that refers to reddish resinous products, and this deep red 
resin has been used as a traditional medicine since ancient times by many cultures. 
Dragon's blood can be found in several forms; granules, powder, lumps or sticks. The 
term “Dragon’s blood” is used for all kinds of resins and saps isolated from four distinct 
plant genera endemic to various regions worldwide; Croton (Euphorbiaceae) from the 
tropics and subtropics countries around the world, Dracaena (Dracaenaceae) Socotra of 
Canary Islands, Madeira and East Africa, Daemonorops (Palmaceae) from South East 
Asia, and Pterocarpus (Fabaceae) of West Indies and South America. The origin of the 
Dragon’s blood is believed to be from Socotra Island which is located on the southern 
coast of Yemen (Alexander & Miller, 1996; Edwards et al., 1997; Gupta et al., 2008).  
Many years ago, Dragon’s blood was used by the Greeks, Romans and Arabs due to 
its medicinal properties. The Dragon’s blood (Dracaena) was used by residents of 
Moomy city on Socotra island and is known as a “cure-all” as it is used for wound healing, 
diarrhea, fevers, dysentery diseases, internal ulcers of the mouth, throat, intestines, 
stomach, as a coagulant, as an antiviral for respiratory and stomach viruses and skin 
disorders such as eczema. In general, it used for curing dysentery, diarrhoea, haemorrhage 
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and external ulcers in Yemeni folk medicine (Milburn, 1984). In addition, a resin of 
Dragon’s Blood in Unani medicine is commonly known as Dammul-akhwain. It has also 
been widely used as an anti-inflammatory, antioxidant and antitumor agent (Milburn, 
1984).  
A resin of Dragon’s blood obtained from Croton urucurana has been evaluated and 
reported to exhibit antibacterial activity against Staphylococcus aureus and Salmonella 
typhimurium (Peres et al., 1997). Other studies reviewed by Jones (2003) and Gonzales 
and Valerio (2006) presented that dragon’s blood resin (Croton spp.) possesses an anti-
diarrheic, anticancer, anti-inflammatory and antirheumatic activity. In addition, dragon's 
blood resin obtained from Daemonorops spp. is a popular traditional Chinese medicine 
used to stimulate circulation, promote tissue regeneration and was also use for healing of 
fractures, sprains, ulcers and for the control of bleeding and pain sensation (Bensky et al., 
1993).  
2.7.2 Dracaena cinnabari Balf.f 
Dracaena cinnabari (DC) (Dragon’s Blood Tree) is an endemic species and the most 
famous plant of the Socotra Island, Republic of Yemen and it is classified under the family 
of Dracaenaceae, genus of Dracaena and species of cinnabari (Gupta et al., 2008; 
Hubálková et al., 2015). It is a large, single-trunked tree with a height of up to 10 m with 
smooth grey barks. Its branches, which are sausage-shaped, form an umbrella-shaped 
crown (Hubálková et al., 2015) (Figure 2.2). The genus Dracaena includes 60 to 100 
species and has been taxonomically classified as three families, i.e. Agavaceae, Liliaceae 
and Dracaenaceae, the latter is a family formerly encompassing the other two (Adolt & 
Pavlis, 2004). Initially, DC was first described by Lieutenant Wellsted of the East India 
Company in 1835 during a survey of Socotra Island and was named Pterocarpus draco. 
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However, in 1880 the Scottish botanist Isaac Bayley Balfour made a 
formal description of the species and renamed it as Dracaena cinnabari (Balfour, 1888).  
  
 
 
 
 
 
 
 
 
Figure 2. 2: Dracaena cinnabari (Yehia et al., 2013) 
 
Locals in Socotra used the resin from DC for many purposes; pottery and house 
decorations, textile dye (wool), glue pottery, breath freshener and even used as a lipstick 
(Alexander & Miller, 1996). In addition, DC resin has been used as a famous traditional 
medicine since ancient times in many cultures. It is used as an astringent for treating 
diarrhoea and dysentery as well as an antiseptic, haemostatic and as an antiulcer remedy 
(Gupta et al., 2008; Gupta et al., 2009; Mothana et al., 2007; Yehia et al., 2013).  
Several active compounds have been subsequently isolated and identified from the DC 
resin. These compounds mainly consist of homoisoflavans, along with flavans, 
flavanones, flavones, chalcones, dihydrochalcones, di- and triflavonoids (Himmelreich et 
al., 1995; Machala et al., 2001; Suchý et al., 1991). The dominant compound in the 
extracts of fresh material of DC resin was 7-hydroxy-3-(4- hydroxybenzyl)-8-methoxy-
chroman (Baumer & Dietemann, 2010). In addition, (2S)-7-hydroxyflavan-4-one, 4,4’- 
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Dihydroxy-2’-methoxychalcone, Cinnabarone 7,4’-Dihydroxyflavone, Damalachawin 
and Dracophane have been identified in previous studies  (Himmelreich et al., 1995; 
Masaoud, Ripperger, Himmelreich, et al., 1995; Masaoud, Ripperger, Porzel, et al., 1995; 
Veselá et al., 2002). 
The DC extract has also been shown to possess numerous therapeutic activities: the 
analgesic and anti-inflammatory effects of the ethanolic extract of DC balf resin have 
been investigated and shown to have a significant peripheral analgesic effect when tested 
using the acetic acid-induced writhing response test. It was then suggested that the release 
of endogenous mediators of pain (such as prostaglandin, kinin, histamine) stimulate the 
nociceptive neurones, which are sensitive to non-steroidal anti-inflammatory drugs and 
opioїds (Alwashli et al., 2012).  
The presence of flavonoids in the methanolic extract of DC may contribute to anti-
inflammatory activities as flavonoids are recognised to target prostaglandins which are 
involved in the late phase of acute inflammation (Gupta et al., 2014). The DC resin has 
also been shown to exert a relaxant effect on rat isolated ileum, uterus and urinary bladder 
and this effect may again be attributed to the presence of flavonoids in the DC resin (Al-
Awthan et al., 2010). Another possible attribute of flavonoids in DC is that DC also 
increases heart contractility (Al-Awthan et al., 2010). Furthermore, in anaesthetized rats, 
the aqueous extract of DC has been reported to reduce both the systolic and diastolic 
blood pressure, and this could have been due to vasodilatation of the blood vessels of the 
smooth muscles which were relaxed. Due to the hypotensive effect related to the 
vasodilation or increased glomerular filtration rate, this can also result in increased 
urinary excretion in conscious rats (Al-Awthan et al., 2010).  
A study performed by Mothana and Lindequist (2005) reported an antimicrobial 
activity of DC resin (chloroform and methanol extract) against Staphylococcus 
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aureus, Bacillus subtilis, Micrococcus flavus and Escherichia coli. The methanol extract 
of DC has also been reported to exert an antiviral activity against herpes simplex and 
human influenza viruses (Mothana et al., 2006). Recently, Ansari et al. (2016) also 
reported antimicrobial activity of the ethanolic extract of DC against Gram-positive, 
Gram-negative pathogens and fungi and concluded that DC could play a major role in 
controlling microbial infections in human. Due to the antimicrobial and antioxidants 
properties of DC resin (Gupta & Gupta, 2011; Yehia et al., 2013), DC resin could be 
considered as a potential food preservative agent due to its inhibitory effect on various 
foodborne pathogens (Gupta & Gupta, 2011). Due to its high cytotoxicity, the methanolic 
extract of DC also exhibited a non-specific inhibition of the parasites (Mothana et al., 
2012) while the anti-diabetic activity of the ethyl acetate extract of DC tested using 
glucose uptake inducing activity (98.86%) indicate that this extract has the potential to be 
utilized as an antidiabetic drug (Mohammed & Khanum, 2016). 
DC has also been investigated for its antitumor and cytotoxicity effect and was found 
to be very effective. In 1995 Vachálková and his colleges studied the carcinogenicity of 
three homo-isoflavonoids and four flavonoids isolated from the resin of DC (Vachálková 
et al., 1995). The cytotoxic activity of DC resin collected from Yemen was investigated 
against human ECV-304 cells and displayed marked toxicity (IC50 of 8.9 µg/ml) (Al-
Fatimi et al., 2005). 
A study on the effect of DC on five human cancer cell lines: two lung cancers (A-427 
and LCLC-103H), two urinary bladder carcinomas (5637 and RT-112) and one breast 
cancer (MCF-7) have been conducted. It was reported that the methanol extract of DC 
demonstrated the highest toxicity on all tumour cell lines with IC50 values ranging 
between 0.29 and 5.54 µg/ml (Mothana et al., 2007). Recently, the methanol extract of 
the DC crude extract was studied by Alabsi et al. (2016) where the cytotoxic effects of 
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DC when observed in a panel of OSCC cell lines were most pronounced in H400 cells, 
grown in a time-dependent manner with an IC50 value of 5.9 μg/ml. It was reported that 
the mode of cell death was achieved through the process of apoptosis (Alabsi et al., 2016). 
2.7.3 Extraction of Plants 
Plants have often been considered as the source for different drugs groups such as anti-
cancer, antimicrobial, antispasmodics, etc. All over the world, the tribal people have 
always depended on many types of plants for curing several types of diseases. Based on 
traditional claims many researchers have continued to evaluate the relationship between 
different types of plants and their ability in treating diseases (Srivastav & Das, 2014; 
Tiwari et al., 2011). 
Extraction is a term used to describe the process of separating active components of 
the plant from the inert plant's constituents by using specific solvents through standard 
procedures. Following extraction, the extracted products may be kept in several forms; 
liquid state, semi-solid state, dry powder or in relatively complex mixtures of metabolites 
and can be intended for external or oral use (Tiwari et al., 2011). 
Following treatment of the plants with a selective solvent (menstruum), extraction of 
the plant extracts can be performed using basic techniques such as maceration, infusion 
and percolation. There are a few factors to be considered when the extraction process is 
completed; the transport rate of solvent into the plant mass, the solubility rate of the 
soluble plant components by the solvent and the transport rate of solution out of the 
insoluble plant mass (Singh, 2008). As stated by Tiwari et al. (2011), the quality and 
quantity of an extract depend on many basic parameters: parts of the plant used for 
extraction, properties of the solvent selected for the extraction process such as its 
concentration, especially when extracting the therapeutic components (obtaining) from 
the inert unwanted plant's components (eliminating) following treatment with a selective 
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solvent (menstruum). Several factors may affect the extraction process such as the 
polarity of the extract as this may affect the quantity as well as the presence of a secondary 
metabolite of an extract. Finally, the extraction methods can also play a significant role 
as the type of extraction process, the extent of extraction period and temperature at which 
the process of extraction was carried out can affect the quantity and quality of the obtained 
extract. 
In general, the plant's materials should be grounded into finer portions as this will 
increase the surface area of the plant's materials, and in turn, this will also increase the 
contact area of the plant material with the selected solvent chosen for the extraction 
process. Consequently, increasing the surface area of the plant material will increase the 
rate of the extraction process. It is advocated that the ideal ratio used for mixing the plant 
materials to the solvent be 10:1 (selected solvent volume: weight of plants materials) (Das 
et al., 2010).  
2.7.3.1 Solvents Used in Extraction of Plants 
Many types of solvents have been used in the process of plant extraction. The most 
commonly used solvents are as follow: 
1. Water: Water has been considered as the universal solvent. It is inexpensive and used 
to extract plant products with antimicrobial activity. Investigators have been using 
water extracts for the initial screening of plants for possible antimicrobial activity 
(Cowan, 1999). However, plant extracts obtained using other organic solvents (e.g. 
alcohols) have been found to give better and more consistent antimicrobial activity 
than plants extracts obtained using water as the solvent (Das et al., 2010). 
2. Acetone: It is used to dissolve many types of hydrophilic and lipophilic components 
of the plants. It is volatile, miscible with water and has a low toxicity. It is the solvent 
of choice when more phenolic compounds with anti-microbial activity are required to 
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be extracted (Eloff, 1998). Earlier studies stated that extraction of tannins and other 
phenolic components was better in aqueous acetone than in aqueous methanol (Das 
et al., 2010; Eloff, 1998).  
3. Alcohol: Two of the most common types of alcohol used as a solvent for plant 
extraction are ethanol and methanol (Bimakr et al., 2011; Wang et al., 2010). They 
have been extensively used to extract antioxidant compounds from various types of 
plants and plant-based foods (fruits, vegetables, etc.) (Peschel et al., 2006). Using 
alcohol as a solvent can produce plant extracts with higher antimicrobial activity when 
compared to the use of water as the solvent (Lapornik et al., 2005).  
The combined use of water and organic solvent may facilitate the extraction of 
chemicals that are soluble in water and/or organic solvent. This may explain the 
reason why the yield of plant extracts using solvents such as aqueous methanol, 
ethanol, and acetone extracts are higher than the yield of plant extracts using water, 
methanol, ethanol, and acetone solvents (Do et al., 2014). However, there has been a 
report showing that plant extracts obtained using aqueous methanol as the solvent 
were more effective in recovering the highest amounts of phenolic compounds from 
rice bran (Shahid Chatha et al., 2006). When flavonoid compounds were extracted 
from the leaves of spearmint using different types of solvent, the use of methanol 
produced the highest yield of plant extracts (Bimakr et al., 2011). In general, the 
methanol solvent has more polarity than ethanol, and this could have attributed to the 
extraction process being more efficient and enabling the extraction of more plant 
constituents (Bimakr et al., 2011; Wang et al., 2010). 
2.7.3.2 Extraction Methods 
Many extraction methods have been used for extracting plant extracts. The most 
commonly used techniques are maceration, infusion and percolation. These methods can 
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be utilized for the initial plant extraction process and can also be employed for bulk 
extraction of plant constituents (Handa et al., 2008).  
 Maceration 
Maceration is one of the basic techniques for extraction in medicinal plant research. 
The general procedure of maceration includes soaking a suitable ground plant material 
into a selected solvent (menstruum) in a closed vessel, and following this, the mixture can 
stand at room temperature with constant shaking for at least three days. This step is 
intended to soften and break the plant’s cell wall to enable the release of soluble 
phytochemicals. Following this, the mixture is then strained by filtration leaving behind 
a solid residue of the mixture (marc) which is then pressed to obtain as much occluded 
liquid as possible from the marc. Then, the pressed and strained liquid is mixed and 
filtered to separate it from the coarse plant materials.  
The general principle of maceration, also referred to as leaching, can be affected by 
several factors; the transport rate of the solvent into the plant materials, the solubilizing 
rate of the plant’s soluble constituents into the solvent and the transport rate of the solution 
out of the insoluble plant materials. Thus, grinding the plant material to minimise its size 
is essential to increase the contact surface area between the plant material and the solvent. 
By decreasing the radial distances of the plant solid materials, the transport rate of the 
solvent into the plant materials as well as transport of the solution from the insoluble plant 
materials will improve. Frequent shaking during maceration is a vital step which supports 
the diffusion process and ensures dispersal of the concentrated solution around the plant’s 
material surface and a continuous flow of fresh solvent to the plant’s material surface for 
further extraction (Handa et al., 2008). 
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 Infusion 
Fresh infusions are produced by macerating the plant materials for a short period using 
either cold water or boiling water. The solution produced is the soluble constituents of 
the plant materials (Handa et al., 2008). 
 Percolation 
This procedure is the most frequently used method for extracting active constituents 
in the preparation of tinctures and fluid extracts. A narrow, cone-shaped vessel is opened 
from each end of the percolator, and the plant material is moistened with an appropriate 
amount of solvent and allowed to stand for approximately 4 hours in a well-closed 
container. Following this, the mass is packed, and the top end of the percolator is closed. 
Additional solvent is added until it forms a shallow layer above the mass and the mixture 
is left to macerate in the closed percolator for 24 hours. The outlet of the percolator then 
is opened, and this will allow the liquid to drip down slowly. The plant material is then 
pressed and the expressed liquid is added to the percolator. Sufficient solvent is then 
added to produce the required volume which is then clarified by filtration (Handa et al., 
2008). 
2.8 Chemopreventive Agents 
Cancer chemoprevention was first defined by Sporn (1976). This term refers to the use 
of natural, synthetic, or biologic chemical agents in an attempt to reverse, suppress or 
prevent carcinogenic progression. Chemopreventive agents consist of materials of natural 
or synthetic origin. The difference between these agents and other drugs (which do not 
prevent disease) is that the incidence of diseases such as cancer is reduced before the 
onset of clinical symptoms (Tanaka et al., 2011). It can also suppress the elevation of 
cancer and prevent the transformation of premalignant cells by modifying the cell 
differentiation process (Schwartz, 2000). The mechanism of cancer prevention is targeted 
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at any of the six principles of essential alterations in cell physiology that is required for 
tumour growth: self-sufficiency in growth signals, insensitivity to growth-inhibitory 
(antigrowth) signals, evasion of programmed cell death (apoptosis), limitless replicative 
potential, sustained angiogenesis and tissue invasion and metastasis (Hanahan & 
Weinberg, 2000).  
The strategy for chemoprevention treatment is often classified into three broad 
categories; primary, secondary or tertiary strategy. By exerting a barrier, the primary 
prevention approach (blocking agents) prevents healthy people who are at risk (e.g. 
smokers) from developing cancer, and this involves preventing the carcinogenic agents 
from reaching or reacting with the important target site (Shukla & Pal, 2004; Soria et al., 
2003). Secondary prevention involves patients who are already diagnosed with 
premalignant lesions (e.g. oral leukoplakia). Prevention of the progression of the 
premalignant lesions into cancer involves decreasing the susceptibility of the target tissue 
to carcinogenic stimuli using a chemopreventive agent. Tertiary prevention approach is 
aimed at patients who are cured of their primary cancer or patients who have been treated 
for their premalignant lesions and to prevent the recurrence or development of secondary-
primary tumours (Shukla & Pal, 2004; Soria et al., 2003). The requirements for a 
chemopreventive agents are; (1) minimum toxicity or none at all, (2) high efficacy in 
several sites, (3) proficiency for oral consumption, (4) known mechanism of action, (5) 
low cost, and (6) human acceptance (Lee & Choi, 2011).  
There are several examples of chemopreventive agents that have been used to treat 
head and neck cancers that were induced in animals (in vivo); the benefits of using apple 
extract has been reported to suppress rat tongue carcinogenesis due to its anti-
inflammatory activity and ability to induce apoptosis through the intrinsic mitochondrial 
pathway, particularly by downregulation of COX- 2 and TNF-alpha expression and 
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increased expression of Cytochrome C  and caspase 3 (Ribeiro et al., 2014). Extraction 
of green tea polyphenols inhibits Phase I enzymes (high in rat treated with 4NQO) that 
deactivate the carcinogen, and this plant extract can also induce the expression of Phase 
II enzymes that detoxify 4NQO. It was then suggested that green tea polyphenols play a 
role as a detoxifying agent by preventing/inhibiting the formation of cancer (Srinivasan 
et al., 2008). 
2.9 4NQO Carcinogenesis in Animal Models 
Numerous animal models (such as a hamster, rats and mouse) are currently being 
utilised for research in oral cancer development, and these animal models have been 
established for the evaluation of therapeutic agents (synthetic or natural) (Suzuki et al., 
2006). Many carcinogenic agents such as coal tar, 20 methyl cholanthrene (20MC), 9,10-
dimethyl-1,2-benzanthracene (DMBA) and 4-nitroquinoline-1-oxide (4NQO) have been 
used to induce oral cancer, but 4NQO is the preferred carcinogen in the development of 
experimental oral carcinogenesis (Kanojia & Vaidya, 2006).  
4NQO is a water soluble quinoline derivative (a highly carcinogenic chemical), which 
stimulates tumours development mainly in the oral cavity (Kanojia & Vaidya, 2006) 
especially on the tongue of rats following consumption of 4NQO in drinking water or by 
topical application of 4NQO to the oral mucosa (Long et al., 2007). As a result, the 
development of oral carcinogenesis all stages are produced; hyperplasia, dysplasia, severe 
dysplasia, carcinoma in situ and squamous cell carcinoma (Kanojia & Vaidya, 2006). 
4NQO induces the formation of DNA adducts; whereby adenosine is substituted for 
guanosine and induces intracellular oxidative stress resulting in mutations and DNA 
strand breaks. These genetic alterations are similar to that as provoked by the tobacco 
carcinogens and therefore, 4NQO has been associated as a substitute for tobacco 
exposure (Vitale-Cross et al., 2009).  
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As the 4NQO carcinogenesis in animal models can result in a spectrum of 
preneoplastic and neoplastic lesions, it is the suitable model for studying oral squamous 
cell carcinoma (OSCC) as well as to evaluate the efficiency of chemopreventive and 
chemotherapeutic agents and screening for biomarkers for both tumour progression and 
treatment (Peng & McCormick, 2016). In fact, this model has the advantage as the 
development of the neoplastic lesions was found to be parallel the development of OSCC 
in humans, i.e., the dysplastic lesions are produced by long-term ingestion of small 
amounts of carcinogen (Vered et al., 2005). The 4NQO induced tongue carcinogenesis 
model has been considered quite useful for investigating oral carcinogenesis and 
identification of cancer chemopreventive agents because the most common site for oral 
carcinoma is the tongue and the administration of drinking water containing 4NQO is a 
straightforward and easy method (Tanaka et al., 2011). The oral lesions produced by 
4NQO are similar to human lesions due to the development of dysplasia and the presence 
of many ulcerated, endophytic or exophytic tongue tumours (Yoshida et al., 2005). 
Long et al. (2007) studied the chemopreventive effect of fermented brown rice and rice 
bran on 4NQO induced tongue neoplasms in rats. When 4NQO was given at a 
concentration of 20 ppm in their drinking water for eight weeks, endophytic or exophytic 
tumours developed in the dorsal site of the rat’s tongues. In a related chemopreventive 
study, oral tongue carcinogenesis in rats was also induced following eight weeks of 
4NQO administration in their drinking water (Ribeiro et al., 2014). The primary 
histopathological change for all groups exposed to 4NQO was hyperplasia, 
hyperkeratosis with the spinous cell layer gradually thickened and epithelial dysplasia 
(Ribeiro et al., 2014). The use of 4NQO to induce oral cancer in vivo have been used in 
many animal studies as shown in Table 2.1. 
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2.10 Molecular and Genetic Changes during Carcinogenesis 
Molecular biology can be defined as the study of biology at a molecular level and 
involves understanding the interactions between DNA, RNA, and protein biosynthesis 
and how these interactions are controlled (Ahmed & Jigna, 2009). The ability to the 
identify genes involved in human disease has led to a revolutionary increase in 
the scientific knowledge of genetic disorders, its pathological process and advancement 
in the treatment of genetic disorders. Once a diagnosis of a genetic disorder has been 
made, the clinical application, based on the background knowledge of the disease, will be 
applied for the treatment of the disease. In fact, molecular techniques have provided a 
strong tool for genetic diagnosis in many cases allowing accurate identification of 
individuals who carry a mutation by using any readily accessible source of tissue for 
analysis of DNA (Harada & Korf, 2013). The use of biomarkers in cancer screening 
prevention as well as for detection of the earliest stages of oral mucosal malignant 
transformation is gaining importance. It reveals the genetic and molecular changes related 
to early, intermediate and late end-points processes of oral carcinogenesis. These 
biomarkers will refine the ability to enhance the prognosis, diagnosis, and treatment of 
oral carcinomas. Genetic and molecular biomarkers have also used in studies to determine 
the efficacy and safety of the chemopreventive agents (Tanaka & Ishigamori, 2011).  
Some examples of the molecular analytical tools that have been used for determining 
the diagnosis and treatment of oral cancers are chromosome in situ hybridization, 
cytomorphometry, immunohistochemistry, polymerase chain reaction (PCR), DNA 
image cytometry, DNA microarrays, proteomics and gene therapy (Ahmed & Jigna, 
2009). Tissue biopsies taken on patients is a common procedure used for diagnosis of oral 
cancer although it may be uncomfortable for the patient and time-consuming. Apart from 
tissue biopsy, non-invasive oral screening methods such as brush biopsy, 
autofluorescence imaging and toluidine blue staining have also been used to diagnose oral 
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cancer (Lingen et al., 2008), however, it has been reported that the experience of the 
physician is critical when using those methods (Huang et al., 2017). 
There are various types of mutagenic agents and depending on the type or nature of 
stimuli; chemical (tobacco), physical (radiation) or infection (Human papillomavirus, 
Candida), these mutagenic agents that may cause changes in gene and chromosome 
structure by point mutations, gene amplifications and chromosomal rearrangements. 
Some of these changes may occur spontaneously and these genetic alterations, which can 
occur during carcinogenesis, may be used as targets when detecting cancer cells in clinical 
samples (Todd et al., 1997; Williams, 2000).  
Oral carcinogenesis is a complex, multistep process in which specific genetic events 
within a signal transduction pathways that control the normal cellular physiology are 
changed either quantitatively or qualitatively (Sidransky, 1995; Todd et al., 1997). In 
normal conditions, the basic cellular functions such as cell division, differentiation and 
senescence which are under control in normal tissues are affected in cancer tissue. The 
regulation of oral epithelium involves tightly controlled excitatory and inhibitory 
pathways. The excitatory or inhibitory signals are generated when growth factors bind to 
a cell surface receptor forming a receptor-ligand complex, and the signals are sent through 
intracellular and nuclear messengers that can either directly alter cell function or can 
stimulate the transcription of genes. However, oral cancer may occur when there is an 
accumulation of changes in the excitatory and inhibitory cellular pathways that can occur 
at any level of a given pathway. As the cell collects these alterations or mutations, it 
becomes functionally independent from the surrounding oral epithelium, the normal oral 
keratinocyte neighbours (Sidransky, 1995). The normal cellular functions which are 
strongly controlled by the excitatory and inhibitory pathways are destabilised in a cancer 
cell, allowing it to divide more rapidly, sequester blood vessels to feed that growth, delete 
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or amplify signals to produce abnormal structural or functional changes and invade 
normal tissue at local or distant sites. Accumulation of these changes is believed to 
generate the histologic progression of oral carcinogenesis from hyperplasia to dysplasia, 
followed by severe dysplasia and eventually invasion and metastases (Todd et al., 1997; 
Vokes  et al., 1993).  
Genetic damage to cancer cells can be divided into two categories: “dominant” or 
alteration of genes in the excitatory pathways involving proto-oncogenes and “recessive” 
or mutation of growth inhibitory pathways involving tumour suppressor genes. 
“Dominant” genetic damage results in a gain of function, whereas “recessive” damage 
causes loss of function” (Bishop, 1991). In neoplasms, cell proliferation is excessive and 
autonomous, uncoordinated and despite DNA damage due to loss of cell cycle check-
points, the process of cell division would continue (Nagpal & Das, 2003). 
Proto-oncogenes are known as a group of genes that cause normal cells to become 
cancerous when they are mutated (Weinstein & Joe, 2006). When proto-oncogenes are 
mutated, the mutated version of proto-oncogenes is called oncogenes. Proto-oncogenes 
often encode proteins that function to stimulate cell division, inhibit cell differentiation 
and halt cell death. These processes are necessary for normal human development and the 
maintenance of tissues and organs. However, oncogenes exhibit increased production of 
these proteins, thus leading to increased cell division, decreased cell differentiation and 
inhibition of cell death. Thus, oncogenes are currently a major molecular target for anti-
cancer drug design (Chial, 2008). They were originally described in relation to RNA 
viruses (retrovirus) containing nucleic acid sequences capable of inducing oncogenic 
properties in host cells (Weiner & Cance, 1994). These genes are described as the 
fundamental components of a multistep tumorigenesis. The mechanism by which 
oncogenes are activated includes point mutations, gene amplification and gene 
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overexpression. Accurate regulation of all this positive and negative signalling is essential 
to preserve normal cell growth, and disturbance of such regulation can lead to neoplasia 
(Khan et al., 2010). Epidermal growth factor receptor (EGFR) (a tyrosine kinase receptor 
from the ErbB family) plays a key role in many of the cellular processes involved in 
cancer development and has proven to be a promising target for cancer therapy (Oliveira 
et al., 2006). It is an oncogene that has been overexpressed in numerous malignancies, 
including cancer of the prostate, breast, bladder, pulmonary system and head and neck 
(Oliveira et al., 2006). EGFR appears to be the dominant controlling factor underlying 
the malignant phenotype in squamous cell carcinomas of head and neck, via adjustment 
of the molecules involved in invasive angiogenic and lymphangiogenic processes 
(Pornchai et al., 2002). 
Tumour suppressor genes normally act by inhibiting cell proliferation and tumour 
development. In several tumours, these genes are lost or inactivated resulting in negative 
regulators of cell proliferation and contribute to the abnormal proliferation of tumour cells 
(Cooper & Hausman, 2013b). Many tumour suppressor genes, such as the retinoblastoma 
(Rb) gene, were initially identified in paediatric tumours that are formed early in life and 
the loss of this tumour suppressor activity was reported to be necessary for oral 
carcinogenesis to take place (Todd et al., 1997).  
In approximately 70% of all known tumours presented in the adult, the tumour 
suppressor gene p53 was reported to be mutated (Todd et al., 1997). However, in SCC of 
the head and neck region, 40-50% of the tumours studied have shown mutation of the p53 
gene (Nylander et al., 2000). The name p53 gene is used because it produces a 53 kDa 
nuclear phosphoprotein (wild type or normal p53 protein) which is located on the short 
arm (p) of chromosome17 (Scully et al., 2000). 
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In normal physiological conditions, the p53 gene is expressed at low levels and has a 
short half-life due to the rapid turnover of the p53 protein mediated by ubiquitination and 
proteolysis. p53 is stabilised and activated when responding to some stressful stimuli such 
as exposure of cells to hypoxia, DNA damaging agents, nucleotide depletion or oncogene 
activation. Once p53 is activated, it performs its function as a tumour suppressor through 
some growth controlling endpoints which include: cell cycle arrest, apoptosis, 
senescence, differentiation and anti-angiogenesis. Therefore, p53 has been considered as 
a ‘guardian of the genome’ or ‘gatekeeper for growth and division’ when regulating 
critical checkpoints in response to distinct stresses (El-Deiry, 1998).  
2.11 Cell Cycle  
The cell cycle (cell-division cycle) is a series of events which lead to cell division and 
duplication (Alberts et al., 2008; MacLachlan et al., 1995). The human cells cell cycle as 
demonstrated by tissue culture divides approximately every 24 hours. The cell cycle 
begins with interphase as the first phase, in which the chromosomes amplify and is 
distributed throughout the nucleus. However, during interphase, both cell growth 
and DNA replication occur in order to prepare the cell for the next phase of cell division 
(Cooper & Hausman, 2013a). Interphase consists of three distinct phases: G1 phase (Gap 
1), S phase (synthesis) and G2 (Gap 2) phase, followed by the mitotic phase (M phase) 
(Kleinsmith, 2006). Mitosis (nuclear division) is the most dramatic stage of the cell cycle 
and usually, ends with cell division (cytokinesis) where chromosomes and cytoplasm 
separate into two new daughter cells. Interphase occupies about 95 % of a typical cell 
cycle, whereas the actual process of cell division (M phase) only takes about 5 % (Cooper 
& Hausman, 2013a).  
The cell grows at a steady rate throughout the interphase, with most dividing cells 
doubling in size between one mitosis and the next. It also during a part of interphase that 
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the DNA is synthesised. The M phase of the cycle that corresponds to mitosis is usually 
followed by cytokinesis. The next phase is the G1 phase (gap 1) which corresponds to the 
interval (gap) between mitosis and initiation of DNA replication. During the G1 phase, 
the cell is metabolically active and continuous to grow but does not replicate its DNA. 
G1 is then followed by the S phase (synthesis), during which DNA replication occurs. 
The completion of DNA synthesis is followed by the G2 phase (gap 2), during which cell 
growth continues, and proteins are synthesised in preparation for mitosis (Cooper & 
Hausman, 2013a; Kleinsmith, 2006). When the cell undergoes differentiation, it exits 
from the G1 phase of the cell cycle to enter into an inactive state referred to as the G0 
phase (Pucci et al., 2000). 
The relationship between cell cycle and cancer is understandable: while cell cycle is 
involved in regulating cell proliferation, cancer is a disease involving inappropriate cell 
proliferation (Collins et al., 1997). Therefore, alteration in the expression and/or activity 
of cell cycle related proteins permit cancer cell to survive beyond its normal life span and 
to proliferate abnormally (Feitelson et al., 2015).  
2.12 Cell Death  
In the last two decades, the field of cell death has attracted much attention (Lockshin 
& Zakeri, 2001). Cells respond to stress in different ways ranging from the activation of 
the survival pathways to the initiation of cell death that eliminates damaged cells (Fulda 
et al., 2010). According to the level and mode of stress, different defence mechanisms 
and pro-survival strategies can be triggered; however, if these are ineffective, then the 
cell death programs are activated to eliminate these damaged cells from the organism. 
The mechanism of cell death depends on its ability to deal with the conditions to which it 
is exposed and involve apoptosis, necrosis, pyroptosis, or autophagic cell death (Fulda et 
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al., 2010). There are many morphological differences between necrosis and apoptosis 
(Figure 2.3).  
2.12.1 Apoptosis  
Apoptosis (cell suicide pathway) also known as programmed cell death is essential for 
the elimination of cells that are no longer needed or are damaged (Sayers, 2011) 
(Hongmei, 2012). Apoptosis occurs during normal cell development and turnover, as well 
as in a variety of pathological conditions. However, inappropriate regulation of apoptosis 
can contribute to certain disorders such as viral infection, autoimmune diseases, AIDS, 
neurodegenerative disorders, stroke, anaemia and cancer (Pucci et al., 2000). Apoptosis 
is characterised by specific morphological alterations, including chromatin condensation, 
cell shrinkage, phosphatidylserine translocation, the formation of apoptotic bodies and 
plasma membrane blebbing before cell lysis (Hsu et al., 2004). At the molecular level, 
apoptosis occurs through two distinct pathways. The intrinsic or mitochondrial pathway 
is activated by intracellular events and depends on the release of proapoptotic factors from 
the mitochondria. The extrinsic apoptosis pathway receives signals through the binding 
of extracellular protein death ligands to proapoptotic death receptors (Sayers, 2011). 
Some key proteins linked to the process of apoptosis are Bcl-2 family protein, caspase-3, 
caspase-8, caspase-9, Bid and Bax (Hongmei, 2012).  
2.12.2 Necrosis 
The alternative to apoptotic cell death is necrosis. Certain types of injury/stimuli such 
as heat, radiation, hypoxia or exposure to cytotoxic anticancer drugs at low doses can 
induce apoptosis, but when the types of injury/stimuli become more severe it can result 
in necrosis (Elmore, 2007). Necrosis may occur when cells are exposed to conditions that 
are not related to physiological conditions (e.g., hypothermia) or to compounds that cause 
damage to the cell membrane. Necrosis is initiated when the cell cannot maintain 
45
homeostasis and this will lead to an influx of water and extracellular ions. Intracellular 
organelles, most notably the mitochondria, and the entire cell undergoes swelling and 
may rupture (cell lysis). Due to the ultimate breakdown of the plasma membrane, the 
cytoplasmic contents including lysosomal enzymes are released into the extracellular 
fluid. Therefore, in vivo necrotic cell death is frequently associated with extensive tissue 
damage resulting in an intense inflammatory response (Miret et al., 2006; Yanina et al., 
2011). The morphological changes in necrotic cells are cell swelling, the formation of 
cytoplasmic vacuoles and cytoplasmic blebs, distended endoplasmic reticulum, swollen 
or ruptured mitochondria and lysosomes and accompanied with disrupted organelle or 
cell membranes (Trump et al., 1997).  
 
 
Figure 2. 3: Representation of cell death: apoptosis and necrosis (Kumar et al., 
2014) 
Necrosis          Apoptosis 
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CHAPTER 3: ACUTE AND SUB-ACUTE ORAL TOXICITY OF DRACAENA 
CINNABARI EXTRACT IN RATS 
3.1 Introduction  
Toxicological studies subjected to make a decision about whether a new drug should 
be accepted for clinical use or not (Aneela et al., 2011). Toxicity study gives information 
on toxic doses and therapeutic indices of drugs and xenobiotic (Rahman et al., 2014). The 
outcome of the toxicity study in animals is vitally needed to determine the safety of 
medicinal plants if they are found to be suitable for development into pharmacological 
products. In addition, to determine the appropriate dose for long-term toxicity tests and 
to determine the affected organs at the end of the treatment, the toxicity test is achieved 
(Jothy et al., 2011). It is a scientific, ethical and regulatory requirement that before any 
potential new medicine administered to humans, its safety must be investigated in animals 
to define safe human doses (Robinson et al., 2009).  
Medicinal plants are used worldwide to treat many diseases, and new drugs continue 
to be developed through research from these plants (Gupta et al., 2008). Medicinal plant 
preparations can be formulated into many forms including liquids, and they have been 
used worldwide for many years (Kamal et al., 2012). The use of a medicinal plant for the 
treatment of disease without the scientific foundation to adequately support conclusions 
of safety and efficacy can be potentially dangerous as well as useless. In addition, misuse 
of these medicinal plants may cause serious toxicity for humans (Mir et al., 2013). As 
chemical compositions of the medicinal plant are complex, some moderate to severe side 
effects may arise from the use of herbal medicines. Therefore, it is important to establish 
medicinal plant safety through the use of well-controlled and validated scientific toxicity 
studies or protocols (Bhushan et al., 2014).  
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Dracaena cinnabari (DC) is a perennial tree located on the Southern coast of Yemen 
native to the Socotra Island. This tree produces a deep red resin which called the Dragon’s 
blood or the Twobrother’s Blood (Al-Awthan et al., 2010). DC belongs to Agavaceae 
family, which is commonly known as Damm Alakhwain in Yemen (Yehia et al., 2013). 
The red “dragon's blood” resin of the DC tree exudes from fissures and wounds in 
the bark or branches (Gupta et al., 2008). Phytochemical studies of DC resin have led to 
the isolation of several active compounds belonging to the flavanoids, 
homoisoflavonoids, chalcones, sterols and terpenoids. Some homoisoflavonoids and 
chalcones isolated from the DC resin exhibited a strong antioxidant activity (Machala et 
al., 2001). DC resin is showing enormous potential interaction with antimicrobial and 
antioxidants activities (Gupta & Gupta, 2011; Mothana & Lindequist, 2005; Yehia et al., 
2013) and considered as good source of food preservative due to its inhibitory effect on 
various foodborne pathogens (Gupta & Gupta, 2011).  
Despite its wide uses, no study has been done to know about its oral toxicity which in 
turn will provide proper safety information regarding DC resin and to define safe human 
doses. Thus, the aim of the current study is to evaluate the safety of the DC resin methanol 
extract after single or 28 consecutive daily oral administrations.
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3.2 Materials and Methods  
3.2.1 Preparation of Dracaena cinnabari (DC) Resin Extract 
The resin of DC collected from Socotra Island (Yemen) in May 2013. The plant 
samples were identified and authenticated by Environmental Protection Authority of 
Yemen. A voucher specimen of the resin (DC/2013-8/122) has been deposited at the 
herbarium of Department of Pharmacognosy, Faculty of Pharmacy, University of Sana’a, 
Yemen. 
DC resin was ground into powder form using an electrical blender to ease the 
extraction process. 50 g of the powdered resin of DC placed into a 1L conical flask then 
macerated with methanol (500 ml methanol was added in, where 1g of dried and ground 
DC is to 10 ml methanol) in the ratio of (1:10).  Methanol has high polarity and thus 
greater efficacy towards the extraction of polar phytochemicals such as phenolics and 
flavonoids (Anwar et al., 2010). The conical flask was left at room temperature for 
approximately 3 days on a shaker at 100 rpm. The resultant extract was filtered through 
a fine muslin cloth, and then a filter paper Whatman (Grade 1-Circles, 150 mm) was used 
to remove the crude part. For separating the methanol from the extract, rotary vacuum 
evaporator (EYELA) (Figure 3.1) used under reduced pressure at 40 Co which produced 
a gummy red resin extract. After that, a freeze dryer was used (Figure 3.2) to produce 
28.0 g of a dry powder extract (Figure 3.3). 
The extract was then wrapped with aluminium foil to prevent a photo-oxidation that 
might be occurred and was stored at 4 Co until used. This methanol extract was dissolved 
in (10 % DMSO) before use as mentioned elsewhere (Alabsi et al., 2016).  
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Figure 3. 1: EYELA rotary vacuum evaporator            Figure 3. 2: Freeze dryer 
 
 
 
 
 
 
 
 
Figure 3. 3: Dracaena cinnabari resin methanol extract in a powder form. 
 
3.2.2 Experimental Animals 
Female and male Sprague Dawley (SD) rats were used for the acute and sub-acute oral 
toxicology tests. Nine rats (females) were used in an acute oral toxicity test, whereas 60 
rats (30 males and 30 females) used in sub-acute oral toxicity test (the repeated dose 28 
day). The toxicity tests were carried out according to Organization for Economic 
Cooperation and Development (OECD) test guideline OECD Guideline 423 for the acute 
oral test (OECD, 2001) and OECD Guideline 407 for the sub-acute oral test (OECD, 
2008) with slight modifications. The rats were obtained from the Animal Experimental 
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Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur. SD rats (8-10-week-
old) weight 235±15 g were used. Prior to the start of the experiment, body weight of 
animals was recorded individually for calculating proper treatment dosage. The volume 
was adjusted depending on the body weight of the rat using 10 ml/kg as this is the normal 
volume to be used in the rat as mentioned elsewhere (Perret-Gentil, 2005; Turner et al., 
2011). The female SD rats were nulliparous and non-pregnant. The SD rats were given 
standard rat pellets and reverse osmosis (RO) water ad libitum. They were acclimatised 
to laboratory conditions for 7 days before the experiments and housed in groups of three 
for acute oral toxicity and groups of five for sub-acute oral toxicity. The rats were 
maintained at a room temperature of 24oC, with a 12 h light/dark cycle. Protocols 
approved by the Institutional Animal Care and Use Committee (IACUC), Faculty of 
Medicine, University of Malaya, Malaysia (Ethics No. 2014-02-14/OBBS/R/NAA). The 
endpoint of all rats considered when around 20% of body weight loss has been shown.  
3.2.3 Acute Oral Toxicity 
The DC extract was administered to the female rats under overnight fasting by using 
oral gavage in a volume of 10 ml/kg body weight.  
Nine female SD rats were randomly divided into 3 groups of 3 rats each. The starting 
dose at 300 mg/kg body weight of DC extract that dissolved in 10 % DMSO administered 
to the group 1. The rats were observed for general behavioural changes; symptoms of 
toxicity and mortality after treatment for the first 4 h, then over a period of 48 h. Group 2 
was administrated sequentially at 48-hour intervals with the next higher dose 2000 mg/kg 
body weight of DC extract that dissolved in 10 % DMSO when there were no signs of 
toxicity or mortality showed in group 1 after 48 h of treatment. In parallel, group 3 added 
and treated with vehicle (10% DMSO) to establish a comparative negative control group 
according to the OECD guideline (OECD, 2001). All animals observed at least once 
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during the first 30 minutes in the first 24 hours with great consideration given for the first 
4 h following vehicle or DC extract administration and then once a day for 14 days. This 
observation was done to check the onset of clinical or toxicological symptoms according 
to the OECD guideline (OECD, 2001). All observations included changes in skin and fur, 
eyes and mucous membranes and behavioural pattern were systematically recorded and 
maintained with an individual record. In addition, consideration was given for 
observations of convulsions, tremors, diarrhoea, salivation, lethargy, sleep, coma and 
mortality. The food consumption and water intake recorded daily. The body weights of 
animals recorded shortly before the administration of the tested substance and at the end 
of each week. The percentage of body weight change calculated according to the 
following equation: 
Body weight at the end of each week − initial body weight 
Initial body weight
× 100 
3.2.4 Sub-Acute Oral Toxicity (Repeated Dose 28-Day Oral Toxicity) 
The SD rats were randomly divided into six groups of 10 rats each (n = 10/group, 5 
males and 5 females). Four groups were administered daily with DC extract at different 
concentration dissolved in 10 % DMSO and two groups administered with the vehicle by 
using oral gavage. Group 1 received vehicle (10% DMSO) and served as control. Groups 
2, 3 and 4 received doses of DC extract at 500, 1000 and 1500 mg/kg body weight, 
respectively. The 5th and 6th groups namely satellite groups added to determine the 
reversibility or recovery from toxic effects of the test material and given the vehicle (10% 
DMSO) and the top dose of DC extract 1500 mg/kg body weight, respectively. They were 
handled as the previous groups. The test material was administered orally (gavage) once 
daily for 28 consecutive days. The satellite groups were scheduled for follow-up 
observations for the next 14 days without a vehicle or DC extract administration.  
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Mortality, food consumption and water intake, as well as observation for general 
toxicity signs of the animals, were monitored and recorded daily during the study. The 
Initial body weight of all the groups has been recorded before the tested material is 
administered and at the end of each week.  A summary of the groups of acute and sub-
acute oral toxicity tests is illustrated in Figure. 3.4. 
 
Figure 3. 4: Summary of acute and sub-acute oral toxicity tests groups
Acute oral toxicity (OECD Guideline 
423)
3 females rats/group
Group 1: Rats were given DC 
300 mg/kg 
Group 2: Rats were given 
vehicle (10 % DMSO) 
Group 3: Rats were given the 
next higher dose (DC 2000
mg/kg) 
Sub-acute oral toxicity  (OECD 
Guideline 407)
10 rats/group (5 males & 5 females)
Group 1: Rats (Control group) 
vehicle (10% DMSO)
Group 2: Rats were given DC 
extract 500 mg/kg
Group 3: Rats were given DC 
extract 1000 mg/kg
Group 4: Rats were given DC 
extract 1500 mg/kg
Group 5: (Satellite group) Rats 
were given vehicle (10% 
DMSO)
Group 6: (Satellite group) Rats 
were given DC extract 1500
mg/kg
53
3.2.5 Haematology and Serum Biochemistry 
At the end of each experiment (at 15th day for acute oral toxicity and at 29th day for 
sub-acute oral toxicity tests except the satellite groups which were at 43rd day), the rats 
generally anesthetized by intraperitoneal injection of 80 mg/kg of ketamine 100 mg/ml + 
7 mg/kg of xylazine 100 mg/ml (Troy Laboratories PTY. Limited, Smithfield, Australia). 
Blood sample (5 ml) by cardiac puncture was collected using a disposable syringe. The 
blood kept in K2EDTA tube for analysing haematological parameters [haemoglobin 
(HGB), white blood cell (WBC), Neutrophil, Lymphocyte, Monocyte, Eosinophil and 
Basophil] and in Plain tubes for biochemical parameters [Renal Function - Urea and 
Creatinine, and liver function - Albumin, Globulin, Total bilirubin, Conjugate Bilirubin, 
Alkaline phosphatase (ALP), Alanine transaminase (ALT) and Aspartate 
aminotransferase (AST)]. The blood sample that placed in a plain tube left for 15 - 20 
minutes at room temperature to promote blood coagulation. The blood sample was 
centrifuged at 5000 rpm for 20 min at 4°C; the serum obtained then analysed. 
Immediately, after blood collection, rats were sacrificed by cervical dislocation.  
3.2.6 Relative Organ’s Weight  
Necropsy was done in acute and sub-acute oral toxicity tests groups of animals on day 
15 and 29 respectively, and for the satellite groups, on day 43. After the blood collection, 
rats were sacrificed by cervical dislocation, and the vital organs (liver, kidney, heart, 
spleen and lung) removed through a midline incision in the Rat’s abdomen. The organs 
were cleaned of fat and blotted with clean tissue paper, and then weighed on a balance. 
The relative organ’s weight (ROW) was calculated and recorded in proportion to the body 
weight according to the following equation: 
RWO =
 Absolute organ weight
Body weight at sacrifice
× 100 
54
3.2.7 Histopathological Observation  
Samples from the vital organs (liver, kidney, heart, lung and spleen) of both acute and 
sub-acute oral toxicity tests were subjected to histopathological evaluation. They fixed in 
10% buffered formalin, routinely processed and embedded in paraffin wax. Paraffin 
sections (5 µm) was cut on glass slides and stained with haematoxylin and eosin. An 
experienced pathologist who was unaware of the experimental groups to which each 
section belonged conducted the analysis. The slides were examined under a light 
microscope (Nikon E50i, Nikon Corporation, Japan) as mentioned elsewhere  (Xu et al., 
2014).  
3.3 Statistical analysis 
Results expressed as a mean ± standard deviation. Statistical analysis was performed 
using SPSS version 20. The differences between groups of acute and sub-acute toxicity 
tests determined by one-way analysis of variance (ANOVA) followed by Tukey multiple 
comparison test, and Student t test for satellite groups comparisons. Differences were 
considered significant at p < 0.05. 
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3.4 Results 
3.4.1 General Sign and Behavioural Analysis  
Oral administration of DC extract showed no treatment-related mortality in both sexes 
of rats for both acute and sub-acute oral toxicity tests throughout the study. Physical 
observation of the DC treated rats for both acute and sub-acute oral toxicity tests 
throughout this study indicated that none of them showed signs of toxic effects such as 
changes in skin and fur, eyes and mucous membrane, behaviour pattern, tremors, 
salivation, diarrhoea and coma.  No gross or microscopic pathological abnormalities in 
all groups (acute and sub-acute oral toxicity tests) observed in any animals. Concerning 
the Globally Harmonised Classification System, DC resin methanol extract can be 
classified as Category 5 and this provides direct relevance for protecting animal and 
human health up to the high dose level that used in this study.  
3.4.2 Effect of DC Extract on Body Weight, Organ’s Weight, Food Consumption 
and Water Intake in Acute and Sub-Acute Oral Toxicity Tests 
The body weight of the control and DC treated rats were as shown in Table 3.1 (A and 
B).  There was a gradual increase in body weight of the control and DC treated groups in 
both acute and sub-acute oral toxicity tests. The percentage changes in body weight of the 
DC treated groups were not significantly different compared to the control rats as p > 
0.05 (Table 3.1 A and B). In addition, there is no significant difference has been shown 
in Satellite groups in both sexes with p > 0.05 (Table 3.2).  
There was no statistically significant difference in ROW between control and DC 
treated groups of both tests as p > 0.05 (Table 3.3 A and B). No significant difference has 
been shown in Satellite group in both sexes as p > 0.05 (Table 3.4). 
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The food consumption of the DC treated groups in both tests was not significantly 
different compared to the control group (p > 0.05) measured throughout the study (Table 
3.5 A and B) as well as in the satellite groups in both sexes as p > 0.05 (Table 3.6).  
The water intake of the control and DC treated groups in acute oral toxicity test showed 
no significant difference with p > 0.05 (Table 3.7 A) while in the sub-acute oral toxicity 
test a significant difference has been demonstrated between the control and DC treated 
groups as p < 0.05 (Table 3.7 B). A post hoc Tukey test showed significant differences 
between the DC treated (male and female) and control groups as shown in Table 3.8 with 
p < 0.05. Similarly, a significant difference has been shown in Satellite groups between 
the DC treated group and the control group in both sexes as p < 0.05 (Table 3.9). 
Table 3. 1 (A and B): Percentage of body weight gain of rats in acute and sub-acute 
oral toxicity tests.  
A: Acute oral toxicity 
 Sex  Control  
DC 300 
mg/kg 
DC 2000 mg/kg 
P value 
0 day (g) F (n=3) 235.33±5.03 250.00±8.54 249.67±9.61 
Week 1 (%) F (n=3) 5.82±1.44 4.92±1.62 4.15±0.37 0.340 
Week 2 (%) F (n=3) 8.65±1.96 8.53±1.59 7.37±1.17 0.586 
B: Sub-acute oral toxicity  
 Sex Control  
DC 500 
mg/kg 
DC 1000 mg/kg DC 1500 mg 
P value 
0 day (g) 
M (n=5) 232.00±4.70 223.40±5.22 226.40±5.13 229.80±3.96 
F (n=5) 247.20±6.14 233.40±2.70 228.60±8.02 232.20±2.56 
Week 1 (%) 
M (n=5) 8.28±0.91 8.56±0.79 8.11±1.15 8.61±1.28 0.853 
F (n=5) 5.03±2.44 4.71±1.09 5.44±1.71 5.50±2.21 0.907 
Week 2 (%) 
M (n=5) 16.73±1.03 16.37±1.19 16.78±0.83 16.09±1.87 0.811 
F (n=5) 7.53±3.21 7.62±2.09 7.27±2.59 8.49±2.30 0.889 
Week 3 (%) 
M (n=5) 24.25±2.13 24.17±1.09 23.69±1.64 23.48±2.00 0.881 
F (n=5) 11.42±2.77 10.44±2.82 10.55±2.64 12.30±3.20 .0715 
Week 4 (%) 
M (n=5) 29.34±2.70 28.55±1.60 29.71±2.08 29.75±4.94 0.920 
F (n=5) 13.83±2.76 13.18±2.24 13.36±3.05 15.23±2.94 0.649 
Values expressed as a mean ± standard deviation. Sex (male, M and female, F). *p-value 
less than 0.05, (p < 0.05) significant value. 
 
 
57
Table 3. 2: Satellite group/ Percentage of body weight change of rats in sub-acute 
oral toxicity test 
 Sex Control DC 1500 mg/kg P value 
 0 day 
M (n=5) 229.20±3.70 235.40±3.85 
F (n=5) 222.20±5.12 221.00±6.67 
Week 1 (%) 
M (n=5) 8.38±0.72 8.09±1.21 0.657 
F (n=5) 4.86±0.59 4.90±1.54 0.9601 
Week 2 (%) 
M (n=5) 15.36±1.57 15.13±0.77 0.782 
F (n=5) 7.57±0.66 7.56±1.67 0.994 
Week 3 (%) 
M (n=5) 19.90±1.34 19.89±1.62 0.988 
F (n=5) 10.09±1.12 9.80±1.68 0.756 
Week 4 (%) 
M (n=5) 24.45±1.99 24.30±0.83 0.883 
F (n=5) 12.96±0.96 12.77±1.35 0.807 
Week 5 (%) 
M (n=5) 28.81±2.02 28.48±1.68 0.788 
F (n=5) 15.22±0.71 14.78±1.81 0.631 
Week 6 (%) 
M (n=5) 34.03±2.50 33.16±2.69 0.612 
F (n=5) 17.28±0.75 16.59±1.65 0.415 
Values expressed as a mean ± standard deviation. Sex (male, M and female, F). *p-value 
less than 0.05, (p < 0.05) significant value. 
Table 3. 3 (A and B): Relative organs weight (g%) of rats in acute and sub-acute 
oral toxicity tests 
A: Acute oral toxicity 
 Sex Control 
DC 300 
mg/kg 
DC 2000 
mg/kg 
P value 
Heart F (n=3) 0.37±0.02 0.35±0.01 0.35±0.03 0.422 
Liver F (n=3) 2.58±0.14 2.60±0.12 2.50±0.13 0.601 
Kidney F (n=3) 0.70±0.02 0.67±0.03 0.68±0.02 0.484 
Spleen F (n=3) 0.18±0.02 0.18±0.02 0.18±0.01 0.952 
Lung F (n=3) 0.49±0.01 0.48±0.02 0.48±0.02 0.874 
B: Sub-acute oral toxicity 
 Sex Control 
DC 500 
mg/kg 
DC 1000 
mg/kg 
DC 1500 mg/kg P value 
Heart 
M (n=5) 0.36±0.02 0.35±0.02 0.34±0.02 0.34±0.03 0.757 
F (n=5) 0.37±0.02 0.37±0.03 0.37±0.02 0.38±0.02 0.938 
Liver 
M (n=5) 2.92±0.15 2.81±0.10 2.87±0.17 2.92±0.14 0.593 
F (n=5) 2.45±0.09 2.38±0.07 2.35±0.05 2.43±0.07 0.114 
Kidney 
M (n=5) 0.75±0.02 0.75±0.03 0.76±0.02 0.76±0.03 0.930 
F (n=5) 0.69±0.03 0.70±0.02 0.70±0.05 0.72±0.04 0.639 
Spleen 
M (n=5) 0.19±0.02 0.19±0.02 0.18±0.03 0.19±0.02 0.937 
F (n=5) 0.18±0.02 0.18±0.02 0.18±0.02 0.19±0.02 0.835 
Lung 
M (n=5) 0.40±0.02 0.40±0.02 0.39±0.02 0.42±0.01 0.241 
F (n=5) 0.49±0.02 0.48±0.02 0.49±0.01 0.50±0.02 0.536 
Values expressed as a mean ± standard deviation. Sex (male, M and female, F). *p-value 
less than 0.05, (p < 0.05) significant value. 
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Table 3. 4: Satellite group/ Relative organs weight (g%) of rats in the sub-acute oral 
toxicity test 
 Sex Control DC 1500 mg/kg P value 
Heart 
M  0.34±0.03 0.34±0.02 0.797 
F  0.38±0.01 0.38±0.01 0.493 
Liver 
M 2.73±0.09 2.76±0.08 0.508 
F 2.59±0.13 2.64±0.12 0.524 
Kidney 
M  0.76±0.02 0.75±0.02 0.655 
F  0.72±0.03 0.72±0.03 0.696 
Spleen 
M 0.19±0.01 0.19±0.01 0.370 
F 0.20±0.02 0.20±0.01 0.832 
Lung 
M  0.40±0.02 0.38±0.02 0.308 
F  0.50±0.02 0.50±0.01 0.722 
Values expressed as a mean ± standard deviation. n = 5.  Sex (male, M and female, F). 
*p-value less than 0.05, (p < 0.05) significant value. 
 
Table 3. 5 (A and B): Food consumption (g) of rats in acute and sub-acute oral 
toxicity tests  
A: Acute oral toxicity 
 Sex Control DC 300 mg/kg DC 2000 mg/kg P value 
Week 1 F (n=3) 64.68±2.80 63.43±2.87 59.14±14.67 0.089 
Week 2 F (n=3) 66.16±2.89 67.05±5.14 63.74±2.15 0.236 
B: Sub-acute oral toxicity 
 Sex Control DC 500 mg/kg DC 1000 mg/kg 
DC 1500 
mg/kg 
P 
value 
Week 1 
M (n=5) 81.75±1.21 81.15±2.17 80.99±2.55 79.26±2.42 0.189 
F (n=5) 74.87±2.59 72.99±1.63 72.47±2.28 71.55±2.80 0.089 
Week 2 
M (n=5) 84.52±1.13 83.93±0.93 83.80±1.77 82.59±1.11 0.061 
F (n=5) 78.69±3.26 77.56±3.21 75.99±3.58 74.66±4.64 0.220 
Week 3 
M (n=5) 88.05±2.54 87.92±2.07 86.10±1.94 85.19±2.58 0.075 
F (n=5) 86.55±3.64 86.15±3.11 85.17±3.75 83.21±3.68 0.320 
Week 4 
M (n=5) 91.84±1.60 91.08±0.79 90.30±1.26 90.23±1.11 0.069 
F (n=5) 88.69±3.66 87.35±3.26 87.75±3.32 87.04±2.77 0.798 
Values expressed as a mean ± standard deviation. Sex (male, M and female, F). *p-value 
less than 0.05, (p < 0.05) significant value. 
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Table 3. 6: Satellite group/ Food consumption (g) of rats in the sub-acute oral 
toxicity test 
Values expressed as a mean ± standard deviation. Sex (male, M and female, F). *p-value 
less than 0.05, (p < 0.05) significant value. 
 
Table 3. 7 (A and B): Water intake (ml) of rats in the acute and sub-acute oral 
toxicity tests 
A: Acute oral toxicity 
 Sex Control 
DC 300 
mg/kg 
DC 2000 
mg/kg 
P value 
Week 1 F (n=3) 102.56±1.27 104.03±1.78 104.34±2.12 0.157 
Week 2 F (n=3) 102.54±0.97 104.00±1.77 103.93±2.01 0.199 
B: Sub-acute oral toxicity 
 Sex Control 
DC 500 
mg/kg 
DC 1000 
mg/kg 
DC 1500 
mg/kg 
P 
value 
Week 1 
M (n=5) 123.18±1.39 128.09±2.34 128.03±1.91 127.40±2.11 0.000 
F (n=5) 122.39±0.42 125.51±0.50 125.48±0.37 125.46±0.53 0.000 
Week 2 
M (n=5) 124.06±1.17 127.31±1.50 127.44±1.48 127.97±1.85 0.000 
F (n=5) 123.33±0.55 125.68±0.45 125.99±0.41 125.87±0.41 0.000 
Week 3 
M (n=5) 125.23±0.96 127.99±1.33 127.98±1.80 127.86±1.69 0.004 
F (n=5) 124.44±0.49 127.29±0.66 127.12±0.61 127.16±0.77 0.000 
Week 4 
M (n=5) 125.89±0.78 128.29±1.95 128.54±1.22 128.34±1.61 0.007 
F (n=5) 124.99±0.50 127.28±0.86 127.36±0.63 127.56±0.61 0.000 
Values expressed as a mean ± standard deviation. Sex (male, M and female, F). *p-value 
less than 0.05, (p < 0.05) significant value. 
 
 
 Sex Control DC 1500 mg/kg P value 
Week 1 
M (n=5) 81.92±1.44 79.30±3.81 0.113 
F (n=5) 73.05±3.11 71.26±1.96 0.221 
Week 2 
M (n=5) 84.60±2.38 82.68±1.56 0.099 
F (n=5) 73.68±2.27 72.77±1.93 0.435 
Week 3 
M (n=5) 89.75±1.96 87.72±1.69 0.059 
F (n=5) 81.89±3.76 78.62±4.60 0.170 
Week 4 
M (n=5) 91.96±0.66 91.07±0.93 0.061 
F (n=5) 83.55±2.00 82.43±1.59 0.265 
Week 5 
M (n=5) 92.96±1.63 91.87±1.80 0.256 
F (n=5) 85.81±1.98 83.92±3.91 0.179 
Week 6 
M (n=5) 101.90±3.70 100.25±2.85 0.366 
F (n=5) 86.55±3.82 83.07±4.73 0.155 
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Table 3. 8: Tukey test of water intake (ml) of male and female rats in sub-acute oral 
toxicity test  
Values expressed as a mean ± Standard Error. n = 5. *p-value less than 0.05, (p < 0.05) 
significant value. 
 
Table 3. 9: Satellite group/ Water intake (ml) of rats in the sub-acute oral toxicity 
test  
 Sex Control DC 1500 mg/kg P value 
Week 1 
M 124.39±0.41 125.86±0.85 0.001 
F 121.24±1.79 123.59±1.96 0.037 
Week 2 
M 124.87±0.64 127.14±1.09 0.000 
F 123.33±1.85 125.03±0.76 0.044 
Week 3 
M 126.40±0.87 128.30±1.37 0.009 
F 123.80±0.95 125.80±1.00 0.002 
Week 4 
M 127.48±0.95 128.89±1.21 0.032 
F 124.53±1.10 125.94±1.01 0.027 
Week 5 
M 128.38±1.11 129.03±0.86 0.244 
F 125.68±0.99 125.97±0.68 0.538 
Week 6 
M 128.94±1.28 129.30±1.34 0.620 
F 126.48±0.90 126.58±0.68 0.825 
Values expressed as a mean ± standard deviation. n = 5. Sex (male, M and female, F). *p-
value less than 0.05, (p < 0.05) significant value. 
 
Dependent 
Variable 
(I) 
water 
intake 
(J)   water 
intake 
Mean 
Difference 
(I-J) in 
male rat 
P 
value 
Mean 
Difference 
(I-J) in 
female rat 
P value 
Week 1 Control  
DC 500 mg/kg -4.91*±1.05 0.001 -3.12*±0.24 0.000 
DC 1000 mg/kg -4.86*±1.05 0.001 -3.09*±0.24 0.000 
DC 1500 mg/kg -4.23*±1.05 0.003 -3.07*±0.24 0.000 
Week 2 Control  
DC 500 mg/kg -3.25*±0.81 0.003 -2.35*±0.25 0.000 
DC 1000 mg/kg -3.38*±0.81 0.002 -2.67*±0.25 0.000 
DC 1500 mg/kg -3.91*±0.81 0.000 -2.54*±0.25 0.000 
Week 3 Control  
DC 500 mg/kg -2.77*±0.79 0.009 -2.85*±0.34 0.000 
DC 1000 mg/kg -2.75*±0.79 0.010 -2.68*±0.34 0.000 
DC 1500 mg/kg -2.63*±0.79 0.014 -2.72*±0.34 0.000 
Week 4 Control  
DC 500 mg/kg -2.40*±0.78 0.025 -2.29*±0.35 0.000 
DC 1000 mg/kg -2.65*±0.78 0.012 -2.37*±0.35 0.000 
DC 1500 mg/kg -2.45*±0.78 0.021 -2.57*±0.35 0.000 
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3.4.3 Effect of DC Extract on Haematological Parameters in Acute and Sub-Acute 
Oral Toxicity Tests 
The haematological profile of control and DC treated groups summarised in Table 3.10 
(A and B). The results concluded that all haematological parameters such as haemoglobin 
(HGB) and total white blood cell count are within the normal range in both the control 
and the DC treated groups. In ANOVA test, there is no significant association between 
the groups in both acute and sub-acute toxicity tests as p > 0.05. In the satellite groups, 
there was no significant difference showed in both sexes with p > 0.05 (Table 3.11).  
Table 3. 10 (A and B): Haematological parameters of the rats in acute and sub-acute 
oral toxicity tests 
 
B: Sub-acute oral toxicity 
Haematological 
Parameters 
Sex Control 
DC 500 
mg/kg 
DC1000 
mg/kg 
DC1500 
mg/kg 
P 
value 
HGB (g/l) 
M (n=5) 149.40±6.47 148.80±5.40 150.40±12.72 156.80±12.91 0.575 
F (n=5) 156.40±5.81 148.80±7.82 150.60±3.85 153.40±5.81 0.243 
WBC (10^9/L) 
M (n=5) 9.22±1.03 9.30±2.45 9.46±1.33 9.56±3.67 0.996 
F (n=5) 6.86±0.59 7.40±1.15 7.38±0.93 7.82±0.81 0.431 
Neutrophil 
(10^9/L) 
M (n=5) 0.98±0.12 1.01±0.16 1.03±0.18 1.14±0.30 0.626 
F (n=5) 0.81±0.21 0.77±0.11 0.87±0.17 0.89±0.14 0.646 
Lymphocyte 
(10^9/L) 
M (n=5) 9.66±2.12 9.64±1.67 10.39±1.99 10.77±2.08 0.753 
F (n=5) 8.22±1.07 8.44±1.22 8.67±1.00 9.20±1.14 0.564 
 
A: Acute oral toxicity 
Haematological 
Parameters 
Sex Control DC 300 mg/kg DC2000 mg/kg P value 
HGB (g/l) F(n=3) 153.00±10.00 145.50±9.50 149.33±17.95 0.789 
WBC (10^9/L) F(n=3) 6.83±0.23 7.77±0.38 8.05±0.75 0.057 
Neutrophil 
(10^9/L) 
F(n=3) 0.55±0.13 0.56±0.07 0.58±0.14 0.961 
Lymphocyte 
(10^9/L) 
F(n=3) 6.39±0.87 6.72±1.15 7.29±0.52 0.498 
Monocyte 
(10^9/L) 
F(n=3) 0.14±0.03 0.15±0.02 0.18±0.3 0.228 
Eosinophil 
(10^9/L) 
F(n=3) 0.08±0.02 0.10±0.02 0.11±0.02 0.125 
Basophil 
(10^9/L) 
F(n=3) 0.02±0.01 0.03±0.02 0.03±0.02 0.531 
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Values expressed as a mean ± standard deviation. Sex (male, M and female, F). *p-value 
less than 0.05, (p < 0.05) significant value. 
 
Table 3. 11: Haematological parameters in sub-acute oral toxicity test in Satellite 
group 
 Sex Control DC 1500 mg/kg P value 
HGB (g/l) 
M 152.40±6.80 153.20±7.46 0.863 
F 155.00±6.82 154.80±5.97 0.961 
WBC (10^9/L) 
M 9.30±1.36 10.76±1.23 0.112 
F 6.70±0.72 6.74±0.60 0.926 
Neutrophil (10^9/L) 
M 1.08±0.13 1.31±0.23 0.084 
F  1.25±0.11 1.33±0.11 0.295 
Lymphocyte 
(10^9/L) 
M 9.77±1.07 11.25±1.41 0.098 
F 9.29±0.95 9.31±0.70 0.977 
Monocyte (10^9/L) 
M 0.21±0.06 0.23±0.07 0.649 
F 0.22±0.05 0.23±0.03 0.773 
Eosinophil (10^9/L) 
M 0.10±0.01 0.10±0.02 0.856 
F 0.09±0.02 0.10±0.03 0.596 
Basophil (10^9/L) 
M 0.03±0.02 0.04±0.03 0.636 
F 0.02±0.01 0.03±0.01 0.545 
Values expressed as a mean ± standard deviation. n = 5. Sex (male, M and female, F). *p-
value less than 0.05, (p < 0.05) significant value. 
 
3.4.4 Effect of DC Extract on Biochemical Parameters in Acute and Sub-Acute 
Oral Toxicity Tests 
The data on biochemical parameters (liver and renal functions) in control and DC 
treated groups of the acute and sub-acute oral toxicity tests presented in Table 3.12 and 
Table 3.13, respectively. There was no significant difference shown in the biochemical 
parameters between the groups of acute and sub-acute oral toxicity tests in both sexes 
(male and female rats) as well as in the satellite groups as p > 0.05 (Table 3.14). 
 
Table 3.10 - B continued  
Monocyte 
(10^9/L) 
M (n=5) 0.16±0.02 0.15±0.02 0.17±0.04 0.19±0.04 0.411 
F (n=5) 0.17±0.03 0.16±0.03 0.18±0.02 0.18±0.03 0.623 
Eosinophil 
(10^9/L) 
M (n=5) 0.08±0.02 0.09±0.02 0.10±0.02 0.10±0.03 0.388 
F (n=5) 0.08±0.01 0.09±0.02 0.07±0.03 0.10±0.02 0.215 
Basophil 
(10^9/L) 
M (n=5) 0.06±0.2 0.04±0.03 0.04±0.03 0.04±0.03 0.537 
F (n=5) 0.02±0.02 0.03±0.02 0.03±0.02 0.04±0.02 0.397 
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Table 3. 12: Biochemical parameters of the rats in acute oral toxicity test  
Values expressed as a mean ± standard deviation, n = 3. *p-value less than 0.05, (p < 
0.05) significant value. 
 
Table 3. 13: Biochemical parameters of the rats in sub-acute oral toxicity test  
Biochemical 
parameters 
Groups 
P 
value Sex Control DC 500 mg/kg 
DC 1000 
mg/kg 
DC 1500 
mg/kg 
Urea (mmol/L) 
M 3.76±0.59 3.92±0.34 4.14±0.38 4.18±0.51 0.466 
F 3.90±0.74 4.06±0.44 3.97±0.69 4.16±1.24 0.963 
Creatinine 
(umol/L) 
M 24.20±4.15 24.00±2.55 23.60±6.91 27.20±4.15 0.615 
F 28.60±3.05 28.40±2.70 27.40±2.70 28.80±1.92 0.839 
Albumin (g/L) 
M 35.00±2.24 34.60±1.14 36.20±5.26 34.60±1.67 0.817 
F 35.00±1.58 34.60±2.40 36.20±2.17 34.00±2.55 0.470 
Globulin (g/L) 
M 20.60±1.14 21.00±1.58 21.20±1.48 21.20±1.30 0.890 
F 22.40±1.14 21.80±1.10 22.80±1.30 21.20±1.48 0.245 
Total bilirubin 
(umol/L) 
M 1.00±0.00 1.00±0.00 1.00±0.00 1.00±0.00 - 
F 2.00±0.00 2.00±0.00 2.00±0.00 2.00±0.00 - 
Conjugate 
bilirubin 
(umol/L) 
M 1.40±1.14 1.00±0.00 0.40±0.55 1.00±1.22 0.379 
F 1.00±0.00 1.00±0.00 1.00±0.00 1.00±0.00 - 
ALP (U/L) 
M 216.20±16.99 218.40±12.70 222.40±18.51 236.40±12.74 0.203 
F 204.20±14.64 210.80±29.52 209.60±23.70 197.60±16.33 0.769 
ALT (U/L) 
M 29.60±3.29 29.40±1.52 29.60±2.30 32.00±2.83 0.356 
F 23.40±3.21 23.60±3.05 25.40±3.36 26.80±1.64 0.243 
AST (U/L) 
M 104.80±6.69 106.00±3.94 105.40±5.55 109.00±4.95 0.623 
F 99.60±7.40 103.00±2.30 103.60±3.44 104.60±2.41 0.320 
Values expressed as a mean ± standard deviation, n = 5. Sex (male, M and female, F). *p-
value less than 0.05, (p < 0.05) significant value.  
 
 
 
 
Biochemical parameters Sex 
Groups 
P value 
Control 
DC 300 
mg/kg 
DC 2000 
mg/kg 
Urea (mmol/L) F 3.80±0.53 4.00±0.62 4.13±0.29 0.727 
Creatinine (umol/L) F 32.67±1.53 32.00±4.58 31.67±1.53 0.920 
Albumin (g/L) F 40.67±4.04 37.67±3.51 36.67±1.53 0.350 
Globulin (g/L) F 24.00±1.00 22.33±2.08 20.00±2.65 0.128 
Total bilirubin (umol/L) F 2.00±0.00 1.00±0.00 1.00±0.00 - 
Conjugate bilirubin (umol/L) F 1.00±0.00 1.00±0.00 1.00±0.00 - 
ALP (U/L) F 166.33±4.73 164.67±6.03 177.33±7.02 0.081 
ALT (U/L) F 24.67±1.53 25.67±1.15 26.67±1.53 0.296 
AST (U/L) F 96.00±9.17 99.67±7.57 107.33±3.06 0.216 
64
Table 3. 14: Biochemical parameters of the rats in satellite group for subacute oral 
toxicity test  
Values expressed as a mean ± standard deviation, n = 5. Sex (male, M and female, F). *p-
value less than 0.05, (p < 0.05) significant value. 
 
3.4.5 Histopathological Observation  
A histopathological study carried to confirm biochemical findings and to identify any 
structural changes. Light microscopic examination of the vital organs including liver, 
kidney, heart, lung and spleen of the rats in all the DC treated and control groups for acute 
oral toxicity (Figure 3.5), and sub-acute oral toxicity (Figure 3.6) did not reveal any gross 
pathological lesions.  
The photomicrographs of the liver and kidney of the control and DC treated groups as 
well as of satellite group, both male and female, showed normal morphological 
architecture. Under microscopic examination, the liver of DC treated animals showed 
normal cellular architecture and binucleation and was without any distortions similar to 
the control groups. Furthermore, signs of injury, necrosis, congestion, fatty acid 
accumulation, or haemorrhagic regions around the central vein or sinusoids of the liver 
Biochemical 
parameters 
Satellite group 
P value 
Sex Control DC 1500 mg/kg 
Urea (mmol/L) 
M 3.78±0.34 3.92±0.48 0.608 
F 3.96±0.70 4.06±0.17 0.765 
Creatinine (umol/L) 
M 25..00±3.87 26.40±3.78 0.579 
F 29.40±3.05 27.20±3.96 0.354 
Albumin (g/L) 
M 35.20±1.30 34.40±1.67 0.423 
F 34.20±2.77 32.40±3.36 0.382 
Globulin (g/L) 
M 20.20±0.84 19.40±1.34 0.290 
F 22.00±1.58 21.20±1.30 0.408 
Total bilirubin 
(umol/L) 
M 1.00±0.00 1.00±0.00 - 
F 2.00±0.00 2.00±0.00 - 
Conjugate bilirubin 
(umol/L) 
M 1.00±0.00 1.00±0.00 - 
F 1.00±0.00 1.00±0.00 - 
ALP (U/L) 
M 223.60±29.98 226.20±28.35 0.891 
F 184.40±29.11 190.40±29.21 0.753 
ALT (U/L) 
M 31.00±3.39 30.00±3.81 0.673 
F 25.20±1.79 25.60±2.07 0.752 
AST (U/L) 
M 107.00±6.04 111.40±5.94 0.279 
F 103.40±3.29 105.00±2.74 0.427 
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not observed. The hepatocytes arranged in cords and clearly visible. The cross-section of 
the liver showed no lyses in the blood cells, or infiltration of neutrophil, lymphocyte, or 
macrophage in the acute oral toxicity group and the sub-acute oral toxicity. For the 
kidneys, histologically there was no morphological change for all DC treated groups. The 
appearance of the glomerular architecture showed normal similar to the control groups. 
The glomeruli, distal, and proximal tubules in the kidney appeared normal in both male 
and female rats. In addition, there was no interstitial and intraglomerular congestion or 
tubular atrophies. All the nephron cells showed normal and clearly visible nucleoli with 
no degeneration, bleeding, or necrosis infiltration in acute oral toxicity group as well as 
in the sub-acute oral toxicity. In both the control and DC treated female and male rats, the 
heart shows normal cardiac muscle fibers and lungs show a normal alveolar structure with 
no treatment-related inflammatory response in acute oral toxicity group as well as in the 
sub-acute oral toxicity. Similarly, normal structure and histology of the spleen also 
observed in all the rats of acute and sub-acute oral toxicity tests. There is mild congestion 
seen in the lung, liver, and kidney of the control and DC treated groups of both sexes 
which were incidental or spontaneous with no relation to DC resin methanol extract 
treatment. 
Thus, the histopathological evaluations of the selected organs did not reveal any 
morphological abnormalities that could be attributed to the oral administration of DC 
resin methanol extract to the rats.
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3.5 Discussion 
Herbal medicines have acquired greater importance as a substitute for conventional 
therapy (Ekor, 2014; Ramaswamy et al., 2012). As the use of medicinal plants increases, 
screening plant products to assess and evaluate the toxic characteristics of a natural 
product extract, fraction, or compound consider an initial step (Yuet Ping et al., 2013). 
During the evaluation of the toxic characteristics of medicinal plants, an initial 
assessment of toxic manifestations is one of the initial screening experiments performed 
with all compounds. In addition, Data from the acute toxicity study may serve as the basis 
for classification and labelling of the test material (Ukwuani et al., 2012). Thus, the 
current study was assumed to evaluate and focus on the acute and sub-acute toxicity of 
DC resin methanol extract in an animal model. 
The oral route administration is the most useful and normally used one while doing 
toxicity study. The absorption may be slow; however, this methodology expenses less 
and is painless to the animals. As the crude extracts administered orally, the animals need 
to fast before administering the material because food and other chemicals within the 
digestive system may affect the reaction(s) of the tested materials. All the procedures 
were performed based on the appropriate OECD guideline (Kumar & Lalitha, 2013). 
Test method with a starting dose of 300 mg/kg body weight primarily used in situations 
where the investigator has no information indicating that the test material is likely to be 
toxic (OECD, 2001). In this study, the rats in control and DC treated groups administrated 
with the vehicle and crude extracts, respectively. From the experiment performed, the 
starting dose of 300 mg/kg body weight has revealed no mortality in the experimental 
animals. Thus, the next higher dose of 2000 mg/kg body weight selected as described in 
the OECD Guidelines 423.  The rats monitored daily until the last day of the experiment 
(day 14th) for any toxic signs and mortality. The clinical symptom is one amongst the 
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most important observations to indicate the toxicity effects on organs within the treated 
groups (Jothy et al., 2011). During the 14 days of acute toxicity assessment period, all 
rats orally administrated with DC extract at a single dose of 300 mg/kg and 2000 mg/kg 
showed no obvious signs of distress, and there were no noticeable symptoms of either 
toxicity or deaths. All of the rats showed no significant changes in wellness parameters. 
Physical appearance features such as skin, fur, eyes, mucous membrane, salivation, 
behavioural pattern, the sleep of the animals in control and DC treated groups (300 mg 
and 2000 mg) of DC extract were found to be normal. Lethargy, tremors, diarrhoea and 
coma did not occur in any of the animals. Moreover, the body weight of the rats showed 
an increase in both control and DC treated groups with no significant difference seen 
(Table 3.1 A); this indicates that the DC extract has no adverse effect on the growth of 
the animals. 
This study estimated that DC extract does not cause acute toxicity effects and no rat 
has died. Based on OECD guidelines 423 (Annex 2), the results of this test allow the 
substance to be ranked and classified according to the Globally Harmonised System of 
Classification and Labelling of Chemicals. Thus, the DC extract can be classified as 
category 5 with low acute toxicity hazard, which was the lowest toxicity class (OECD, 
2001). Therefore, it can be concluded that DC extract is tolerated up to 2000 mg/kg body 
weight when administered at a single dose. In a like manner, a study performed by 
Ramaswamy et al. (2012) using Nuna Kadugu (a Siddha medicine prepared from leaves 
and fruits of Morinda Pubescens) revealed that Nuna Kadugu can be classified under 
category-5 when administered at single dose 2000 mg/kg in accordance with Globally 
Harmonised System of Classification and Labelling of Chemicals, and this provides a 
direct relevance for protecting human and animal health.  
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Acute toxicity information is of limited clinical application because cumulative toxic 
effects do occur even at very low doses. Consequently, multiple dose studies are typically 
useful in evaluating the safety profile of phytomedicines. Therefore, sub-acute (Repeated 
dose 28-day oral toxicity) test has been used. Body weight changes are an indicator of 
adverse side effects (Chitra et al., 2015), and lose more than 20% of the animal body 
weight is regarded as critical and has been defined as one of the humane endpoints in 
several international guidelines (CCAC, 1998; OECD, 2000). In this study, all rats in the 
vehicle control and DC treated groups were gaining weight; however, there were no 
significant changes in body weight gain between the groups in a sub-acute oral test at 
each week (Table 1 B). Moreover, no significant change detected between the groups in 
both acute and sub-acute oral toxicity test regarding the ROW (Table 3 A and B). In 
satellite groups, nothing abnormal detected, and no significant difference was shown in 
body weight gain (Table 3.2) and ROW (Table 3.4).  
Sub-acute oral toxicity test was conducted to evaluate the adverse effects of test 
medicinal plant DC extract and was carried out to provide information about the possible 
health threats that probable to arise from sub-acute exposure over a period of time, the 
possibilities of cumulative effects, and an estimate of the dose at which there is no 
observed adverse effect. Evaluation of safety margin between different dose level that 
produces the therapeutic effect and that which produces the adverse effects is necessary. 
Evaluation of safety is exactly to provide benefit to risk assessment. Animal experimental 
model is the only method that can assess this matter (Prajapati et al., 2006). Determination 
of food consumption is an important to study the safety of a product with therapeutic 
purpose as proper intake of nutrients is essential to the physiological status of the animal 
and give a good impression of the appropriate response to the treatment (Sathish et al., 
2012).  
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For food consumption, no significant changes observed in all groups (vehicle and DC 
extract treated groups) in both acute and subacute oral toxicity tests and this reveals that 
it did not adversely affect the basic metabolic processes of the experimental animals. On 
the other hand, water intake showed more in the DC extract treated groups than the 
control, with a significant difference showed in sub-acute oral toxicity test (Table 3.8) 
and satellite group (Table 3.9) for both male and female rats during the administration 
period. This result could be referred to that DC resin extract can produce vasodilatation 
(hypotension) due to relaxation of smooth muscles of blood vessels (Al-Awthan et al., 
2010) which in turn stimulate thirst and increase water intake (Thunhorst et al., 2010).   
Haematological and biochemistry data play a major role in determining the toxicity 
induced by drugs (Petterino & Argentino-Storino, 2006). Blood parameters analysis is 
appropriate to risk evaluation as the haematological system has a higher prognostic value 
for toxicity (Olson et al., 2000). Blood serves as the main medium of transport for many 
drugs and xenobiotics in the body and for that reason components of the blood exposed 
to substantial concentrations of toxic compounds. Damage to and destruction of the blood 
cells are inimical to normal functioning of the body both in humans and animals (Abotsi 
et al., 2011). In the present study, the haematological parameters data indicated that DC 
extract did not affect blood cells production as there was no significant difference between 
the groups in acute and sub-acute oral toxicity tests (Table 3.10 A and B). In the satellite 
group, no significant difference showed between the two groups (Table 3.11). The change 
in haematological parameters was within the normal range as showed elsewhere (Abiola 
& Said, 2014; Petterino & Argentino-Storino, 2006).  
Evaluation of Kidney and Liver function is important in the assessment toxicity of 
plant extracts as both of them are necessary for the survival of an organism  (Olorunnisola 
et al., 2012). In animal model toxicity studies, the serum level of creatinine remains the 
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most widely used laboratory test to estimate renal function. It kept within a relatively 
stable range as daily production and renal excretion are continuous in healthy mammals 
(Yilmaz et al., 2007). In the present study, for kidney function test, two serum renal 
biochemical parameters, namely urea and creatinine were analysed as previously 
mentioned (P'ng et al., 2013). There were no significant changes observed in urea and 
creatinine levels between the control and all doses of DC extract groups in both acute and 
sub-acute oral toxicity tests.  
The enzymatic activity of the liver such as alanine aminotransferase (ALT), aspartate 
aminotransferase (AST) and alkaline phosphatase (ALP) was studied to evaluate liver 
malfunctions. Liver enzymes levels are usually raised in acute hepatoxicity but tend to 
decrease with prolonged intoxication due to damage to the liver (Imafidon & Okunrobo, 
2012). In the present study, there were no significant differences shown in the 
biochemical analysis in acute and sub-acute oral toxicity test. The level was within normal 
expected range for the rat species used in this study. Bilirubin formed from the breakdown 
of haemoglobin in the liver, spleen, and bone marrow. An increase in tissue or serum 
bilirubin level occurs through increased breakdown of RBC (haemolysis) or in the case 
of hepatitis or bile duct obstruction (liver damage) (Chitra et al., 2015). Reduction in 
serum albumin level may suggest infection or continuous loss of albumin (Yakubu et al., 
2003). Thus, the insignificant change in serum concentration of albumin and globulin in 
control and DC treated groups at all doses used in this study proposed that DC extracts 
not do damage in hepatocellular or secretory functions of the liver which in turn indicated 
non-adverse effects of the tested material. For biochemical analysis, in the satellite group, 
there was no significant difference has been noted which concluded that the tested 
material (DC extract) would not produce the delayed onset of toxicity. 
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The assessment of histopathological alterations in organs considered as a basic test in 
the safety assessment of tested materials (Greaves, 2012). No abnormality observed on 
gross or histopathological evaluations of organs examined in this study. Histopathological 
findings of liver, kidney, heart, lung and spleen were normal in all animals that given 
different doses of DC resin methanol extract in both acute and sub-acute oral toxicity 
tests. 
3.6 Conclusions 
In conclusion, according to Globally Harmonised Classification System, DC resin 
methanol extract can be classified as Category 5. In addition, we may conclude 
that DC resin methanol extract is well tolerated up to the dose of 1500 mg/kg body weight 
administered daily for 28 days. DC resin methanol extract did not cause any lethality or 
produce any serum chemical alteration or important histopathological signs. The present 
investigation demonstrates, at least in part, the safety of DC resin methanol extract 
suggesting its promising potential for pharmaceutical uses.  
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CHAPTER 4: CHEMOPREVENTIVE AND CHEMOTHERAPEUTIC 
ACTIVITIES OF DRACAENA CINNABARI EXTRACT IN VIVO 
4.1 Introduction    
Oral squamous cell carcinoma (OSCC) is one of the most common human cancers in 
the world. Almost 60–70% of oral-cavity carcinoma cases are diagnosed only after the 
tumours have become locally progressive (Tang et al., 2014). The World Health 
Organization (WHO) stated that the oral cavity cancer is having one of the highest 
mortality ratios of all malignancies because of extensive local invasion and distant 
metastasis even at initial diagnosis (Koh et al., 2011). Importantly, the mortality ratios do 
not take into account severe morbidity arising from the facial defacement and 
aerodigestive dysfunction that associated with surgery/radiotherapy (Wali et al., 2012). 
Unfortunately, unacceptable results always associated with the commonly used cancer 
chemotherapy, as the therapy is detrimental to patient health by making patients more 
vulnerable to other diseases and often cause death by debilitating the immune system of 
the patient body (Carelle et al., 2002). In addition, the drug-resistant cancer cells that 
remain alive after chemotherapy are responsible for the recurrence of tumours and the 
poor prognosis for patients. The occurrence of drug resistance leads to the failure of 
tumour treatment (Gottesman, 2002). Therefore, prevention of this malignancy represents 
a major healthcare imperative (Wali et al., 2012).  
In a period of 2006 to 2012, United states collected data for patients with oral or 
pharyngeal cancer, and they demonstrate that a 5-year survival rate was 64% which is 
more than the rate reported in 1975-1977 as it was 52.5% (Howlader N et al., 2016).  A 
relatively improvement in 5-year survival of patients with oral or pharyngeal cancer over 
more than four decades, propose that presence of primary prevention efforts to decrease 
exposure to major risk factors (e.g., tobacco, alcohol and HPV) and secondary prevention 
efforts to reduce mortality from this disease that involving cancer chemoprevention are 
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necessary (McCormick et al., 2015). Cancer chemoprevention was first well defined by 
Sporn (1976). This term refers to the use of natural, synthetic, or biologic chemical agents 
in an attempt to reverse, suppress, or prevent carcinogenic progression. A material of 
natural or synthetic origin considered as chemopreventive agents. The difference between 
these agents and other drugs (which do not prevent disease) is by reducing the incidence 
of diseases such as cancer before clinical symptoms have to take place (Tanaka et al., 
2011). It can suppress the elevation of cancer and prevent the transformation of 
premalignant cells by modifying differentiation (Schwartz, 2000).  
Dracaena cinnabari (DC) (Dragon’s Blood Tree) is an endemic species, and the most 
iconic plant of the Socotra Island belongs to the Republic of Yemen (Hubálková et al., 
2015). The resin of DC has been reported to possess a wide spectrum of therapeutic 
properties, including antimicrobial activity (Mothana & Lindequist, 2005) and 
antioxidant activity (Gupta et al., 2014). Recently, the methanol extract of the DC resin 
was studied by Alabsi et al. (2016), and the cytotoxic effects were observed in a panel of 
OSCC cell lines and were most pronounced in H400 with an IC50 value of 5.9 μg/ml. DC 
resin methanol extract inhibited H400 cells growth in a time-dependent manner, and the 
mode of cell death that induced was via apoptosis (Alabsi et al., 2016). Therefore, in the 
present study, the activity of DC resin methanol extract that daily administered orally in 
4NQO induced oral cancer for a short interval to decrease the oral tumour burden (tumour 
size) and as inhibitors of the induction of OSCC was evaluated.  
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4.2 Materials and Methods 
4.2.1 Animals Studies and Tumour Induction 
Prior to the beginning of in vivo study, animal protocols were reviewed and approved 
by the Institutional Animal Care and Use Committee (IACUC), Faculty of Medicine, 
University of Malaya, Malaysia (Ethics No. 2014-02-14/OBBS/R/NAA). Humane 
endpoint of all rats was considered following specific criteria in the present study as 
described elsewhere (McCormick et al., 2015) which included: loss of > 15% of body 
weight in one week; steady but constant decrease in body weight; sufficient signals that 
a study rat may not survive until the next scheduled observation; and protracted unhealthy 
appearance such as rough coat or hunched posture. 
Male Sprague Dawley (SD) rats (6-8 weeks) weigh between (160-200 g) were housed 
in a climate controlled environment (24 Co, with a 12 h light/dark cycle). They were 
acclimatised to laboratory conditions for 7 days prior to the experiments. 
Rats were provided ad libitum rat chow and drinking water supplemented with 4-
nitroquinoline 1-oxide (4NQO) (Sigma Aldrich) to a final concentration of 0.02 g/l (20 
ppm) to induce hyperplastic and neoplastic lesions in the tongue of the rats as described 
by Tanaka and Ishigamori (2011). Freshly made 4NQO supplemented water was 
dispensed to rats in bottles wrapped with foil to preclude possible photodegradation of 
the carcinogen. Animals received drinking water containing 4NQO for 8 weeks that were 
changed at two- to three-day intervals throughout the administration period.  
 
4.2.2 Dracaena cinnabari (DC) Resin Extract Preparation and Dose Selection  
Preparation of DC resin methanol extract was done as mentioned previously in section 
(3.2.1. Preparation of Dracaena cinnabari (DC) Resin Extract).  
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The dose levels of DC extract used in chemopreventive and chemotherapeutic studies 
were selected based on the results of the acute and sub-acute oral toxicity studies that 
performed in our laboratory. The result indicated that DC resin methanol extract is well 
tolerated up to the dose of 1500 mg/kg body weight administered daily for 28 days and 
did not produce any toxic signs or symptoms. The aims of oral toxicity studies were to 
identify levels of DC resin methanol extract that induced no mortality, body weight 
suppression, or other evidence of limiting toxicity (McCormick et al., 2015). On this 
basis, in this study, doses of DC resin methanol extract lesser than 1500 mg/kg such as 
100 mg/kg (low), 500 mg/kg (medium) and 1000 mg/kg (high) body weight were chosen 
for the present study and administered orally once per day for 10 consecutive weeks.  
4.2.3 Cisplatin Preparation  
Cisplatin 50 mg Freeze-dried yellowish crystalline powder, soluble in physiological 
saline solution, purchased from (Axon scientific sdn Bhd) was used. Preparation: 50 mg 
of the powder was diluted in 50 ml of saline solution 0.9 %, making up a final 
concentration of 1 mg/ml (Freitas et al., 2009). In clinical practice, administration of 
Cisplatin 100 mg/m2 once every 3 weeks parallel with radiotherapy is a commonly 
recommended schedule for head and neck SCC treatment. Chemotherapy protocol 
schedule was achieved by administration of Cisplatin in week 1, 4 and 7 (Cisplatin 100 
mg/m2) over a period of 2 to 3 days every 3 weekly chemotherapy (Geeta et al., 2006; 
Tsan et al., 2012). In the present study, the dose of Cisplatin was decided based on the 
clinical doses converted into animal doses using surface area and weight factors. 
Therefore, Cisplatin 3 mg/kg body weight was administered in week 9, 12 and 15 over a 
period of 2 to 3 days every 3 weeks.  
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4.2.4 Chemoprevention Study  
This study was designed to evaluate the effects of DC resin methanol extract during 
the initiation phase of 4NQO-induced oral carcinogenesis in male SD rats. 
The SD rats were divided randomly into 6 groups of seven rats per each. Group I was 
provided with normal reverse osmosis (RO) water ad libitum and served as normal control 
group and kept in the same conditions. These rats were left untreated but weighed every 
week to compare their body weights and other parameters with those of the experimental 
rats in which 4NQO was administered. Group II was received only 4NQO supplemented 
water ad libitum and served as induced cancer or positive control. Group III was received 
4NQO supplemented water ad libitum and given a vehicle (10% DMSO) orally. Groups 
IV, V and VI were orally given DC extract in different concentrations 100, 500 and 1000 
mg/kg respectively, starting one week before exposure to the carcinogen (4NQO) until 
one week after the stop of the carcinogen exposure (total of 10 consecutive weeks) 
parallel with 4NQO supplemented water ad libitum which was administered for 8 
consecutive weeks as previously described (Tanaka et al., 1998; Zhang et al., 2013). Then, 
animals from groups II-VI were switched to RO water and continued on this water until 
study termination after week 22 (Figure 4.1). Oral administration to the rats was done by 
gastric intubation using force-feeding needle size 18G (Harvard Apparatus, INC). 
Figure 4. 1: Diagrammatic representation of experimental protocol in 
chemopreventive study 
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4.2.5 Chemotherapeutic Study 
This study was designed to evaluate the effects of DC resin methanol extract during 
the post-initiation phase of 4NQO-induced oral carcinogenesis in male SD rats. 
A total of 70 male SD rats were used in this study (10 groups of seven rats per each).  
Group 1 was provided with RO water ad libitum and served as normal control group. The 
rats in this group were left untreated but weighed every week to compare their body 
weights and other parameters with those of the experimental rats in which 4NQO was 
administered. The remaining 63 male SD rats were given 4NQO (20 ppm) for 8 weeks in 
their drinking water ad libitum; after 8 weeks, rats received drinking water without added 
4NQO. Then, the rats were randomized into nine groups of 7 rats per each. From 9-22 
weeks, Group 2 served as induced cancer group. Group 3 was given 10% DMSO (orally) 
and served as a vehicle. In group 4, Cisplatin 3 mg/kg (axon scientific sdn Bhd) (a widely 
used chemotherapeutic agent for oral cancer) was administered I.P to the rats. DC extract 
100 mg/kg, DC extract 500 mg/kg and DC extract 1000 mg/kg were administered orally 
to group 5, 6 and 7 respectively. Cisplatin 3 mg/kg and DC extract at doses of 100, 500 
and 1000 mg/kg were given as a combination to group 8, 9 and 10, respectively, (i.e. DC 
extract was administered orally 2 h before the Cisplatin 3 mg/kg I.P). The Cisplatin 3 
mg/kg was administered once every three weeks, whereas the DC extract was given 
orally/day. Oral administration to the rats was done by gastric intubation using force-
feeding needle size 18G (Harvard Apparatus, INC) starting 1 week after cessation of 
4NQO exposure and maintained on this treatment for 10 consecutive weeks as described 
elsewhere (Tanaka et al., 1998; Zhang et al., 2013). The experiment was terminated after 
week 22 (Figure 4.2). All animals were sacrificed to assess the incidences of pre-
neoplastic and neoplastic lesions in the tongue. 
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Figure 4. 2: Diagrammatic representation of experimental protocol in 
chemotherapeutic study 
 
For both studies, cage-side observations were done at least twice daily to assess animal 
health and identify possible toxicities resulting from administration of carcinogen 
(4NQO). The body weights of the rats were recorded weekly throughout the study. Body 
weight is a key metric in oral cancer chemoprevention studies in the 4NQO model since 
body weight loss provides a useful indication of the clinical progression of OSCC (Tanaka 
& Ishigamori, 2011). Hand-held observations were performed weekly to monitor the 
presence of oral lesions. 
The food consumption and water intake were recorded daily. The body weight gain 
was calculated by the difference between the body weight at the end of each week and 
the body weight at the beginning of the study (Study Day 0) (Barcessat et al., 2014). 
The surviving rats were generally anaesthetized by intraperitoneal injection of 80 
mg/kg of ketamine 100 mg/ml + 7 mg/kg of xylazine 100 mg/ml (Troy laboratories PTY. 
Limited, Smithfield, Australia). Blood sample (5 ml) by cardiac puncture was collected 
using a disposable syringe for analysing the haematological and biochemical parameters 
as described in section (3.2.5 Haematology and serum biochemistry), then the rats were 
euthanised by cervical dislocation. All rats (whether found dead, euthanised in extremis, 
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or euthanised at study termination) received a limited gross necropsy that focused on the 
tongue and oral cavity. The tongue from each rat was carefully excised, all gross lesions 
were recorded, and the tongue was bisected longitudinally. At necropsy, one-half of each 
tongue tissue was fixed in 10% buffered formalin, routinely processed, embedded in 
paraffin wax and subjected to histological processing and immunohistochemical analysis. 
The other half was stored in RNAlater solution (Qiagen) to ensure the stability of RNA 
and then transferred and frozen at -80°C for use in molecular analyses.  
 
4.2.6 Estimation of Tumour Volume (Size) 
The dissected tongues were inspected for the presence of overt tumours. The tumour 
volume (size) was measured according to the formula (π/6 × width × length × height) as 
mentioned elsewhere (Tomayko & Reynolds, 1989; Wali et al., 2012). Detected lesions 
were having different sizes ranging from small well-defined white papules to extensive 
exophytic formations. Histopathological evaluations for the presence of epithelial 
changes in the tongue tissue were performed after staining with haematoxylin and eosin. 
 
4.2.7 Histopathological Evaluation (H&E) on the Incidence of Pre-Neoplasms and 
Neoplasms in the Tongue of the Rats 
4.2.7.1 Tissue Preparation  
 Fixation  
The tongue tissue specimen fixed in 10 % natural buffer formalin (NBF). The half of 
the tongue placed in a container containing 10% NBF and fixed for 24 hours. The ratio 
of tissue to fixative volume was 1:10.  
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 Processing for blocking 
The block processing was carried out using a Leica TP 1020 tissue processor. It is an 
automatic machine where the specimen underwent a long cycle schedule. The samples 
were treated through twelve stations with series of graded concentrations of ethanol (70 
%, 95 %, 100 %, 100 % and 100 %) and xylene, and then Paraplast wax (56°C melting 
point). Finally, the samples were embedded in molten (56°C) paraffin wax. The blocks 
were stored in airtight container for future use. 
 
 Sectioning  
A microtome (Leica, Germany), with disposable microtome blade (Leica 818 high 
profile disposable microtome blade) was used for sectioning to get a ribbon section. Four 
µm thin sections were floated on a water bath (45 ᵒC) before being mounted on the glass 
slide, MUTO. Then, forceps was used to put a section on a glass slide and followed by a 
drop of 20% Alcohol. 
 
 Staining  
Fixed sections were placed in fresh xylene bath and incubated at room temperature for 
5 minutes. The previous step was repeated with fresh xylene for 4 minutes. Excess liquid 
was drained, and the slides were placed in a fresh absolute ethyl alcohol bath, 95 %, 70 
% alcohol bath for 3 minutes and then running water bath for 3 minutes at room 
temperature. Sections were stained with Harris’ haematoxylin working solution for 5 
minutes. Then, it washed in slow running tap water until excess blue colour went off (3 
minutes). Sections were differentiated by dipping in 0.5% acid alcohol (count from 1 to 
10) and washed well in running tap water for 3 minutes.  Sections were dipped in 2% 
sodium acetate (4 dips) and washed well in running tap water (3 minutes). The slides were 
placed in 80 % alcohol bath for 1 minute, and sections were stained with Eosin working 
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solution for 2-3 minutes. The slides were placed in 95 %, 95 % alcohol bath for four dips 
then 100% twice for 2 minutes. The sections were placed in xylene I, II and III bath for 3 
minutes and finally, the slides mounted and coverslipped with mounting medium and 
checked under the microscope. H&E stain slides were evaluated for the incidence of pre-
neoplastic and neoplastic lesions in the tongue.  
The histopathological evaluation in this study was performed using a light microscope 
(Nikon E50i). An experienced pathologist who was unaware of the experimental groups 
to which each section belonged conducted the analysis. The tongue sections were 
analysed and graded as normal, hyperplasia, dysplasia and squamous cell carcinoma per 
animal as described by Ribeiro et al. (2007) and El-Rouby (2011). The dysplastic lesion 
was further graded as mild, moderate and severe according to the 2005 WHO 
Classification (Barnes et al., 2005).  
 
4.2.8 Histopathological Evaluation of Oral Cancer Metastasis  
To illustrate and examine the inhibitory effect of DC extract and/or in combination 
with Cisplatin on metastasis as well as Cisplatin group, we performed chemotherapy in a 
4NQO-induce rat model and compared the inhibition of metastasis to the cervical lymph 
nodes histologically. 
In the current study, cervical lymph nodes of all rats in the chemotherapeutic study 
were excised at the end of the study (after week 22). All samples were fixed in 10% NBF, 
embedded in paraffin and serial sections were cut and stained with haematoxylin and 
eosin as described previously in section (4.2.7 Histopathological Evaluation). The slides 
were stained and examined in detail to identify foci of metastasis.  
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4.2.9 Immunohistochemical (IHC) Analysis  
The tongue tissue sections were subjected to IHC analysis to determine the effect of 
DC 1000 mg/kg on the expression of the following tumour marker; Cyclin D1, Ki-67, 
Bcl-2, p53, β-catenin and E-cadherin.  
The effect of DC extracts was in a dose-dependant manner as presented in the 
histopathological part of this study. The highest dosage of DC extract showed the best 
inhibition effect on the 4NQO-induced oral cancer in rats for both the chemopreventive 
and chemotherapeutic studies. For this reason, a group of rats with the dose of DC 1000 
mg /kg was selected to perform the IHC analysis and gene analysis evaluations.  
Formalin-fixed paraffin-embedded (FFPE) blocks were sent to the Pathology Lab, 
Department of Pathology, Faculty of Medicine, University of Malaya.  Sections at 4 µm 
were cut, mounted on slides, deparaffinized and rehydrated.  Immunohistochemistry was 
performed with Ventana Benchmark XT autostainer (Ventana Medical Systems Inc., 
Tucson, Arizona) using the following antibodies; Bcl-2 (clone 124, Dako, Japan), p53 
(clone DO-7, Dako, Japan), Ki-67 (clone MIB-1, Dako, Japan), E-cadherin (clone NCH-
38, Dako Japan), beta-catenin (clone b-Catenin-1, Dako, Japan) and cyclin D1 (clone SP4, 
Thermo Fisher Scientific). Automated IHC staining was performed according to routine 
guidelines of Department of Pathology Faculty of Medicine, University of Malaya.   
4.2.9.1 Digital Image Analysis of Immunohistochemical Stain Expression  
The verification for the immunohistochemical reaction of Cyclin D1, Ki-67, Bcl-2, 
p53, β-catenin and E-cadherin in three samples (Dysplastic epithelia and SCC) from each 
group was done by light microscope. Then, immunostained sections were digitised using 
a digital slide scanner Panoramic Desk Scanner (3DHistech, Budapest, Hungary). Five 
fields at 400x magnification were randomly selected for each sample. Images were taken 
of these five fields. The immunoreactivity for each tumour marker was measured in the 
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form of area percent by using computer assisted image analysis (ImageJ, National 
Institute of Mental Health, Bethesda, MD, USA) with an IHC toolbox plugin 
(https://imagej.nih.gov/ij/plugins/ihc-toolbox/index.html) as mentioned in another study 
(Katsha et al., 2017). The percent area occupied by positive (brown) staining could be 
assessed by the functions of semi-automatic colour selection and automatic statistical 
colour detection model that presented in ImageJ's IHC Toolbox. Thresholds was set that 
successfully quantified staining in a positive staining specimen and this was then 
duplicated in every image for comparison purpose.  
4.2.10 Gene Expression Analysis  
The tongue tissue sections that stored in RNAlater solution (Qiagen) at -80°C were 
subjected to gene analysis study to determine the effect of DC 1000 mg/kg on the 
expression of selected apoptosis and proliferative gene related to oral cancer.  
4.2.10.1 RNA Extraction 
In both chemopreventive and chemotherapeutic studies, total cellular ribonucleic acid 
(RNA) was extracted from the tissue fragments dissected out of the posterior region of 
tongues of the induced cancer and DC 1000 mg/kg groups by using RNeasy Plus 
Universal Mini Kit (Qiagen, Hilden, Germany) according to manufacturer’s protocol.  
Briefly, Fresh-frozen tissue sections were incubated in 350 µl Buffer RLT which 
contained 3.5 µl beta mercaptoethanol. The mixture was homogenised with 1 ml syringe. 
One volume of 70% ethanol was added to the mixture followed by vortexing for 30 
seconds. The mixture was transferred into RNeasy MinElute spin column assembly with 
2 ml collection tube and centrifuged for 15 seconds at 10,000 rpm. The flow through 
solution was discarded. The amount of 350 µl of buffer RW1 was added to the RNeasy 
MinElute spin column assembly with 2 ml collection tubes and centrifuged for 15 seconds 
at 10,000 rpm to wash the spin column. The flow through solution and collection tubes 
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was discarded. RNeasy MinElute spin column was placed in a new 2 ml collection tube 
and 500 µl Buffer RPE was added to the spin column continued by centrifuged for 15 
seconds at 10,000 rpm to wash the spin column membrane. A total of 500 µl of 80% 
ethanol was added to the RNeasy MinElute spin column and centrifuged for 15 seconds 
at 10,000 rpm to wash the spin column membrane. The flow through solution and 
collection tube was discarded. The RNeasy MinElute spin column was placed in a new 2 
ml collection tube. The lid of the spin column was opened during centrifugation at full 
speed for 5 minutes. The flow through solution and collection tube was discarded. The 
RNeasy MinElute spin column was placed in a new 1.5 ml collection tube. A total of 32 
µl of RNase free water was directly added to the center of the spin column membrane and 
centrifuged for 3 minutes at full speed to elute the RNA.  
The integrity of RNA was accessed using the Agilent Bioanalyzer-2100 (Agilent 
Technologies, CA, USA) to determine the quality of the extracted RNA from the samples. 
The Agilent Bioanalyzer-2100 software (Agilent Technologies, CA, USA) can detect the 
ratio of the 18S and 28S ribosomal RNA (rRNA) and generate the RNA integrity number 
(RIN). This RIN is classified from 1 to 10, with 1 being the most degraded total RNA and 
10 being the most intact total RNA. RNA integrity number ≥ 7 were used for further 
analysis. 
4.2.10.2 RNA Quantitation  
RNA was assessed by measuring absorbance at 260 nm (A260) and 280 nm (A280) 
by using the NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, 
MA, USA). A260/A280 ratio between 1.8 - 2.1 indicated high-quality RNA, while A260 
determined the yield of total RNA.  
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4.2.10.3 First Strand cDNA Synthesis 
Complementary DNA (cDNA) synthesis was carried out using the RT² First Strand 
Kit (Qiagen, USA) in a total of 1 µg of total RNA. Random hexamers and oligo-dT 
primed the reverse transcription reactions, and a reverse transcriptase synthesised the 
cDNA product. 
The first step in cDNA synthesis was the genomic DNA elimination step. This step 
was done by addition of genomic DNA elimination mixture (Table 4.1) to total RNA 
isolated from tissues (1 µg of total RNA) followed by incubation at 42°C for 5 min. The 
mixture was then placed on ice immediately for at least one minute. 
Table 4. 1: Genomic DNA Elimination Mixture 
For each RNA sample, the following solutions were combined in a sterile PCR tube: 
Total RNA 25.0 ng to 5.0 µg 
GE (5X gDNA Elimination Buffer) 2.0 µl 
RNase free H2O to a final volume of 10 µl 
 
The next step was reverse transcription using random hexamers and oligo-dT primers. 
This step was done by addition of RT cocktail (Table 4.2) to the above mixture, followed 
by incubation at 42°C for exactly 15 min in a PCR machine (Applied Biosystems Veriti 
Thermal Cycler). Then, the reaction was immediately stopped by heating at 95°C for 5 
minutes. Sterile water (91 µL) was then added to each 20 µL of cDNA synthesis reaction 
and mixed well. The cDNA was then stored at -20 °C until further use. 
Table 4. 2: RT Cocktail 
RT Cocktail 1 reaction 
BC3 (5X RT Buffer 3) 4 µl 
P2 (Primer and External Control Mix) 1 µl 
RE3 (RT Enzyme Mix 3) 2 µl 
RNase free H2O 3 µl 
Final Volume 10 µl 
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4.2.10.4 Real-time qPCR 
A total of 675 µl of master mix was prepared by mixing 25.5 µl of 1 µg of cDNA 
synthesised from each sample with 337.5 µl RT2 SYBR Green/ROX qPCR Master Mix 
(SABiosciences) and water. Then, 25 μl of the aliquot mixture was loaded onto 
each well of a pre-designed 96-well RT2 Profiler PCR Array (SABiosciences) customised 
for 4 samples. Each well from the Array plate was pre-hybridized with primers pair for a 
gene member that listed in Table 4.3. A housekeeping gene, Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), was used as an internal control. 
Real-time PCR was performed by ABI 7500 HT FAST thermal cycler with 
recommended thermal cycler program: 95°C 10 mins; 40 cycles of 95°C for 15 secs and 
60°C for 60 secs; Dissociation 95°C for 1 min, 60°C 2 mins and 95°C 2 mins. The 
reactions were performed in triplicate. The mRNA level of housekeeping gene GAPDH was 
used to normalize the gene expression data. Data were analysed using the GeneGlobe Data 
Analysis Centre on QIAGEN’s website (https://www.qiagen.com/my/shop/genes-and-
pathways/data-analysis-center-overview-page/).  
 
Table 4. 3: List of the selected genes  
Symbol Description 
Bax - 
Casp3 Caspase 3 
BcI-2 
Ptgs2 Ccnd 1 
B-cell CLL/lymphoma 2 
Tp53 Tumour protein p53 
Ptgs2 (Cox-2) Prostaglandin-endoperoxide e synthase 2 
Ccnd1 Cyclin D1 
EGFR Epidermal growth factor receptor 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
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4.2.11 Reliability of Histopathological Evaluation (H&E) on the Incidence of Pre-
Neoplasms and Neoplasms in the Tongue of the Rats 
Intra-examiner reliability was assessed by re-evaluation of all samples twice after a 
seven-day interval and without the knowledge of the previous reading. Cohen’s kappa (k) 
was run to determine if there was agreement between the two readings of the incidence 
of OSCC. There was a substantial agreement between the two readings, k = 0.774, p = 
0.000 in chemopreventive study (Table 4.4), and k = 0.777, p = 0.000 in chemotherapeutic 
study (Table 4.5). 
Table 4. 4: Reliability test (Kappa test) for chemopreventive study 
Symmetric Measures 
Value 
Asymp. Std. 
Errora 
Approx. 
Tb 
Approx. 
Sig. 
Measure of Agreement Kappa 0.774 0.092 6.354 0.000 
N of Valid Cases 35 
Table 4. 5: Reliability test (Kappa test) for chemotherapeutic study 
Symmetric Measures 
Value 
Asymp. Std. 
Errora 
Approx. 
Tb 
Approx. 
Sig. 
Measure of Agreement Kappa 0.777 0.069 8.597 0.000 
N of Valid Cases 63 
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4.2.12 Statistical Analysis 
The measured values were expressed as a mean ± standard deviation. Statistical 
analysis was performed using SPSS version 20.  
Food consumption, water intake, body weights gain, haematological and biochemical 
parameters were compared by analysis of variance (ANOVA), with post-hoc comparisons 
made using Dunnett's test.  
Comparison of the histopathological incidence (normal, hyperplasia, dysplasia and 
squamous cell carcinoma) was made using descriptive statistics and chi-square test.  
For RT2 Profiler PCR Array, Data were analysed using GeneGlobe Data Analysis Center 
on QIAGEN’s website (https://www.qiagen.com/my/shop/genes-and-pathways/data-
analysis-center-overview-page/).  
For IHC, area percent of stained detection data was performed by independent t test 
and one-way ANOVA test for the chemopreventive and chemotherapeutic experiments, 
respectively.  
Evidence of chemopreventive and chemotherapeutic activity was defined as a 
statistically significant (p < 0.05).
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4.3 Results 
4.3.1 Effect of DC Extract on Mean Food Consumption 
The mean food consumption of all rats in each group was recorded daily throughout 
the study and the data were expressed in 1-week cumulative value/group as illustrated in 
Figures 4.3. and 4.4. For chemopreventive study, there were no significant differences 
presented in the first 11 weeks of the study, however, the significant differences were 
presented at 12 through 22 weeks between the groups (Appendix A). Whereas, in the 
chemotherapeutic study, no significant differences have been seen in the first 9 weeks 
and at week 11 (p > 0.05), however, the significant differences were presented at 10 and 
12 through 22 weeks between the groups as p < 0.05 (Appendix B). 
Figure 4. 3: Mean food consumption during 4NQO-induced oral carcinogenesis in 
the chemopreventive study 
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Figure 4. 4: Mean food consumption during 4NQO-induced oral carcinogenesis in 
the chemotherapeutic study 
Additionally, in the chemopreventive study, a post hoc Dunnett's test showed that the 
food consumption decreased in induced cancer and vehicle groups with statistically 
significant differences showed at the following times: 12 through 22 weeks compared to 
the normal control group (p < 0.05). At 16 through 22 weeks, DC 100 mg/kg group 
showed a significantly decreased food consumption compared to the normal control group 
(p < 0.05). The food consumption of DC resin treated groups at doses 500 and 1000 mg/kg 
were comparable to the normal control group throughout the study except at the last two 
weeks (21 and 22 weeks) where a significant decreased of food consumption was showed 
in DC 500 mg/kg group and in the DC 1000 mg/kg group at week 22 compared to the 
normal control group as p < 0.05 (Table 4.6). 
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Table 4. 6: Mean Food consumption of rats during 4NQO-induced oral carcinogenesis 
in the chemopreventive study. A post hoc Dunnett's test. 
Dependent 
Variable 
(I) Food 
Consumption 
(J) Food 
Consumption 
Mean 
Difference (I-
J) 
Std. 
Error 
P value 
Week 12 
Induced Cancer Normal -2.93* 0.98 0.022 
Vehicle Normal -2.62* 0.98 0.046 
DC 100 mg/kg Normal -1.60 0.98 0.359 
DC 500 mg/kg Normal -0.43 0.98 0.991 
DC 1000 mg/kg Normal -1.02 0.98 0.753 
Week 13 
Induced Cancer Normal -2.69* 0.80 0.008 
Vehicle Normal -3.53* 0.80 0.000 
DC 100 mg/kg Normal -1.13 0.80 0.492 
DC 500 mg/kg Normal -0.76 0.80 0.809 
DC 1000 mg/kg Normal -1.36 0.80 0.322 
Week 14 
Induced Cancer Normal -3.75* 0.73 0.000 
Vehicle Normal -3.90* 0.73 0.000 
DC 100 mg/kg Normal -0.95 0.73 0.567 
DC 500 mg/kg Normal -0.70 0.73 0.803 
DC 1000 mg/kg Normal -0.51 0.73 0.930 
Week 15 
Induced Cancer Normal -4.38* 0.77 0.000 
Vehicle Normal -4.16* 0.77 0.000 
DC 100 mg/kg Normal -2.02 0.77 0.050 
DC 500 mg/kg Normal -0.47 0.77 0.960 
DC 1000 mg/kg Normal -0.23 0.77 0.998 
Week 16 
Induced Cancer Normal -6.79* 0.84 0.000 
Vehicle Normal -6.35* 0.84 0.000 
DC 100 mg/kg Normal -4.21* 0.84 0.000 
DC 500 mg/kg Normal -0.68 0.84 0.883 
DC 1000 mg/kg Normal -0.57 0.84 0.938 
Week 17 
Induced Cancer Normal -7.96* 0.89 0.000 
Vehicle Normal -7.04* 0.89 0.000 
DC 100 mg/kg Normal -5.46* 0.89 0.000 
DC 500 mg/kg Normal -1.14 0.89 0.579 
DC 1000 mg/kg Normal -1.02 0.89 0.675 
Week 18 
Induced Cancer Normal -12.33* 1.10 0.000 
Vehicle Normal -11.32* 1.10 0.000 
DC 100 mg/kg Normal -8.49* 1.10 0.000 
DC 500 mg/kg Normal -1.54 1.10 0.497 
DC 1000 mg/kg Normal -0.97 1.10 0.845 
Week 19 
Induced Cancer Normal -13.20* 1.01 0.000 
Vehicle Normal -11.52* 1.01 0.000 
DC 100 mg/kg Normal -10.00* 1.01 0.000 
DC 500 mg/kg Normal -1.41 1.01 0.499 
DC 1000 mg/kg Normal -1.35 1.01 0.538 
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Table 4.6 continued 
Week 20 
Induced Cancer Normal -18.71* 1.19 0.000 
Vehicle Normal -15.38* 1.19 0.000 
DC 100 mg/kg Normal -12.51* 1.19 0.000 
DC 500 mg/kg Normal -1.98 1.19 0.342 
DC 1000 mg/kg Normal -1.75 1.19 0.455 
Week 21 
Induced Cancer Normal -22.83* 1.07 0.000 
Vehicle Normal -19.84* 1.07 0.000 
DC 100 mg/kg Normal -17.53* 1.07 0.000 
DC 500 mg/kg Normal -5.78* 1.07 0.000 
DC 1000 mg/kg Normal -2.39 1.07 0.118 
Week 22 
Induced Cancer Normal -25.08* 0.62 0.000 
Vehicle Normal -24.04* 0.62 0.000 
DC 100 mg/kg Normal -21.63* 0.62 0.000 
DC 500 mg/kg Normal -8.70* 0.62 0.000 
DC 1000 mg/kg Normal -5.22* 0.62 0.000 
*p value less than 0.05, (p < 0.05) significant value.
Similarly, in the chemotherapeutic study, a post hoc Dunnett's test showed a reduction 
in food consumption in induced cancer and vehicle groups with statistically significant 
differences showed at the following times: 12 through 22 weeks compared to the normal 
control group (p < 0.05). At 10 and 14 through 22 weeks, both a Cisplatin and DC 100 
mg/kg + Cisplatin groups showed statistically significant decreased in food consumption 
compared to the normal control group (p < 0.05). The food consumption of DC 100 mg/kg 
group was decreased significantly at 15 through 22 weeks compared to the normal control 
group (p < 0.05). DC extract treated groups at doses of 500 and 1000 mg/kg with or 
without Cisplatin were practically comparable to the normal control group throughout the 
study except at the last three weeks (20, 21 and 22 weeks) as p < 0.05. However, DC 500 
mg/kg showed a significant decrease in food consumption start from 20 through 22 
weeks, and DC 500 mg/kg with Cisplatin, DC 1000 mg/kg with or without Cisplatin 
showed a significant decrease in food consumption only at 21 and 22 weeks compared to 
the normal control group with p < 0.05 (Table 4.7). 
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Table 4. 7: Mean food consumption of rats during 4NQO-induced oral carcinogenesis 
in the chemotherapeutic study. A post hoc Dunnett's test. 
Dependent 
Variable 
(I) Food consumption 
(J) Food 
consumption 
Mean 
Difference 
(I-J) 
Standard 
Error 
P 
value 
Week 10 
Induced cancer Normal -1.90 0.98 0.295 
Vehicle Normal -1.76 0.98 0.377 
Cisplatin Normal -3.98 0.98 0.001* 
DC 100 mg/kg Normal -0.61 0.98 0.995 
DC 100 mg/kg + Cisplatin Normal -3.16 0.98 0.015* 
DC 500 mg/kg Normal -2.10 0.98 0.200 
DC 500 mg/kg + Cisplatin Normal -2.00 0.98 0.244 
DC 1000 mg/kg Normal -1.23 0.98 0.757 
DC 1000 mg/kg + Cisplatin Normal -0.78 0.98 0.973 
Week 12 
Induced cancer Normal -5.20 1.07 0.000* 
Vehicle Normal -4.39 1.07 0.001* 
Cisplatin Normal -2.09 1.07 0.293 
DC 100 mg/kg Normal -0.80 1.07 0.981 
DC 100 mg/kg + Cisplatin Normal -1.04 1.07 0.920 
DC 500 mg/kg Normal -1.37 1.07 0.739 
DC 500 mg/kg + Cisplatin Normal -1.19 1.07 0.849 
DC 1000 mg/kg Normal -1.45 1.07 0.684 
DC 1000 mg/kg + Cisplatin Normal -1.01 1.07 0.929 
Week 13 
Induced cancer Normal -5.80 1.02 0.000* 
Vehicle Normal -4.93 1.02 0.000* 
Cisplatin Normal -1.02 1.02 0.905 
DC 100 mg/kg Normal -0.48 1.02 0.999 
DC 100 mg/kg + Cisplatin Normal -1.23 1.02 0.786 
DC 500 mg/kg Normal -1.50 1.02 0.596 
DC 500 mg/kg + Cisplatin Normal -1.33 1.02 0.723 
DC 1000 mg/kg Normal -0.86 1.02 0.961 
DC 1000 mg/kg + Cisplatin Normal -0.52 1.02 0.999 
Week 14 
Induced cancer Normal -6.48 0.98 0.000* 
Vehicle Normal -6.32 0.98 0.000* 
Cisplatin Normal -4.47 0.98 0.000* 
DC 100 mg/kg Normal -1.70 0.98 0.407 
DC 100 mg/kg + Cisplatin Normal -5.69 0.98 0.000* 
DC 500 mg/kg Normal -1.65 0.98 0.443 
DC 500 mg/kg + Cisplatin Normal -1.47 0.98 0.574 
DC 1000 mg/kg Normal -2.13 0.98 0.187 
DC 1000 mg/kg + Cisplatin Normal -1.29 0.98 0.707 
Week 15 
Induced cancer Normal -6.30 0.96 0.000* 
Vehicle Normal -5.70 0.96 0.000* 
Cisplatin Normal -3.72 0.96 0.002* 
DC 100 mg/kg Normal -3.51 0.96 0.004* 
DC 100 mg/kg + Cisplatin Normal -3.84 0.96 0.001* 
DC 500 mg/kg Normal -2.11 0.96 0.180 
DC 500 mg/kg + Cisplatin Normal -2.58 0.96 0.061 
DC 1000 mg/kg Normal -2.47 0.96 0.080 
DC 1000 mg/kg + Cisplatin Normal -2.51 0.96 0.072 
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Table 4.7 continued 
Week 16 
Induced cancer Normal -8.53 0.84 0.000* 
Vehicle Normal -7.49 0.84 0.000* 
Cisplatin Normal -4.45 0.84 0.000* 
DC 100 mg/kg Normal -3.60 0.84 0.001* 
DC 100 mg/kg + Cisplatin Normal -4.60 0.84 0.000* 
DC 500 mg/kg Normal -2.19 0.84 0.076 
DC 500 mg/kg + Cisplatin Normal -2.30 0.84 0.056 
DC 1000 mg/kg Normal -2.04 0.84 0.114 
DC 1000 mg/kg + Cisplatin Normal -2.18 0.84 0.079 
Week 17 
Induced cancer Normal -9.88 0.65 0.000* 
Vehicle Normal -8.79 0.65 0.000* 
Cisplatin Normal -6.73 0.65 0.000* 
DC 100 mg/kg Normal -6.65 0.65 0.000* 
DC 100 mg/kg + Cisplatin Normal -6.81 0.65 0.000* 
DC 500 mg/kg Normal -1.45 0.65 0.170 
DC 500 mg/kg + Cisplatin Normal -1.50 0.65 0.144 
DC 1000 mg/kg Normal -1.50 0.65 0.141 
DC 1000 mg/kg + Cisplatin Normal -1.72 0.65 0.067 
Week 18 
Induced cancer Normal -10.55 0.60 0.000* 
Vehicle Normal -9.27 0.60 0.000* 
Cisplatin Normal -9.62 0.60 0.000* 
DC 100 mg/kg Normal -8.68 0.60 0.000* 
DC 100 mg/kg + Cisplatin Normal -7.15 0.60 0.000* 
DC 500 mg/kg Normal -1.36 0.60 0.158 
DC 500 mg/kg + Cisplatin Normal -1.58 0.60 0.069 
DC 1000 mg/kg Normal -1.13 0.60 0.326 
DC 1000 mg/kg + Cisplatin Normal -1.21 0.60 0.253 
Week 19 
Induced cancer Normal -11.42 0.80 0.000* 
Vehicle Normal -10.50 0.80 0.000* 
Cisplatin Normal -11.18 0.80 0.000* 
DC 100 mg/kg Normal -11.29 0.80 0.000* 
DC 100 mg/kg + Cisplatin Normal -8.85 0.80 0.000* 
DC 500 mg/kg Normal -2.12 0.80 0.069 
DC 500 mg/kg + Cisplatin Normal -2.09 0.80 0.075 
DC 1000 mg/kg Normal -2.08 0.80 0.077 
DC 1000 mg/kg + Cisplatin Normal -2.06 0.80 0.080 
Week 20 
Induced cancer Normal -14.06 0.83 0.000* 
Vehicle Normal -12.47 0.83 0.000* 
Cisplatin Normal -10.52 0.83 0.000* 
DC 100 mg/kg Normal -10.18 0.83 0.000* 
DC 100 mg/kg + Cisplatin Normal -10.20 0.83 0.000* 
DC 500 mg/kg Normal -3.11 0.83 0.003* 
DC 500 mg/kg + Cisplatin Normal -1.57 0.83 0.318 
DC 1000 mg/kg Normal -2.01 0.83 0.111 
DC 1000 mg/kg + Cisplatin Normal -1.16 0.83 0.644 
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Table 4.7 continued 
Week 21 
Induced cancer Normal -16.40 0.73 0.000* 
Vehicle Normal -15.31 0.73 0.000* 
Cisplatin Normal -14.64 0.73 0.000* 
DC 100 mg/kg Normal -12.70 0.73 0.000* 
DC 100 mg/kg + Cisplatin Normal -12.57 0.73 0.000* 
DC 500 mg/kg Normal -6.10 0.73 0.000* 
DC 500 mg/kg + Cisplatin Normal -5.76 0.73 0.000* 
DC 1000 mg/kg Normal -5.60 0.73 0.000* 
DC 1000 mg/kg + Cisplatin Normal -5.83 0.73 0.000* 
Week 22 
Induced cancer Normal -18.28 0.80 0.000* 
Vehicle Normal -16.57 0.80 0.000* 
Cisplatin Normal -14.93 0.80 0.000* 
DC 100 mg/kg Normal -14.59 0.80 0.000* 
DC 100 mg/kg + Cisplatin Normal -14.61 0.80 0.000* 
DC 500 mg/kg Normal -6.52 0.80 0.000* 
DC 500 mg/kg + Cisplatin Normal -5.98 0.80 0.000* 
DC 1000 mg/kg Normal -6.10 0.80 0.000* 
DC 1000 mg/kg + Cisplatin Normal -5.57 0.80 0.000* 
*p value less than 0.05, (p < 0.05) significant value.
4.3.2 Effect of DC Extract on Mean Water Intake 
The mean water intake of all rats in each group was recorded daily throughout the 
study and the data were expressed in 1-week cumulative value/group as illustrated in 
Figures 4.5 and 4.6. In chemopreventive study, analysis of variance (one-way ANOVA) 
showed a significant difference at all weeks of the study (p < 0.05), except at the 1st, 
10th,11th and 12th week between the groups (Appendix C). Whereas, in the 
chemotherapeutic study, no significant difference detected in the first 11 weeks of the 
study, however, a significant difference was showed at 12 through 22 weeks between the 
groups with p < 0.05 (Appendix D). 
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Figure 4. 5: Mean water intake during 4NQO-induced oral carcinogenesis in the 
chemopreventive study 
Figure 4. 6: Mean water intake during 4NQO-induced oral carcinogenesis in the 
chemotherapeutic study 
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Furthermore, in chemopreventive study, a post hoc Dunnett's test showed a significant 
increase in water intake in DC treated groups at doses 100, 500 and 1000 mg/kg in the 
following time: 2 through 9 weeks compared to the normal control group (p < 0.05). There 
was no significant difference between the normal control group and both induced cancer 
and vehicle groups at the first 12 weeks as p > 0.05 (Table 4.8). However, a significant 
decrease in water intake in both induced cancer and vehicle groups was detected at the 
following times: 13 through 22 weeks compared to normal control group (p < 0.05). At 
week 17 until the end of the study, DC 100 mg/kg group showed a significantly decreased 
in water intake compared to the normal control group (p < 0.05). The water intake in DC 
resin treated groups at doses of 500 and 1000 mg/kg from week 13 until the end of the 
study were comparable to the normal control group with p > 0.05 as shown in Table 4.8. 
Table 4. 8: Water intake of rats during 4NQO-induced oral carcinogenesis in the 
chemopreventive study. A post hoc Dunnett's test. 
Dependent 
Variable 
(I) Water Intake 
(J) Water 
Intake 
Mean 
Difference (I-J) 
Standard 
Error 
P value 
Week 2 
Induced Cancer Normal -0.80 0.83 0.792 
Vehicle Normal -0.76 0.83 0.827 
DC 100 mg/kg Normal 2.22 0.83 0.044* 
DC 500 mg/kg Normal 2.26 0.83 0.039* 
DC 1000 mg/kg Normal 2.36 0.83 0.029* 
Week 3 
Induced Cancer Normal -0.08 0.79 1.000 
Vehicle Normal -0.37 0.79 0.987 
DC 100 mg/kg Normal 2.27 0.79 0.029* 
DC 500 mg/kg Normal 2.56 0.79 0.011* 
DC 1000 mg/kg Normal 2.30 0.79 0.026* 
Week 4 
Induced Cancer Normal 0.03 0.92 1.000 
Vehicle Normal -0.28 0.92 0.998 
DC 100 mg/kg Normal 3.19 0.92 0.006* 
DC 500 mg/kg Normal 3.05 0.92 0.009* 
DC 1000 mg/kg Normal 2.73 0.92 0.021* 
Week 5 
Induced Cancer Normal 0.03 0.92 1.000 
Vehicle Normal -0.28 0.92 0.998 
DC 100 mg/kg Normal 3.19 0.92 0.006* 
DC 500 mg/kg Normal 3.05 0.92 0.009* 
DC 1000 mg/kg Normal 2.73 0.92 0.021* 
Week 6 
Induced Cancer Normal -0.12 0.85 1.000 
Vehicle Normal -0.19 0.85 1.000 
DC 100 mg/kg Normal 2.48 0.85 0.026* 
DC 500 mg/kg Normal 2.30 0.85 0.043* 
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Table 4.8 continued 
 DC 1000 mg/kg Normal 2.70 0.85 0.014* 
Week 7 
Induced Cancer Normal -0.75 0.82 0.823 
Vehicle Normal 0.58 0.82 0.928 
DC 100 mg/kg Normal 2.17 0.82 0.047* 
DC 500 mg/kg Normal 2.89 0.82 0.005* 
DC 1000 mg/kg Normal 3.25 0.82 0.001* 
Week 8 
Induced Cancer Normal -1.26 0.86 0.452 
Vehicle Normal 0.68 0.86 0.890 
DC 100 mg/kg Normal 2.72 0.86 0.013* 
DC 500 mg/kg Normal 3.21 0.86 0.003* 
DC 1000 mg/kg Normal 3.05 0.86 0.005* 
Week 9 
Induced Cancer Normal -0.70 0.68 0.750 
Vehicle Normal -0.24 0.68 0.996 
DC 100 mg/kg Normal 1.79 0.68 0.049* 
DC 500 mg/kg Normal 1.97 0.68 0.026* 
DC 1000 mg/kg Normal 2.24 0.68 0.009* 
Week 13 
Induced Cancer Normal -2.37 0.58 0.001* 
Vehicle Normal -1.85 0.58 0.006* 
DC 100 mg/kg Normal -0.19 0.58 0.719 
DC 500 mg/kg Normal -0.12 0.58 0.766 
DC 1000 mg/kg Normal -0.10 0.58 0.778 
Week 14 
Induced Cancer Normal -3.78 0.52 0.000* 
Vehicle Normal -2.72 0.52 0.000* 
DC 100 mg/kg Normal -0.22 0.52 0.679 
DC 500 mg/kg Normal -0.03 0.52 0.817 
DC 1000 mg/kg Normal -0.01 0.52 0.827 
Week 15 
Induced Cancer Normal -4.71 0.53 0.000* 
Vehicle Normal -3.42 0.53 0.000* 
DC 100 mg/kg Normal -0.29 0.53 0.621 
DC 500 mg/kg Normal -0.24 0.53 0.663 
DC 1000 mg/kg Normal -0.22 0.53 0.683 
Week 16 
Induced Cancer Normal -6.08 0.78 0.000* 
Vehicle Normal -3.86 0.78 0.000* 
DC 100 mg/kg Normal -1.20 0.78 0.206 
DC 500 mg/kg Normal -0.63 0.78 0.505 
DC 1000 mg/kg Normal -0.28 0.78 0.705 
Week 17 
Induced Cancer Normal -6.89 0.69 0.000* 
Vehicle Normal -4.83 0.69 0.000* 
DC 100 mg/kg Normal -3.02 0.69 0.000* 
DC 500 mg/kg Normal -0.54 0.69 0.515 
DC 1000 mg/kg Normal -0.24 0.69 0.708 
Week 18 
Induced Cancer Normal -3.54 1.13 0.007* 
Vehicle Normal -4.58 1.13 0.001* 
DC 100 mg/kg Normal -3.22 1.13 0.015* 
DC 500 mg/kg Normal -0.38 1.13 0.713 
DC 1000 mg/kg Normal -0.10 1.13 0.804 
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Table 4.8 continued 
Week 19 
Induced Cancer Normal -9.06 0.85 0.000* 
Vehicle Normal -7.76 0.85 0.000* 
DC 100 mg/kg Normal -5.64 0.85 0.000* 
DC 500 mg/kg Normal -0.90 0.85 0.394 
DC 1000 mg/kg Normal -0.43 0.85 0.643 
Week 20 
Induced Cancer Normal -9.87 0.72 0.000* 
Vehicle Normal -9.39 0.72 0.000* 
DC 100 mg/kg Normal -7.41 0.72 0.000* 
DC 500 mg/kg Normal -1.33 0.72 0.121 
DC 1000 mg/kg Normal -0.83 0.72 0.345 
Week 21 
Induced Cancer Normal -11.04 0.54 0.000* 
Vehicle Normal -9.94 0.54 0.000* 
DC 100 mg/kg Normal -10.99 0.54 0.000* 
DC 500 mg/kg Normal -1.00 0.54 0.122 
DC 1000 mg/kg Normal -0.84 0.54 0.202 
Week 22 
Induced Cancer Normal -11.78 0.66 0.000* 
Vehicle Normal -11.09 0.66 0.000* 
DC 100 mg/kg Normal -11.27 0.66 0.000* 
DC 500 mg/kg Normal -1.38 0.66 0.079 
DC 1000 mg/kg Normal -1.30 0.66 0.100 
*p value less than 0.05, (p < 0.05) significant value. 
 
Likewise, in the chemotherapeutic study, a post hoc Dunnett's test showed a significant 
decrease in water intake in groups of induced cancer, vehicle and Cisplatin compared to 
normal control group at the following times: 12 through 22 weeks (p < 0.05). At week 16 
until the end of the study, DC 100 mg/kg with or without Cisplatin showed a significantly 
decrease in water intake compared to the normal control group (p < 0.05). The reduction 
of water intake in the combination of DC 500 mg/kg + Cisplatin group was detected at 
20 through 22 weeks compared to normal control group. Whereas, DC 500 mg/kg group 
showed a significant decrease in water intake at the last two weeks 21 and 22 where p < 
0.05. However, there was no significant difference detected in DC 1000 mg/kg groups 
with or without Cisplatin throughout the study compared to the normal control group as 
p > 0.05 (Table 4.9).   
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Table 4. 9: Mean water intake of rats during 4NQO-induced oral carcinogenesis in the 
chemotherapeutic study. A post hoc Dunnett's test. 
Dependent 
Variable 
(I) Water intake 
(J) Water 
intake 
Mean 
Difference 
(I-J) 
Standard 
Error 
P value 
Week 12 
Induced cancer Normal -2.82* 0.98 0.039 
Vehicle Normal -3.12* 0.98 0.017 
Cisplatin Normal -3.22* 0.98 0.013 
DC 100 mg/kg Normal 0.22 0.98 1.000 
DC 100 mg/kg + Cisplatin Normal -0.70 0.98 0.987 
DC 500 mg/kg Normal 0.13 0.98 1.000 
DC 500 mg/kg + Cisplatin Normal -1.31 0.98 0.702 
DC 1000 mg/kg Normal 1.29 0.98 0.713 
DC 1000 mg/kg + Cisplatin Normal -1.06 0.98 0.868 
Week 13 
Induced cancer Normal -4.29* 0.92 0.000 
Vehicle Normal -4.16* 0.92 0.000 
Cisplatin Normal -4.69* 0.92 0.000 
DC 100 mg/kg Normal -0.62 0.92 0.990 
DC 100 mg/kg + Cisplatin Normal -2.31 0.92 0.092 
DC 500 mg/kg Normal 0.76 0.92 0.966 
DC 500 mg/kg + Cisplatin Normal -1.68 0.92 0.355 
DC 1000 mg/kg Normal 1.33 0.92 0.614 
DC 1000 mg/kg + Cisplatin Normal -1.19 0.92 0.725 
Week 14 
Induced cancer Normal -5.15* 0.70 0.000 
Vehicle Normal -4.41* 0.70 0.000 
Cisplatin Normal -2.95* 0.70 0.001 
DC 100 mg/kg Normal -0.68 0.70 0.922 
DC 100 mg/kg + Cisplatin Normal -1.43 0.70 0.250 
DC 500 mg/kg Normal 0.01 0.70 1.000 
DC 500 mg/kg + Cisplatin Normal -0.22 0.70 1.000 
DC 1000 mg/kg Normal 0.60 0.70 0.960 
DC 1000 mg/kg + Cisplatin Normal -0.55 0.70 0.974 
Week 15 
Induced cancer Normal -5.83* 0.83 0.000 
Vehicle Normal -5.61* 0.83 0.000 
Cisplatin Normal -4.93* 0.83 0.000 
DC 100 mg/kg Normal -1.83 0.83 0.180 
DC 100 mg/kg + Cisplatin Normal -1.97 0.83 0.125 
DC 500 mg/kg Normal 1.63 0.83 0.284 
DC 500 mg/kg + Cisplatin Normal -0.72 0.83 0.953 
DC 1000 mg/kg Normal 1.30 0.83 0.530 
DC 1000 mg/kg + Cisplatin Normal -0.57 0.83 0.989 
Week 16 
Induced cancer Normal -5.70* 0.69 0.000 
Vehicle Normal -5.32* 0.69 0.000 
Cisplatin Normal -4.73* 0.69 0.000 
DC 100 mg/kg Normal -2.10* 0.69 0.024 
DC 100 mg/kg + Cisplatin Normal -2.35* 0.69 0.009 
DC 500 mg/kg Normal -0.86 0.69 0.761 
DC 500 mg/kg + Cisplatin Normal -0.39 0.69 0.997 
DC 1000 mg/kg Normal 0.93 0.69 0.686 
DC 1000 mg/kg + Cisplatin Normal -0.88 0.69 0.737 
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Week 17 
Induced cancer Normal -9.49* 0.84 0.000 
Vehicle Normal -9.00* 0.84 0.000 
Cisplatin Normal -7.64* 0.84 0.000 
DC 100 mg/kg Normal -4.22* 0.84 0.000 
DC 100 mg/kg + Cisplatin Normal -5.32* 0.84 0.000 
DC 500 mg/kg Normal 1.72 0.84 0.239 
DC 500 mg/kg + Cisplatin Normal -0.50 0.84 0.996 
DC 1000 mg/kg Normal 2.11 0.84 0.089 
DC 1000 mg/kg + Cisplatin Normal -1.06 0.84 0.745 
Week 18 
Induced cancer Normal -10.72* 0.80 0.000 
Vehicle Normal -10.16* 0.80 0.000 
Cisplatin Normal -8.61* 0.80 0.000 
DC 100 mg/kg Normal -5.68* 0.80 0.000 
DC 100 mg/kg + Cisplatin Normal -6.04* 0.80 0.000 
DC 500 mg/kg Normal 1.18 0.80 0.600 
DC 500 mg/kg + Cisplatin Normal -0.74 0.80 0.937 
DC 1000 mg/kg Normal 1.81 0.80 0.164 
DC 1000 mg/kg + Cisplatin Normal -1.78 0.80 0.176 
Week 19 
Induced cancer Normal -10.51* 0.81 0.000 
Vehicle Normal -10.02* 0.81 0.000 
Cisplatin Normal -8.66* 0.81 0.000 
DC 100 mg/kg Normal -5.24* 0.81 0.000 
DC 100 mg/kg + Cisplatin Normal -6.34* 0.81 0.000 
DC 500 mg/kg Normal 0.70 0.81 0.958 
DC 500 mg/kg + Cisplatin Normal -1.52 0.81 0.331 
DC 1000 mg/kg Normal 0.82 0.81 0.900 
DC 1000 mg/kg + Cisplatin Normal -2.08 0.81 0.082 
Week 20 
Induced cancer Normal -14.51* 0.87 0.000 
Vehicle Normal -13.92* 0.87 0.000 
Cisplatin Normal -11.27* 0.87 0.000 
DC 100 mg/kg Normal -8.34* 0.87 0.000 
DC 100 mg/kg + Cisplatin Normal -8.70* 0.87 0.000 
DC 500 mg/kg Normal -2.38 0.87 0.055 
DC 500 mg/kg + Cisplatin Normal -3.40* 0.87 0.002 
DC 1000 mg/kg Normal -1.48 0.87 0.438 
DC 1000 mg/kg + Cisplatin Normal -2.05 0.87 0.131 
Week 21 
Induced cancer Normal -15.58* 0.99 0.000 
Vehicle Normal -13.93* 0.99 0.000 
Cisplatin Normal -11.02* 0.99 0.000 
DC 100 mg/kg Normal -8.57* 0.99 0.000 
DC 100 mg/kg + Cisplatin Normal -8.28* 0.99 0.000 
DC 500 mg/kg Normal -2.93* 0.99 0.031 
DC 500 mg/kg + Cisplatin Normal -3.91* 0.99 0.002 
DC 1000 mg/kg Normal -0.82 0.99 0.965 
DC 1000 mg/kg + Cisplatin Normal -1.06 0.99 0.868 
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Table 4.9 continued 
Week 22 
Induced cancer Normal -23.16* 0.88 0.000 
Vehicle Normal -22.05* 0.88 0.000 
Cisplatin Normal -19.22* 0.88 0.000 
DC 100 mg/kg Normal -16.29* 0.88 0.000 
DC 100 mg/kg + Cisplatin Normal -15.20* 0.88 0.000 
DC 500 mg/kg Normal -8.32* 0.88 0.000 
DC 500 mg/kg + Cisplatin Normal -9.20* 0.88 0.000 
DC 1000 mg/kg Normal -2.15 0.88 0.108 
DC 1000 mg/kg + Cisplatin Normal -2.35 0.88 0.064 
*p value less than 0.05, (p < 0.05) significant value.
4.3.3 Effect of DC Extract on Mean Body Weight Gain 
Mean body weights gain for all groups/week is illustrated in Figures 4.7 and 4.8. For 
chemopreventive study, there were no significant differences showed in the first 11 weeks 
of the study with p > 0.05, however, started from week 12 until the end of the study a 
significant difference was detected between the groups as p < 0.05 (Appendix E). 
Whereas, in the chemotherapeutic study, no statistically significant differences were 
presented in the first 9 weeks (p > 0.05), however, at 10 throughout 22 weeks significant 
difference were detected between the groups (p < 0.05) as shown in Appendix F. 
Figure 4. 7: Mean body weights gain during 4NQO-induced oral carcinogenesis in 
the chemopreventive study 
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Figure 4. 8: Mean body weights gain during 4NQO-induced oral carcinogenesis in 
the chemotherapeutic study 
Moreover, in the chemopreventive study, a post hoc Dunnett's test showed that the 
mean body weight gain of the induced cancer and vehicle groups was decreased with a 
significant difference at the following times: 12 through 22 weeks compared to normal 
control group (p < 0.05). For the DC 100 mg/kg group, a statistically significant difference 
was shown at 16 through 22 weeks compared to normal control group (p < 0.05). 
Whereas, DC 500 mg/kg group showed a significant decrease to the normal control group 
at the last two weeks (21 and 22 weeks) as p < 0.05. Mean body weights gain in the DC 
1000 mg/kg group was comparable to the normal control group throughout the study and 
no significant difference was presented with p > 0.05 (Table 4.10). 
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Table 4. 10: Mean Body weights gain of rats during 4NQO-induced oral carcinogenesis 
in the chemopreventive study. A post hoc Dunnett's test. 
Dependent 
Variable 
(I) Body weights 
gain 
(J) Body weights 
gain 
Mean Difference 
(I-J) 
Std. 
Error 
P 
value 
Week 12 
Induced Cancer Normal -4.89 1.23 0.001* 
Vehicle Normal -5.24 1.23 0.001* 
DC 100 mg/kg Normal -1.85 1.23 0.431 
DC 500 mg/kg Normal -1.49 1.23 0.629 
DC 1000 mg/kg Normal -1.57 1.23 0.583 
Week 13 
Induced Cancer Normal -6.68 1.56 0.001* 
Vehicle Normal -4.58 1.56 0.024* 
DC 100 mg/kg Normal -0.02 1.56 1.000 
DC 500 mg/kg Normal -0.32 1.56 1.000 
DC 1000 mg/kg Normal 0.52 1.56 0.997 
Week 14 
Induced Cancer Normal -7.99 1.82 0.000* 
Vehicle Normal -6.58 1.82 0.004* 
DC 100 mg/kg Normal -2.91 1.82 0.375 
DC 500 mg/kg Normal -0.80 1.82 0.990 
DC 1000 mg/kg Normal -1.25 1.82 0.937 
Week 15 
Induced Cancer Normal -8.43 2.21 0.002* 
Vehicle Normal -8.41 2.21 0.002* 
DC 100 mg/kg Normal -3.55 2.21 0.369 
DC 500 mg/kg Normal -0.60 2.21 0.999 
DC 1000 mg/kg Normal -0.33 2.21 1.000 
Week 16 
Induced Cancer Normal -20.58 3.20 0.000* 
Vehicle Normal -21.57 3.20 0.000* 
DC 100 mg/kg Normal -16.57 3.20 0.000* 
DC 500 mg/kg Normal -7.10 3.20 0.123 
DC 1000 mg/kg Normal -3.65 3.20 0.679 
Week 17 
Induced Cancer Normal -32.61 3.32 0.000* 
Vehicle Normal -35.06 3.32 0.000* 
DC 100 mg/kg Normal -30.63 3.32 0.000* 
DC 500 mg/kg Normal -8.25 3.32 0.070 
DC 1000 mg/kg Normal -3.80 3.32 0.678 
Week 18 
Induced Cancer Normal -48.45 3.96 0.000* 
Vehicle Normal -51.45 3.96 0.000* 
DC 100 mg/kg Normal -43.52 3.96 0.000* 
DC 500 mg/kg Normal -10.22 3.96 0.056 
DC 1000 mg/kg Normal -4.22 3.96 0.729 
Week 19 
Induced Cancer Normal -66.13 5.73 0.000* 
Vehicle Normal -74.31 5.73 0.000* 
DC 100 mg/kg Normal -56.22 5.73 0.000* 
DC 500 mg/kg Normal -9.22 5.73 0.368 
DC 1000 mg/kg Normal -2.80 5.73 0.984 
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Table 4.10 continued 
Week 20 
Induced Cancer Normal -95.27 9.20 0.000* 
Vehicle Normal -94.26 9.58 0.000* 
DC 100 mg/kg Normal -74.05 9.20 0.000* 
DC 500 mg/kg Normal -9.50 9.20 0.755 
DC 1000 mg/kg Normal -5.52 9.20 0.963 
Week 21 
Induced Cancer Normal -90.55 3.54 0.000* 
Vehicle Normal -94.73 3.54 0.000* 
DC 100 mg/kg Normal -74.11 3.36 0.000* 
DC 500 mg/kg Normal -11.11 3.23 0.008* 
DC 1000 mg/kg Normal -3.44 3.23 0.744 
Week 22 
Induced Cancer Normal -106.02 3.47 0.000* 
Vehicle Normal -109.80 3.47 0.000* 
DC 100 mg/kg Normal -88.52 3.30 0.000* 
DC 500 mg/kg Normal -14.06 3.17 0.001* 
DC 1000 mg/kg Normal -8.44 3.17 0.050 
*p value less than 0.05, (p < 0.05) significant value. 
 
Accordingly, in the chemotherapeutic study, a post hoc Dunnett's test showed that the 
mean body weight gain in the induced cancer and vehicle groups was significantly 
decrease at the following times: 12 through 22 weeks compared to the normal control 
group (p < 0.05). For both groups, Cisplatin and combination of DC 100 mg/kg + 
Cisplatin, a statistically significant decrease showed at 10, 11 and 15 through 22 weeks. 
The DC 100 mg/kg group showed a statistically significant decrease at the following 
weeks: 15 through 22 compared to the normal control group (p < 0.05). However, at the 
last two weeks (21 and 22) a significant decrease has been shown in the combination of 
DC 500 mg/kg + Cisplatin group compared to normal control group with p < 0.05. No 
significant differences were shown between the normal control group and both groups of 
DC extract at 500 and 1000 mg/kg. Mean body weights gain in normal control and DC 
extract treated groups at 500 and 1000 mg/kg were comparable throughout the study as p 
> 0.05 (Table 4.11).  
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Table 4. 11: Mean body weights gain of rats during 4NQO-induced oral carcinogenesis 
in the chemotherapeutic study. A post hoc Dunnett's test. 
Dependent 
Variable 
(I) Body weights gain 
(J) Body 
weights gain 
Mean 
Difference 
(I-J) 
Standard 
Error 
P value 
Week 10 
Induced cancer Normal -4.40 1.71 0.081 
Vehicle Normal -3.85 1.71 0.163 
Cisplatin Normal -6.13* 1.71 0.005 
DC 100 mg/kg Normal -3.33 1.71 0.292 
DC 100 mg/kg + Cisplatin Normal -6.01* 1.71 0.007 
DC 500 mg/kg Normal 0.59 1.71 1.000 
DC 500 mg/kg + Cisplatin Normal -4.01 1.71 0.134 
DC 1000 mg/kg Normal -1.26 1.71 0.983 
DC 1000 mg/kg + Cisplatin Normal -4.69 1.71 0.053 
Week 11 
Induced cancer Normal -4.13 1.77 0.137 
Vehicle Normal -3.27 1.77 0.345 
Cisplatin Normal -6.33* 1.77 0.005 
DC 100 mg/kg Normal -2.85 1.77 0.498 
DC 100 mg/kg + Cisplatin Normal -5.61* 1.77 0.017 
DC 500 mg/kg Normal -1.54 1.77 0.953 
DC 500 mg/kg + Cisplatin Normal -4.30 1.77 0.111 
DC 1000 mg/kg Normal -0.16 1.77 1.000 
DC 1000 mg/kg + Cisplatin Normal -4.30 1.77 0.111 
Week 12 
Induced cancer Normal -5.12* 1.55 0.012 
Vehicle Normal -5.09* 1.55 0.013 
Cisplatin Normal -0.77 1.55 0.999 
DC 100 mg/kg Normal -1.85 1.55 0.797 
DC 100 mg/kg + Cisplatin Normal -1.85 1.55 0.797 
DC 500 mg/kg Normal -1.89 1.55 0.779 
DC 500 mg/kg + Cisplatin Normal -1.88 1.55 0.783 
DC 1000 mg/kg Normal -0.86 1.55 0.998 
DC 1000 mg/kg + Cisplatin Normal -1.28 1.55 0.965 
Week 13 
Induced cancer Normal -8.17* 1.74 0.000 
Vehicle Normal -7.95* 1.74 0.000 
Cisplatin Normal -3.87 1.74 0.170 
DC 100 mg/kg Normal -2.74 1.74 0.520 
DC 100 mg/kg + Cisplatin Normal -3.53 1.74 0.247 
DC 500 mg/kg Normal -1.16 1.74 0.991 
DC 500 mg/kg + Cisplatin Normal -2.68 1.74 0.546 
DC 1000 mg/kg Normal -0.76 1.74 1.000 
DC 1000 mg/kg + Cisplatin Normal -2.48 1.74 0.631 
Week 14 
Induced cancer Normal -8.79* 1.96 0.000 
Vehicle Normal -8.97* 1.96 0.000 
Cisplatin Normal -3.15 1.96 0.497 
DC 100 mg/kg Normal -5.20 1.96 0.066 
DC 100 mg/kg + Cisplatin Normal -2.91 1.96 0.586 
DC 500 mg/kg Normal -0.23 1.96 1.000 
DC 500 mg/kg + Cisplatin Normal -0.23 1.96 1.000 
DC 1000 mg/kg Normal -0.82 1.96 1.000 
DC 1000 mg/kg + Cisplatin Normal -1.53 1.96 0.975 
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Table 4.11 continued  
Week 15 
Induced cancer Normal -11.05* 2.13 0.000 
Vehicle Normal -11.40* 2.13 0.000 
Cisplatin Normal -7.53* 2.13 0.006 
DC 100 mg/kg Normal -11.00* 2.13 0.000 
DC 100 mg/kg + Cisplatin Normal -6.10* 2.13 0.039 
DC 500 mg/kg Normal -3.86 2.13 0.365 
DC 500 mg/kg + Cisplatin Normal -4.69 2.13 0.178 
DC 1000 mg/kg Normal -1.31 2.13 0.995 
DC 1000 mg/kg + Cisplatin Normal -4.45 2.13 0.223 
Week 16 
Induced cancer Normal -15.46* 2.48 0.000 
Vehicle Normal -16.20* 2.48 0.000 
Cisplatin Normal -11.98* 2.48 0.000 
DC 100 mg/kg Normal -9.87* 2.48 0.002 
DC 100 mg/kg + Cisplatin Normal -11.01* 2.48 0.000 
DC 500 mg/kg Normal -5.47 2.48 0.179 
DC 500 mg/kg + Cisplatin Normal -6.36 2.48 0.082 
DC 1000 mg/kg Normal -2.45 2.48 0.910 
DC 1000 mg/kg + Cisplatin Normal -8.24* 2.48 0.011 
Week 17 
Induced cancer Normal -19.05* 2.48 0.000 
Vehicle Normal -19.79* 2.48 0.000 
Cisplatin Normal -15.57* 2.48 0.000 
DC 100 mg/kg Normal -13.46* 2.48 0.000 
DC 100 mg/kg + Cisplatin Normal -14.60* 2.48 0.000 
DC 500 mg/kg Normal -5.47 2.48 0.179 
DC 500 mg/kg + Cisplatin Normal -6.36 2.48 0.082 
DC 1000 mg/kg Normal -2.45 2.48 0.911 
DC 1000 mg/kg + Cisplatin Normal -6.81 2.48 0.053 
Week 18 
Induced cancer Normal -24.85* 2.99 0.000 
Vehicle Normal -29.76* 2.99 0.000 
Cisplatin Normal -21.65* 2.99 0.000 
DC 100 mg/kg Normal -20.86* 2.99 0.000 
DC 100 mg/kg + Cisplatin Normal -17.57* 2.99 0.000 
DC 500 mg/kg Normal -6.39 2.99 0.203 
DC 500 mg/kg + Cisplatin Normal -7.00 2.99 0.133 
DC 1000 mg/kg Normal -6.55 2.99 0.183 
DC 1000 mg/kg + Cisplatin Normal -6.21 2.99 0.228 
Week 19 
Induced cancer Normal -40.44* 5.20 0.000 
Vehicle Normal -44.14* 5.20 0.000 
Cisplatin Normal -24.11* 5.20 0.000 
DC 100 mg/kg Normal -23.44* 5.20 0.000 
DC 100 mg/kg + Cisplatin Normal -20.79* 5.20 0.001 
DC 500 mg/kg Normal -6.40 5.20 0.772 
DC 500 mg/kg + Cisplatin Normal -6.81 5.20 0.717 
DC 1000 mg/kg Normal -3.04 5.20 0.996 
DC 1000 mg/kg + Cisplatin Normal -5.21 5.20 0.905 
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Week 20 
Induced cancer Normal -56.21* 9.91 0.000 
Vehicle Normal -55.78* 9.91 0.000 
Cisplatin Normal -39.86* 9.52 0.001 
DC 100 mg/kg Normal -43.63* 9.52 0.000 
DC 100 mg/kg + Cisplatin Normal -39.49* 9.52 0.001 
DC 500 mg/kg Normal -6.52 9.52 0.990 
DC 500 mg/kg + Cisplatin Normal -14.42 9.52 0.571 
DC 1000 mg/kg Normal -4.54 9.52 0.999 
DC 1000 mg/kg + Cisplatin Normal -6.80 9.52 0.986 
Week 21 
Induced cancer Normal -53.99* 2.85 0.000 
Vehicle Normal -50.58* 2.85 0.000 
Cisplatin Normal -32.11* 2.71 0.000 
DC 100 mg/kg Normal -36.60* 2.71 0.000 
DC 100 mg/kg + Cisplatin Normal -33.29* 2.71 0.000 
DC 500 mg/kg Normal -3.70 2.60 0.650 
DC 500 mg/kg + Cisplatin Normal -15.16* 2.60 0.000 
DC 1000 mg/kg Normal -2.64 2.60 0.908 
DC 1000 mg/kg + Cisplatin Normal -7.18 2.60 0.055 
Week 22 
Induced cancer Normal -60.35* 3.12 0.000 
Vehicle Normal -57.42* 3.12 0.000 
Cisplatin Normal -35.02* 2.96 0.000 
DC 100 mg/kg Normal -44.27* 2.96 0.000 
DC 100 mg/kg + Cisplatin Normal -39.79* 2.96 0.000 
DC 500 mg/kg Normal -4.85 2.84 0.448 
DC 500 mg/kg + Cisplatin Normal -20.03* 2.84 0.000 
DC 1000 mg/kg Normal -6.10 2.84 0.210 
DC 1000 mg/kg + Cisplatin Normal -9.95* 2.84 0.007 
*p value less than 0.05, (p < 0.05) significant value. 
 
4.3.4 Effect of DC extract on haematological and biochemical parameters  
4.3.4.1 Haematological parameters  
The mean values ± SD of haematological and biochemical parameters for the all 
groups are presented in Appendix G and H. In the chemopreventive study, no significant 
differences have been shown with respect to the values of HGB, lymphocyte, eosinophil 
and basophil (p > 0.05), however, significant differences were detected in the values of 
WBC, neutrophil and monocyte between the groups with p < 0.05 (Appendix G). 
Whereas, in the chemotherapeutic study, no significant differences have been shown with 
respect to the values of lymphocyte and basophil (p > 0.05), however, significant 
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differences were detected in the values of HGB, WBC, neutrophil, monocyte and 
eosinophil between the groups as p < 0.05 (Appendix H). 
Particularly, in the chemopreventive study, a post hoc Dunnett's test showed a 
significantly lower total white blood cell (WBC) and monocyte counts in the induced 
cancer and vehicle groups than those observed in the normal control group (p < 0.05). In 
addition, elevated neutrophil value showed with significant difference in the induced 
cancer and vehicle groups compared to the normal control group (p < 0.05). The 
administration of DC extract at various concentrations (100, 500 and 1000 mg/kg) 
returned the values of WBC, neutrophils and monocytes to near normal value compared 
to the normal control group as p > 0.05 (Table 4.12).  
Table 4. 12: Effect of DC extract on haematological parameters in the chemopreventive 
study A post hoc Dunnett's test. 
Dependent 
Variable 
(I) Blood 
Analysis 
(J) Blood 
Analysis 
Mean Difference 
(I-J) 
Standard 
Error 
P value 
WBC 
Induced Cancer Normal -3.59* 1.08 0.011 
Vehicle Normal -2.95* 1.08 0.044 
DC 100 mg/kg Normal 0.19 1.03 1.000 
DC 500 mg/kg Normal 0.04 0.99 1.000 
DC 1000 mg/kg Normal -0.14 0.99 1.000 
Neutrophil 
Induced Cancer Normal 0.53* 0.15 0.006 
Vehicle Normal 0.51* 0.15 0.009 
DC 100 mg/kg Normal 0.09 0.14 0.947 
DC 500 mg/kg Normal 0.10 0.14 0.925 
DC 1000 mg/kg Normal 0.06 0.14 0.993 
Monocyte 
Induced Cancer Normal -0.17* 0.03 0.000 
Vehicle Normal -0.17* 0.03 0.000 
DC 100 mg/kg Normal -0.04 0.03 0.622 
DC 500 mg/kg Normal -0.03 0.03 0.835 
DC 1000 mg/kg Normal -0.02 0.03 0.904 
*p value less than 0.05, (p < 0.05) significant value. 
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As well as, in the chemotherapeutic study, a post hoc Dunnett's test showed a 
significant reduction in the values of haemoglobin (HGB) and eosinophil in Cisplatin-
treated rats (p < 0.05), which returned to near normal level in rats that treated with DC 
extract. 4NQO administration to the rats does not affect the levels of HGB and eosinophil 
as the induced cancer and vehicle groups showed no significant difference compared to 
the normal control group (p > 0.05). The level of WBC was decreased in the groups of 
induced cancer, vehicle and Cisplatin compared to the normal control group (p > 0.05). 
However, a significant difference showed in the induced cancer group (p < 0.05). The 
value of monocyte was significantly decreased in the induced cancer and vehicle group. 
However, DC extract returned the value of monocyte to near normal value compared to 
the normal control group with p > 0.05 (Table 4.13).  
 
Table 4. 13: Effect of DC extract on haematological parameters in the 
chemotherapeutic study. A post hoc Dunnett's test. 
Dependent 
Variable 
(I) Blood Analysis 
(J) Blood 
Analysis 
Mean 
Difference 
(I-J) 
Standard 
Error 
P value 
HGB 
Induced cancer Normal -0.37 4.05 1.000 
Vehicle Normal -2.57 4.05 0.994 
Cisplatin Normal -24.57* 3.85 0.000 
DC 100 mg/kg Normal -1.07 3.78 1.000 
DC 100 mg/kg + Cisplatin Normal -9.57 3.85 0.103 
DC 500 mg/kg Normal -1.00 3.70 1.000 
DC 500 mg/kg + Cisplatin Normal -4.57 3.70 0.782 
DC 1000 mg/kg Normal -1.57 3.70 1.000 
DC 1000 mg/kg + Cisplatin Normal -4.43 3.70 0.807 
WBC 
Induced cancer Normal -3.30* 1.17 .046 
Vehicle Normal -2.15 1.09 .292 
Cisplatin Normal -1.73 1.00 .427 
DC 100 mg/kg Normal 1.00 1.04 .927 
DC 100 mg/kg + Cisplatin Normal 1.70 1.04 .492 
DC 500 mg/kg Normal 0.47 1.00 .999 
DC 500 mg/kg + Cisplatin Normal 0.71 1.00 .988 
DC 1000 mg/kg Normal 1.89 1.00 .334 
DC 1000 mg/kg + Cisplatin Normal 0.74 1.00 .984 
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Table 4.13 continued  
Neutrophils 
Induced cancer Normal 0.54* 0.04 0.000 
Vehicle Normal 0.53* 0.04 0.000 
Cisplatin Normal 0.41* 0.04 0.000 
DC 100 mg/kg Normal 0.13* 0.04 0.020 
DC 100 mg/kg + Cisplatin Normal 0.30* 0.04 0.000 
DC 500 mg/kg Normal 0.09 0.04 0.177 
DC 500 mg/kg + Cisplatin Normal 0.10 0.04 0.073 
DC 1000 mg/kg Normal 0.08 0.04 0.236 
DC 1000 mg/kg + Cisplatin Normal 0.11 0.04 0.062 
Monocyte 
Induced cancer Normal -0.12* 0.04 0.038 
Vehicle Normal -0.14* 0.04 0.007 
Cisplatin Normal 0.02 0.04 0.997 
DC 100 mg/kg Normal 0.01 0.04 1.000 
DC 100 mg/kg + Cisplatin Normal -0.02 0.04 0.999 
DC 500 mg/kg Normal 0.00 0.04 1.000 
DC 500 mg/kg + Cisplatin Normal -0.02 0.04 0.999 
DC 1000 mg/kg Normal -0.01 0.04 1.000 
DC 1000 mg/kg + Cisplatin Normal -0.03 0.04 0.989 
Eosinophil 
Induced cancer Normal 0.02 0.02 0.942 
Vehicle Normal 0.02 0.02 0.903 
Cisplatin Normal -0.07* 0.02 0.010 
DC 100 mg/kg Normal 0.01 0.02 0.999 
DC 100 mg/kg + Cisplatin Normal -0.02 0.02 0.887 
DC 500 mg/kg Normal 0.01 0.02 0.998 
DC 500 mg/kg + Cisplatin Normal -0.01 0.02 0.990 
DC 1000 mg/kg Normal 0.01 0.02 1.000 
DC 1000 mg/kg + Cisplatin Normal -0.01 0.02 0.980 
*p value less than 0.05, (p < 0.05) significant value. 
 
4.3.4.2 Biochemical parameters  
The mean values ±SD of biochemical parameters for all groups are presented in 
Appendix I and J. In the chemopreventive study, no significant differences have been 
shown with respect to the values of albumin and total bilirubin (p > 0.05), however, the 
value of albumin was lower in the induced cancer and vehicle groups than other groups 
(p < 0.05). A significant difference was detected in the values of urea, creatinine, ALP, 
ALT and AST between the groups (Appendix I). Whereas, in the chemotherapeutic study, 
statistically significant changes in all biochemical parameters were presented between the 
groups as p < 0.05 (Appendix J). 
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Furthermore, in the chemopreventive study as shown in Table 4.14, both induced 
cancer and vehicle groups exhibited significantly higher values for urea, creatinine, ALP, 
ALT, and AST compared to normal control group (p < 0.05). When rats were orally 
administered with DC extract, the values of biochemical parameters almost returned to 
the normal especially at doses of DC 500 and 1000 mg/kg. The DC extract showed values 
comparable to the normal control group with p > 0.05. 
Table 4. 14: Effect of DC extract on biochemical parameters in the chemopreventive 
study A post hoc Dunnett's test. 
*p value less than 0.05, (p < 0.05) significant value 
 
Dependent 
Variable 
(I) Blood Analysis 
(J) Blood 
Analysis 
Mean 
Difference 
(I-J) 
Standard 
Error 
P value 
Urea (mmol/L) 
Induced Cancer Normal 3.90 0.80 0.000* 
Vehicle Normal 2.74 0.80 0.008* 
DC 100 mg/kg Normal 1.26 0.76 0.360 
DC 500 mg/kg Normal 1.07 0.73 0.475 
DC 1000 mg/kg Normal 0.64 0.73 0.859 
Creatinine 
(umol/L) 
Induced Cancer Normal 31.00 2.95 0.000* 
Vehicle Normal 31.20 2.95 0.000* 
DC 100 mg/kg Normal 7.33 2.80 0.055 
DC 500 mg/kg Normal 3.29 2.69 0.638 
DC 1000 mg/kg Normal 3.00 2.69 0.711 
ALP (U/L) 
Induced Cancer Normal 46.20 15.06 0.019* 
Vehicle Normal 55.20 15.06 0.004* 
DC 100 mg/kg Normal 8.33 14.31 0.969 
DC 500 mg/kg Normal 11.71 13.74 0.871 
DC 1000 mg/kg Normal 7.57 13.74 0.976 
ALT (U/L) 
Induced Cancer Normal 16.91 3.35 0.000* 
Vehicle Normal 18.31 3.35 0.000* 
DC 100 mg/kg Normal 2.21 3.18 0.938 
DC 500 mg/kg Normal 2.43 3.06 0.899 
DC 1000 mg/kg Normal 3.00 3.06 0.799 
AST (U/L) 
Induced Cancer Normal 67.94 13.20 0.000* 
Vehicle Normal 73.14 13.20 0.000* 
DC 100 mg/kg Normal 5.98 12.54 0.987 
DC 500 mg/kg Normal 2.57 12.05 1.000 
DC 1000 mg/kg Normal 4.00 12.05 0.997 
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Moreover, in the chemotherapeutic study as shown in Table 4.15, a higher value of 
urea was showed in both groups of Cisplatin and combination of DC 100 mg/kg + 
Cisplatin with a significant difference presented in the Cisplatin group compared to the 
normal control group (p < 0.05). Serum creatinine was significantly higher in the induced 
cancer, vehicle and Cisplatin groups compared to the normal control group (p < 0.05). 
However, the highest level was showed in Cisplatin group. The values of ALP, ALT and 
AST were significantly higher in the induced cancer, vehicle and Cisplatin groups 
compared to the normal control group. In addition, a significantly lower serum albumin 
value was seen in Cisplatin treated group (p < 0.05). In contrast, the administration of DC 
extract (especially at doses of DC 500 and DC 1000 mg/kg) with or without Cisplatin 
showed a considerable improvement of the tested parameters, which looks to be 
comparable to the normal control group (p > 0.05). 
Table 4. 15: Effect of DC extract on biochemical parameters in chemotherapeutic 
study A post hoc Dunnett's test. 
Dependent 
Variable 
(I) Blood Analysis 
(J) Blood 
Analysis 
Mean 
Difference 
(I-J) 
Std. 
Error 
P value 
Urea 
Induced cancer Normal 2.19 1.28 0.443 
Vehicle Normal 1.81 1.28 0.655 
Cisplatin Normal 7.21* 1.22 0.000 
DC 100 mg/kg Normal 2.18 1.22 0.392 
DC 100 mg/kg + Cisplatin Normal 3.40 1.22 0.050 
DC 500 mg/kg Normal 0.67 1.17 0.997 
DC 500 mg/kg + Cisplatin Normal 2.61 1.17 0.175 
DC 1000 mg/kg Normal 0.67 1.17 0.997 
DC 1000 mg/kg + Cisplatin Normal 2.06 1.17 0.413 
Creatinine 
Induced cancer Normal 21.63* 4.16 0.000 
Vehicle Normal 22.83* 4.16 0.000 
Cisplatin Normal 44.93* 3.95 0.000 
DC 100 mg/kg Normal 2.76 3.95 0.989 
DC 100 mg/kg + Cisplatin Normal 17.26* 3.95 0.000 
DC 500 mg/kg Normal 2.43 3.80 0.994 
DC 500 mg/kg + Cisplatin Normal 8.43 3.80 0.181 
DC 1000 mg/kg Normal 3.00 3.80 0.977 
DC 1000 mg/kg + Cisplatin Normal 9.14 3.80 0.122 
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Table 4.15 continued 
albumin 
Induced cancer Normal -3.31 2.27 0.620 
Vehicle Normal -4.31 2.27 0.325 
Cisplatin Normal -8.05* 2.15 0.004 
DC 100 mg/kg Normal -2.38 2.15 0.862 
DC 100 mg/kg + Cisplatin Normal -4.71 2.15 0.192 
DC 500 mg/kg Normal -2.14 2.07 0.897 
DC 500 mg/kg + Cisplatin Normal -3.00 2.07 0.630 
DC 1000 mg/kg Normal -0.43 2.07 1.000 
DC 1000 mg/kg + Cisplatin Normal -2.71 2.07 0.730 
ALP 
Induced cancer Normal 59.89* 12.08 0.000 
Vehicle Normal 56.09* 12.08 0.000 
Cisplatin Normal 50.12* 11.48 0.000 
DC 100 mg/kg Normal 14.12 11.48 0.786 
DC 100 mg/kg + Cisplatin Normal 19.12 11.48 0.475 
DC 500 mg/kg Normal 10.86 11.03 0.920 
DC 500 mg/kg + Cisplatin Normal 17.86 11.03 0.507 
DC 1000 mg/kg Normal 6.57 11.03 0.996 
DC 1000 mg/kg + Cisplatin Normal 15.29 11.03 0.677 
ALT 
Induced cancer Normal 24.54* 2.60 0.000 
Vehicle Normal 25.54* 2.60 0.000 
Cisplatin Normal 21.48* 2.47 0.000 
DC 100 mg/kg Normal 5.98 2.47 0.120 
DC 100 mg/kg + Cisplatin Normal 6.31 2.47 0.089 
DC 500 mg/kg Normal 5.71 2.38 0.123 
DC 500 mg/kg + Cisplatin Normal 5.29 2.38 0.179 
DC 1000 mg/kg Normal 5.61 2.38 0.135 
DC 1000 mg/kg + Cisplatin Normal 5.14 2.38 0.202 
AST 
Induced cancer Normal 74.43* 8.56 0.000 
Vehicle Normal 75.23* 8.56 0.000 
Cisplatin Normal 55.93* 8.14 0.000 
DC 100 mg/kg Normal 12.60 8.14 0.558 
DC 100 mg/kg + Cisplatin Normal 21.76 8.14 0.067 
DC 500 mg/kg Normal 12.14 7.82 0.555 
DC 500 mg/kg + Cisplatin Normal 18.00 7.82 0.153 
DC 1000 mg/kg Normal 7.86 7.82 0.912 
DC 1000 mg/kg + Cisplatin Normal 11.71 7.82 0.595 
*p value less than 0.05, (p < 0.05) significant value. 
 
4.3.5 Effect of DC Extract on Rat’s Survival Rate and Tongue Tumour size  
In the chemopreventive study, the administration of DC extract started one week 
before the administration of 4NQO and continued one week more after the secession of 
4NQO. The administration of DC extract for 10 consecutive weeks increase the survival 
rate to 100% in both DC 500 and 1000 mg/kg and significantly decrease the tongue 
117
tumour size induced by 4NQO as shown in Table 4.16 and Figure 4.9. However, the Chi 
square test that used to compare the survival rate showed no significant difference (Chi.Sq 
= 4.667; p = 0.323) between the groups. 
 
The induced cancer and vehicle groups developed large tumours in the oral cavity, 
mostly seen in the posterior region of the tongue. As presented in Table 4.16, the 
administration of DC extracts to the rats at doses of 100, 500 and 1000 mg/kg developed 
smaller tumours (tumour volume) than those seen in the induced cancer and vehicle 
groups.  
Table 4. 16: Effect of DC extract on survival rate and tongue tumour size in 4NQO-
induced oral carcinogenesis in the chemopreventive study. 
Group Survivala (%) 
P value 
- Chi 
square test 
Tongue Tumour Size 
(Mean± 
SD) 
P value 
one-way 
ANOVA 
test 
Induced cancer 5/7 (71.4) 
0.323 
110.16±21.26 
0.000* 
Vehicle 5/7 (71.4) 113.75±45.79 
DC 100 mg/kg 6/7 (85.7) 74.50±29.52 
DC 500 mg/kg 7/7 (100) 56.99±31.75 
DC 1000 mg/kg 7/7 (100) 31.85±31.75 
a all early mortality was the result of oral neoplasia. 30/35 rats were survived until the end 
of the study; 5 rats were found dead prior to the terminal necropsy.  
*p value less than 0.05, (p < 0.05) significant value.  
A post hoc Dunnett's test showed significant differences between the DC groups (DC 
500 and 1000 mg/kg) compared to the induced cancer group (p < 0.05) as shown in Table 
4.17. These results indicated that the administration of DC extract, especially at the doses 
of 500 and 1000 mg/kg, during the 4NQO administration could effectively stood the 
development of tumours. 
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Table 4. 17: Effect of DC extract on tumour size in the chemopreventive study. A 
post hoc Dunnett's test. 
*p value less than 0.05, (p < 0.05) significant value. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 9: Tongue tumour in different groups (A) normal control group. Following 
oral carcinogenesis induced by 4NQO and treated with DC extract. (B) Induced cancer 
group. (C) Vehicle group. (D) DC 100 mg/kg. (E) DC 500 mg/kg. (F) DC 1000 mg/kg 
 
(I) Group (J) Group Mean Difference (I-J) 
Standard 
Error 
P value 
Vehicle Induced cancer 3.59 18.67 0.999 
DC 100 mg/kg Induced cancer -35.66 18.67 0.195 
DC 500 mg/kg Induced cancer -53.17 18.67 0.027* 
DC 1000 mg/kg Induced cancer -78.31 18.67 0.001* 
A                                                      B                               
E                    F      
C                                                       D                          
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Nevertheless, in the chemotherapeutic study, the administration of DC extract is 
beginning after 1 week from the secession of 4NQO administration (after week 9) and 
continued for 10 consecutive weeks. Chemotherapeutic activity was showed as an 
increase in animal survival rate which was 100% in the groups that treated with DC 
extract at doses of 500 and 1000 mg/kg, and significantly decrease the tongue tumour size 
induced by 4NQO as shown in Table 4.18 and Figure 4.10. However, the Chi square test 
that used to compare the survival rate showed no significant difference (Chi.Sq = 8.877; 
p = 0.353) between groups.  
 
The induced cancer and vehicle groups developed large tumours in the oral cavity, 
mostly seen in the posterior region of the tongue. As presented in Table 4.18, the 
administration of DC extract to the rats at doses of 100, 500 and 1000 mg/kg with or 
without Cisplatin, as well as Cisplatin alone, developed smaller tumours (tumour volume) 
than those seen in the induced cancer and vehicle groups. 
Table 4. 18: Effect of DC extract on survival rate and tongue tumour size in 4NQO-
induced oral carcinogenesis in the chemotherapeutic study. 
Group 
Survivala 
(%) 
P value 
Chi-
square test 
Tongue Tumour 
Size (Mean± 
SD) 
P value 
one-way 
ANOVA 
test 
Induced cancer 5/7 (71.4) 
0.353 
106.11±19.52 
0.000* 
Vehicle 5/7 (71.4) 111.85±33.17 
Cisplatin 5/7 (71.4) 30.37±36.02 
DC 100 mg/kg 6/7 (85.7) 75.41±31.05 
DC 100 mg/kg + Cisplatin 6/7 (85.7) 34.60±37.69 
DC 500 mg/kg 7/7 (100) 45.67±35.50 
DC 500 mg/kg + Cisplatin 7/7 (100) 28.36±30.21 
DC 1000 mg/kg 7/7 (100) 34.86±36.45 
DC 1000 mg/kg + Cisplatin 7/7 (100) 24.25±33.38 
a all early mortality was the result of oral neoplasia. 55/63 rats were survived until the end 
of the study; 7 rats were found dead prior to the terminal necropsy. 
*p value less than 0.05, (p < 0.05) significant value. 
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A post hoc Dunnett's test showed significant decrease in the tongue tumour size 
between all the DC extract groups with or without Cisplatin (except DC 100 mg/kg) as 
well as Cisplatin group compared to the induced cancer group with p < 0.05 (Table 4.19). 
These results indicated that the administration of DC extract, especially at doses of 500 
and 1000 mg/kg, after the secession of 4NQO administration conferred significant 
protection and can effectively stood the development of tumours in this animal model.  
 
Table 4. 19: Effect of DC extract on tumour size in the chemotherapeutic study. A post 
hoc Dunnett's test. 
(I) Group (J) Group 
Mean 
Difference (I-J) 
Standard 
Error 
P value 
Vehicle Induced cancer 5.73 17.62 1.000 
Cisplatin Induced cancer -75.75 17.62 0.001* 
DC 100 mg/kg Induced cancer -30.71 17.62 0.384 
DC 100 mg/kg + Cisplatin Induced cancer -71.51 17.62 0.001* 
DC 500 mg/kg Induced cancer -60.44 17.62 0.008* 
DC 500 mg/kg + Cisplatin Induced cancer -77.75 17.62 0.000* 
DC 1000 mg/kg Induced cancer -71.26 17.62 0.001* 
DC 1000 mg/kg + Cisplatin Induced cancer -81.87 17.62 0.000* 
*p value less than 0.05, (p < 0.05) significant value. 
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Figure 4. 10: Tongue tumour size in different groups (A) normal control group. 
Following oral carcinogenesis induced by 4NQO and treated with DC extract 
with/without Cisplatin or Cisplatin. (B) Induced cancer. (C) Vehicle. (D) Cisplatin. (E) 
DC 100 mg/kg. (F) DC 100 mg/kg + Cisplatin. (G) DC 500 mg/kg. (H) DC 500 mg/kg 
+ Cisplatin. (I) DC 1000 mg/kg. (J) DC 1000 mg/kg + Cisplatin 
A B 
C D 
E F 
G H 
I J 
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4.3.6 Effect of DC Extract on the Incidence of Pre-Neoplasms and Neoplasms  
The descriptive analysis indicated that most of the gross lesions associated with our 
model of 4NQO-induced rat oral cancer were seen in the posterior region of the tongue 
(on the dorsal surface of the tongue).  
On microscopic examination, tongues of the normal control group showed normal oral 
mucosa of the tongue with surface keratinized stratified squamous epithelium with normal 
architecture, normal sizes and orientation of the papillae with underlying connective 
tissue and skeletal muscle bundle in both chemopreventive (Figure 4.11. A) and 
chemotherapeutic (Figure 4.12 A) studies.  
Microscopic examination revealed that different histopathological changes such as 
hyperplasia, dysplasia and SCC appeared in all groups that given 20 ppm of 4NQO in 
their drinking water. The incidence of SCC was detected by the presence of 
discontinuation of the basement membrane and submucosal invasion of epithelial tumour 
cells as islands, nests and sheets. The epithelial tumour cells show nuclear and cellular 
pleomorphism, hyperchromatic nuclei, and altered nucleus: cytoplasmic ratio and keratin 
pearls in connective tissue (Figures. 4.13 A and B). These were observed in induced 
cancer (Figures. 4.11 B) and vehicle (Figures. 4.11 C) groups of chemopreventive and 
induced cancer (Figures. 4.12 B) and vehicle (Figures. 4.12 C) groups of 
chemotherapeutic studies.  
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Figure 4. 11: Photomicrographs (A) normal control group showing normal oral mucosa 
with papillae having surface keratinized epithelium, underlying connective tissue and 
skeletal muscle bundles. Following oral carcinogenesis induced by 4NQO and treated 
with DC extract. (B) Induced cancer group & (C) vehicle group showing SCC invading 
the underlying connective tissue. (D)  DC 100 mg/kg - Dysplasia. (E) DC 500 mg/kg - 
Dysplasia. (F) DC 1000 mg/kg - Hyperplasia.  H&E stain, 100× magnification 
 
  
 
A B 
C D 
E F 
124
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
C D 
E F 
125
 Figure 4.12, continued 
 
 
 
 
 
 
 
 
 
Figure 4. 12: Photomicrographs (A) normal control group showing normal oral mucosa 
with papillae having surface keratinized epithelium, underlying connective tissue and 
skeletal muscle bundles. Following oral carcinogenesis induced by 4NQO and treated 
with DC extract with/without Cisplatin or Cisplatin. (B) Induced cancer - SCC. (C) 
Vehicle - SCC. (D) Cisplatin - Dysplasia. (E) DC 100 mg/kg - Dysplasia. (F) DC 100 
mg/kg + Cisplatin - Hyperplasia. (G) DC 500 mg/kg - Dysplasia. (H) DC 500 mg/kg + 
Cisplatin – Hyperplasia. (I) DC 1000 mg/kg- Hyperplasia. (J) DC 1000 mg/kg + 
Cisplatin- Hyperplasia. H&E stain, 100× magnification 
G H 
I J 
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Figure 4. 13: Photomicrographs following oral carcinogenesis induced by 4NQO 
showed (A) the presence of keratin pearls in connective tissue (Black arrow) (100×) and 
(B) pleomorphic tumour cells (Black circle) (400×). H&E stain 
 
In the chemopreventive study, administration of DC extracts conferred significant 
protection against the induction of OSCC by 4NQO. In the induced cancer and vehicle 
groups, the incidence of OSCC induced by 4NQO was 85.7% while in rats treated with 
DC extract at 100, 500 and 1000 mg/kg was 42.9%, 28.6 % and 14.3%, respectively, 
which was accompanied by an obvious decrease in the incidence of SCC, especially in 
the group received DC extract at 1000 mg/kg. Chemopreventive activity was confirmed 
as a statistically significant decrease in the incidence of OSCC (Table 4.20). The Chi 
square test that used to compare the incidence of development of hyperplasia, dysplasia 
and squamous cell carcinoma showed a statistical significant difference (Chi.Sq = 19.646; 
p = 0.012) between groups.  
Moreover, in chemoprevention study, the hyperplasia with clearly defined basement 
membrane was seen in some samples in groups treated with DC 500 mg/kg (28.6%) and 
1000 mg/kg (57.1%).  
 
B A 
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 Table 4. 20: Effect of DC extract on the incidence of pre-neoplasms and neoplasms in 
4NQO-induced oral carcinogenesis in the chemopreventive study. 
 
Incidence pre-neoplasms and neoplasms (%) 
within Treatment P value 
Hyperplasia Dysplasia SCC 
Induced cancer 0/7 (0.0) 1/7 (14.3) 6/7 (85.7) 
0.012* 
Vehicle 0/7 (0.0) 1/7 (14.3) 6/7 (85.7) 
DC 100 mg/kg 0/7 (0.0) 4/7 (57.1) 3/7 (42.9) 
DC 500 mg/kg 2/7 (28.6) 3/7 (42.9) 2/7 (28.6) 
DC 1000 mg/kg 4/7 (57.1) 2/7 (28.6) 1/7 (14.3) 
*p value less than 0.05, (p < 0.05) significant value. 
 
The incidence of dysplasia in chemopreventive study was detected and graded into 
three grades of epithelial dysplasia (mild, moderate and severe), which are premalignant 
lesions, where mostly presented in the tongue of the rats that treated with DC extract at 
100 mg/kg, 500 mg/kg and 1000 mg/kg during 4NQO administration (Table 4.21). The 
tongues in DC 1000 mg/kg group did not show severe dysplastic changes; two samples 
of mild dysplastic changes were detected in this group. Mild histological changes 
including basal cell hyperplasia, few mitosis, hyperchromatic nuclei and the level of 
atypia in the lower 1/3 with normal epithelial stratification were evident in the tongue 
epithelia of DC 1000 mg/kg group. These incidences were less than those seen in the 
other groups. While, only one rat in DC 500 mg/kg group, had mild dysplasia and two 
rats presented with moderate dysplasia. The moderate histological changes including 
hyperplasia of stratum spinosum, basal cell hyperplasia, superficial mitosis, increased 
number and size of nucleoli and level of atypia in the middle 1/3 with irregular epithelial 
stratification were evident in the tongue base epithelia of DC 500 mg/kg group. Whereas 
in DC 100 mg/kg group, two samples with moderate and two samples with severe 
dysplastic changes were seen. The severe histological changes including irregular rete 
ridges with keratin pearls within rete ridges, abnormally superficial mitotic figures, 
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premature keratinization in single cells (dyskeratosis), atypical mitotic figures in the basal 
layer, increased number and size of nucleoli and level of atypia in the upper 1/3 with 
irregular epithelial stratification were evident in the tongue base epithelia of DC 100 
mg/kg group. One sample from each group (induced cancer and vehicle) demonstrated a 
sever dysplastic change.  
Table 4. 21: Effect of DC extract on the severity of dysplastic lesions in the 
chemopreventive study. 
 
Incidence of Tongue Dysplasia 
Total Mild Moderate Severe 
Induced cancer 1/7 0 0 1 
Vehicle 1/7 0 0 1 
DC 100 mg/kg 4/7 0 2 2 
DC 500 mg/kg 3/7 1 2 0 
DC 1000 mg/kg 2/7 2 0 0 
 
To illustrate, in the chemotherapeutic study, administration of DC extracts conferred 
significant protection against the induction of OSCC by 4NQO. In the induced cancer and 
vehicle groups, the incidence of OSCC that induced by 4NQO was 85.7% per each, while 
in rats treated with DC extracts at 100, 500 and 1000 mg/kg was 57.1%, 28.6% and 14.3%, 
respectively, which was accompanied by an obvious decrease in the incidence of OSCC, 
especially in the group received DC extract at 1000 mg/kg. Whereas, the incidence of 
OSCC in the group of Cisplatin and combination groups at 100 and 500 mg/kg with 
Cisplatin was 14.3% per each. Finally, in the combination group of DC 1000 mg/kg + 
Cisplatin, no incidence of OSCC was detected as the incidence was 0%, offering the best 
protection to the rats exposed to 4NQO. The chemotherapeutic activity of DC extract was 
confirmed as a statistical significant decrease in OSCC incidence (Table 4.22). The Chi 
square test that used to compare the incidence of development of hyperplasia, dysplasia 
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and SCC showed a statistical significant difference (Chi.Sq = 29.442; p = 0.021) between 
groups.  
Furthermore, in the chemotherapeutic study, the hyperplasia was seen in some samples 
treated with Cisplatin (42.9%), DC100 mg/kg + Cisplatin (42.9%), DC500 mg/kg 
(28.6%), DC500 mg/kg + Cisplatin (42.9%), DC1000 mg/kg (42.9%) and DC1000 mg/kg 
+ Cisplatin (71.4%). 
Table 4. 22: Effect of DC extract on the incidence of pre-neoplasms and neoplasms in 
4NQO-induced oral carcinogenesis in the chemotherapeutic study. 
Group 
 
Incidence pre-neoplasms and 
neoplasms (%) within Treatment P value 
Hyperplasia Dysplasia SCC 
Induced cancer 0/7 (0) 1/7 (14.3) 6/7 (85.7) 
0.021* 
Vehicle 0/7 (0) 1/7 (14.3) 6/7 (85.7) 
Cisplatin 2/7 (28.6) 4/7 (57.1) 1/7 (14.3) 
DC100 mg/kg 0/7 (0) 3/7 (42.9) 4/7 (57.1) 
DC100 mg/kg + Cisplatin 2/7 (28.6) 4/7 (57.1) 1/7 (14.3) 
DC500 mg/kg 2/7 (28.6) 3/7 (42.9) 2/7 (28.6) 
DC500 mg/kg + Cisplatin 3/7 (42.9) 3/7 (42.9) 1/7 (14.3) 
DC1000 mg/kg 3/7 (42.9) 3/7 (42.9) 1/7 (14.3) 
DC1000 mg/kg + Cisplatin 3/7 (42.9) 4/7 (57.1) 0/7 (0) 
*p value less than 0.05, (p < 0.05) significant value. 
 
The incidence of dysplasia in chemotherapeutic study was detected with three grades 
of epithelial dysplasia (mild, moderate and severe), were most presented in the tongues 
of the rats that given Cisplatin, DC extract at 100, 500 and 1000 mg/kg with or without 
Cisplatin after cessation of 4NQO administration (Table 4.23). The tongues with mild 
dysplastic changes were detected in one sample of Cisplatin, combination of DC 100 
mg/kg + Cisplatin, combination of DC 500 mg/kg + Cisplatin and DC 1000 mg/kg groups, 
whereas two samples with mild dysplastic changes detected in the combination of DC 
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1000 mg/kg + Cisplatin group. Moderate dysplasia was seen in one sample of the 
combination of DC 500 mg/kg + Cisplatin, whereas two samples were detected in 
Cisplatin, combination of DC 100 mg/kg + Cisplatin, DC 500 and 1000 mg/kg groups. 
Severe dysplastic changes were presented in three samples of the DC 100 mg/kg group 
and one sample of DC 500 mg/kg, induced cancer and vehicle groups. The mild, moderate 
and severe histological changes are same as described earlier in the chemopreventive 
study.  
Table 4. 23: Effect of DC extract on the severity of dysplastic lesions in the 
chemotherapeutic study. 
Group 
 
Incidence of Tongue Dysplasia 
Total Mild Moderate Severe 
Induced cancer 1/7 0 0 1 
Vehicle 1/7 0 0 1 
Cisplatin 3/7 1 2 0 
DC 100 mg/kg 3/7 0 0 3 
DC 100 mg/kg + Cisplatin 3/7 1 2 0 
DC 500 mg/kg 3/7 0 2 1 
DC 500 mg/kg + Cisplatin 2/7 1 1 0 
DC 1000 mg/kg 3/7 1 2 0 
DC 1000 mg/kg + Cisplatin 2/7 2 0 0 
 
In both chemopreventive and chemotherapeutic studies, groups that subjected to the 
effect of DC extract, Cisplatin and combination of both of them against 4NQO-induced 
oral cancer presented with different degrees of epithelial dysplasia as illustrated in Figure 
4.14. Dysplastic lesions demonstrated both cytological and architectural changes 
extending to various thickness of the epithelium; severe dysplasia (Figure 4.14. A1), 
moderate dysplasia (Figure 4.14. B1) and mild dysplasia (Figure 4.14. C1).  
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Figure 4. 14: Photomicrographs following oral carcinogenesis induced by 4NQO and 
treated with DC extract. (A1 and A2) shows features of severe dysplasia (DC 100 
mg/kg), (B1 and B2) Moderate dysplasia with few mitosis (DC 500 mg/kg), and (C1 
and C2) Mild dysplasia (DC 1000 mg/kg). (H&E stain, A1, B1 and C1 100× 
magnification and A2, B2 and C2 400× magnification) 
 
 
 
A 1 
B 1 
C 1 
A 2 
B 2 
C 2 
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4.3.7 Histological Findings of Oral Cancer Metastasis  
In chemotherapeutic study, after 22 weeks, metastatic tumour in the cervical lymph 
node was presented and localised in the marginal sinus of the lymph node from one rat in 
each group of the induce cancer and vehicle (Figure 4.15), and thus, the metastasis rate 
was 14.3% per each. In general, normally functioning lymph nodes contain densely 
packed lymphocytes which usually exhibit strong nucleic acid signals, while metastatic 
cancer contains nucleic acid with reducing density in the sample volume, as epithelial 
cells have a higher relative volume of cytoplasm (Lloyd et al., 2013). Among the DC 
treated groups with or without Cisplatin as well as Cisplatin group, the cervical lymph 
node metastasis rate was 0%, which represented the effect of chemotherapy on a 4NQO-
induced rat model. Lymph node metastasis was inhibited in the DC treated groups with 
or without Cisplatin as well as in the Cisplatin group compared to the induced cancer and 
vehicle groups.  
 
 
 
 
 
 
 
 
 
 
Figure 4. 15: Photomicrograph shows lymph node tissue and metastatic invasion of 
squamous cell carcinoma in a cervical lymph node of induced cancer group. (H&E 
stain, 20× magnification)
Normal lymph node tissue  
Metastatic cancer  
Metastatic cancer  
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4.3.8 Immunohistochemical (IHC) Analysis 
Immunohistochemical expression analysis of the selected tumour marker in the 
chemopreventive and the chemotherapeutic studies was performed to assess the 
localization and compare the positive (brown) stained tumour cell percentage area 
between the induced cancer group that given 4NQO alone and DC treated group that 
given DC 1000 mg/kg during (as in the chemopreventive study) or after secession (as in 
the chemotherapeutic study) of 4NQO administration. In addition, groups of Cisplatin 
and Combination of Cisplatin + DC 1000 mg/kg were added to analyse the IHC 
expression in the chemotherapeutic study.  
Generally, in the chemopreventive study, photomicrographs of haematoxylin and 
eosin (H&E) stained tissue sections of the oral administered DC 1000 mg/kg group 
(Figure 4.16 b) showed decreased proliferation indices in 4NQO-treated rats when 
compared to the induced cancer (4NQO alone) group (Figure 4.16 a). Moreover, in the 
chemotherapeutic study, photomicrographs of H&E stained tissue sections of DC 1000 
mg/kg (Figure 4.17 b), Cisplatin (Figure 4.17 c), and the combination of DC 1000 mg/kg 
+ Cisplatin groups (Figure 4.17 d) decreased proliferation indices in 4NQO-treated rats 
when compared to induced cancer (4NQO alone) group (Figure 4.17 a).  
4.3.8.1 Immunohistochemical Analysis of Cyclin D1 and Ki-67 (Cell-cycle proteins) 
In the induced cancer (4NQO alone) group, there was an increase in the proliferation 
as represented with high Cyclin D1 and Ki-67-labelled epithelial cells. The Cyclin D1 
and Ki-67 proliferative area found in the basal and parabasal compartment of the 
keratinized stratified squamous epithelium of induced cancer rats and extended into the 
epithelial tumour cells that have invaded the underlying connective tissue as shown in 
chemopreventive (Figure 4.16 c and e) and in chemotherapeutic (Figure 4.17 a1 and a2) 
studies. Inversely, administration of DC 1000 mg/kg (Figure 4.16 d) in chemopreventive  
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study, as well as DC 1000 mg/kg (Figure 4.17 b1), Cisplatin (Figure 4.17 c1) and the 
combination of DC 1000 mg/kg + Cisplatin (Figure 4.17 d1) in chemotheraputic study, 
does not show SCC and the surface epithelium show intense staining of Cyclin D1 at the 
basal and parabasal region of the surface parakeratinized stratified squamous epithelium 
(proliferative area). The immunostaining was almost negative for Ki-67 in DC 1000 
mg/kg (Figure 4.16 f) of chemopreventive study, and DC 1000 mg/kg (Figure 4.17 b2), 
Cisplatin (Figure 4.17 c2) and the combination of DC 1000 mg/kg + Cisplatin (Figure 
4.17 d2) in chemotheraputic study, indicating strong antiproliferative effects. 
4.3.8.2 Immunohistochemical Analysis of Bcl-2 and p53 (Apoptotic proteins) 
Bcl-2 and p53 proteins expression showed a characteristic cellular localisation. In 
induced cancer group, high positive Bcl-2 and p53 stained cells found in basal and 
parabasal layers and extended into the epithelial tumour cells that have invaded into the 
connective tissue as shown in the chemopreventive study (Figures 4.16 g and i) and 
chemotherapeutic study (Figures 4.17 a3 and a4). However, few positive Bcl-2 and p53 
stained cells were detected in the DC 1000 mg/kg group (Figures 4.16 h and j) of the 
chemopreventive study, and in DC 1000 mg/kg (Figures 4.17 b3 and b4), Cisplatin 
(Figures 4.17 c3 and c4) and combination of DC 1000 mg/kg + Cisplatin (Figures 4.17 
d3 and d4) groups of the chemotherapeutic study.  
4.3.8.3 Immunohistochemical Analysis of β-catenin and E-cadherin (Cell adhesion 
proteins). 
A membranous pattern of β-catenin and E-cadherin protein expression with strong 
positive expression in the parabasal layer and weak expression in the most superficial 
layers was showed in the group DC 1000 mg/kg of chemopreventive study (Figures 4.16 
l for β-catenin and n for E-cadherin) and in the groups DC 1000 mg/kg, Cisplatin and DC 
1000 mg/kg + Cisplatin of chemotherapeutic study (Figures 4.17 b5, c5 and d5 for β-
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catenin) and (Figures 4.17 b6, c6 and d6 for E-cadherin). The immunostaining was 
principally limited to the basal and spinous layers, as opposite to the induced cancer group 
where β-catenin and E-cadherin protein expression exhibited a partially absent 
membranous staining with an altered distribution in the cytoplasm and was combined in 
the keratin pearl nest of the tumour as illustrated in chemopreventive study (Figures 4.16 
k and m) and chemotherapeutic study (Figures 4.17 a5 and a6).
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Figure 4.16, continued 
Figure 4. 16: Photomicrograph of induced cancer and DC 1000 mg/kg groups showing (a and b) 
H&E stained, immunohistochemical expression of (c and d) Ki-67, (e and f) Cyclin D1, (g and h) 
Bcl-2, (I and j) p53, (k and l) β-catenin and (m and n) E-cadherin, respectively, ×100 magnification
P53 
β-catenin 
E-cadherin 
Induced Cancer              
i j 
k l 
m n 
g h 
Bcl-2 
 DC 1000 mg/kg 
137
      
 
 
H
&
E
 
C
yc
li
n 
D
1 
D
C
 1
00
0 
m
g/
k
g 
  
In
du
ce
d 
C
an
ce
r 
 
C
is
p
la
ti
n 
  
D
C
 1
00
0 
m
g/
k
g+
 C
is
p
la
ti
n
  
  
a 
b 
c 
d 
a1
 
b1
 
c1
 
d1
 
138
B
cl
-2
 
K
i-
67
 
a2
 
b2
 
c2
 
d2
 
a3
 
b3
 
c3
 
d3
 
p5
3 
a4
 
b4
 
c4
 
d4
 
In
du
ce
d 
C
an
ce
r 
  
D
C
 1
00
0 
m
g/
k
g 
    
C
is
p
la
ti
n 
    
D
C
 1
00
0 
m
g/
k
g+
 C
is
p
la
ti
n
  
  
 F
ig
ur
e 
4.
17
, c
on
ti
nu
ed
 
 
 
         
 
 
 
  
139
Fi
gu
re
 4
.1
7,
 c
on
ti
nu
ed
 
      
 
F
ig
u
re
 4
. 1
7:
 P
ho
to
m
ic
ro
gr
ap
hs
 o
f 
H
&
E
. (
a)
 I
nd
uc
ed
 c
an
ce
r 
gr
ou
p.
 (
b)
 D
C
 1
00
0 
m
g/
kg
. (
c)
 C
is
pl
at
in
. (
d)
 D
C
 1
00
0 
m
g/
kg
 +
 C
is
pl
at
in
. 
P
ho
to
m
ic
ro
gr
ap
hs
 o
f 
im
m
un
oh
is
to
ch
em
ic
al
 e
xp
re
ss
io
n 
of
 C
yc
li
n 
D
1:
 (
a1
) 
In
du
ce
d 
ca
nc
er
 g
ro
up
. (
b1
) 
D
C
 1
00
0 
m
g/
kg
. (
c1
) 
C
is
pl
at
in
. (
d1
) 
D
C
 1
00
0 
m
g/
kg
 +
 C
is
pl
at
in
. K
i-
67
: (
a2
) 
In
du
ce
d 
ca
nc
er
 g
ro
up
. (
b2
) 
D
C
 1
00
0 
m
g/
kg
. (
c2
) 
C
is
pl
at
in
. (
d2
) 
D
C
 1
00
0 
m
g/
kg
 +
 C
is
pl
at
in
. B
cl
-2
: (
a3
) 
In
du
ce
d 
ca
nc
er
 g
ro
up
. (
b3
) 
D
C
 1
00
0 
m
g/
kg
. (
c3
) 
C
is
pl
at
in
. (
d3
) 
D
C
 1
00
0 
m
g/
kg
 +
 C
is
pl
at
in
. p
53
: (
a4
) 
In
du
ce
d 
ca
nc
er
 g
ro
up
. (
b4
) 
D
C
 1
00
0 
m
g/
kg
. (
c4
) 
C
is
pl
at
in
. (
d4
) 
D
C
 1
00
0 
m
g/
kg
 +
 C
is
pl
at
in
. β
-c
at
en
in
: (
a5
) 
In
du
ce
d 
ca
nc
er
 g
ro
up
. (
b5
) 
D
C
 1
00
0 
m
g/
kg
. (
c5
) 
C
is
pl
at
in
. (
d5
) 
D
C
 1
00
0 
m
g/
kg
 +
 
C
is
pl
at
in
. E
-c
ad
he
ri
n:
 (
a6
) 
In
du
ce
d 
ca
nc
er
 g
ro
up
. (
b6
) 
D
C
 1
00
0 
m
g/
kg
. (
c6
) 
C
is
pl
at
in
. (
d6
) 
D
C
 1
00
0 
m
g/
kg
 +
 C
is
pl
at
in
, 1
00
×
 m
ag
ni
fi
ca
ti
on
In
du
ce
d 
C
an
ce
r 
 
β-
ca
te
ni
n 
E
-c
ad
he
ri
n 
D
C
 1
00
0 
m
g/
kg
 
   
C
is
p
la
ti
n 
   
D
C
 1
00
0 
m
g/
kg
+
 C
is
p
la
ti
n 
 
  
a5
 
b5
 
c5
 
d5
 
a6
 
b6
 
c6
 
d6
 
140
4.3.8.4 Image Analysis of Immunohistochemical Stain Expression 
The immunoreactivity for each tumour marker was measured in the form of area 
percent by using ImageJ software with an IHC toolbox plugin. In the chemopreventive 
study, DC 1000 mg/kg group showed low positive stained tumour cell percentage area 
with statistical significant difference for the following antibodies; Cyclin D1, Ki-67, Bcl-
2 and p53 compared to Induced cancer group (p < 0.05). Whereas β-catenin and E-
cadherin tumour marker antibodies showed slightly higher positive stained tumour cell 
percentage area (no significant difference) compared to the induced cancer group as p > 
0.05 (Table 4.24).  
 
Table 4. 24: The positive stained percentage area of tumour cell during oral 
carcinogenesis induced by 4NQO in rats for the chemopreventive study (Independent t 
test). 
*p value less than 0.05, (p < 0.05) significant value. 
 
 
Tumour marker 
antibodies 
Groups Mean ±SD P value 
Cyclin D1 
Induced cancer 12.86±4.35 
0.040* 
DC 1000 mg/kg 2.67±1.96 
Ki-67 
Induced cancer 1.96±1.49 
0.016* 
DC 1000 mg/kg 0.68±0.68 
Bcl-2 
Induced cancer 10.17±5.98 
0.015* 
DC 1000 mg/kg 4.35±2.15 
p53 
Induced cancer 0.51±0.41 
0.000* 
DC 1000 mg/kg 0.09±0.05 
Β-catenin 
Induced cancer 21.77±6.28 
0.909 
DC 1000 mg/kg 23.90±5.42 
E-cadherin 
Induced cancer 19.09±6.28 
0.478 
DC 1000 mg/kg 22.82±7.25 
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Similarly, In the chemotherapeutic study, DC 1000 mg/kg group showed low positive 
stained tumour cell percentage area for the following antibodies; Cyclin D1, Ki-67, Bcl-
2 and p53 compared to induced cancer group. Whereas, β-catenin and E-cadherin tumour 
marker antibodies showed slightly higher positive stained tumour cell percentage area 
when compared with the induced cancer group (Table 4.25). Statistical significant 
difference (p < 0.05) was observed between the groups in all selected antibodies except 
in β-catenin and E-cadherin. A post hoc Dunnett's test was used to detect the differences 
between the groups as presented in Table 4.26. However, Cyclin D1 positive stained 
tumour cell percentage area was slightly higher in the Cisplatin group than DC 1000 
mg/kg with or without Cisplatin. Interestingly, the combination group of DC 1000 mg/kg 
+ Cisplatin showed superior result than either DC 1000 mg/kg or Cisplatin group alone.  
 
Table 4. 25: The positive stained percentage area of the tumour cell after oral 
carcinogenesis induced by 4NQO in rats for the chemotherapeutic study (one-way 
ANOVA). 
Values are expressed as mean ± standard deviation. *p value less than 0.05, (p < 0.05) 
significant value. 
 
 
 
 
Tumour 
marker 
antibodies 
Induced 
cancer (%) 
area 
DC 1000 
mg/kg (%) 
area 
Cisplatin 
(%) area 
DC 1000 mg/kg 
+ Cisplatin (%) 
area 
P value 
Cyclin D1 10.30±4.62 0.94±0.91 1.85±1.13 0.70±0.33 0.000* 
Ki-67 1.76±2.19 0.13±0.09 0.12±0.11 0.10±0.10 0.000* 
Bcl-2 11.90±7.40 4.34±4.32 2.30±1.23 0.71±0.82 0.000* 
p53 0.18±0.19 0.05±0.11 0.04±0.02 0.02±0.02 0.001* 
β-catenin 22.16±3.06 24.40±7.25 25.00±5.14 26.59±4.47 0.146 
E-cadherin 20.80±3.86 22.44±6.55 21.32±5.86 25.50±7.97 0.176 
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Table 4. 26: Immunohistochemical analysis for chemotherapeutic study. A post hoc 
Dunnett's test. 
Dependent 
Variable 
(I) IHC expression 
(J) IHC 
expression 
Mean 
Difference 
(I-J) 
Std. 
Error 
P value 
Cyclin D1 
DC 1000 mg/kg 
Induced cancer 
-9.36 0.89 0.000* 
Cisplatin -8.45 0.89 0.000* 
DC 1000 mg + Cisplatin -9.60 0.89 0.000* 
Ki-67 
DC 1000 mg/kg 
Induced cancer 
-1.63 0.40 0.000* 
Cisplatin -1.64 0.40 0.000* 
DC 1000 mg + Cisplatin -1.66 0.40 0.000* 
Bcl-2 
DC 1000 mg/kg 
Induced cancer 
-7.56 1.59 0.000* 
Cisplatin -9.60 1.59 0.000* 
DC 1000 mg + Cisplatin -11.19 1.59 0.000* 
p53 
DC 1000 mg/kg 
Induced cancer 
-0.12 0.04 0.008* 
Cisplatin -0.13 0.04 0.004* 
DC 1000 mg + Cisplatin -0.15 0.04 0.001* 
β-catenin 
DC 1000 mg/kg 
Induced cancer 
2.24 1.90 0.506 
Cisplatin 2.84 1.90 0.317 
DC 1000 mg + Cisplatin 4.43 1.90 0.060 
E-cadherin 
DC 1000 mg/kg 
Induced cancer 
1.64 2.28 0.813 
Cisplatin 0.52 2.28 0.992 
DC 1000 mg + Cisplatin 4.70 2.28 0.110 
*p value less than 0.05, (p < 0.05) significant value. 
 
4.3.9 Gene Expression Analysis   
A custom RT² PCR array was performed to assess and compare the expression of some 
selected gene in the induced cancer group that given 4NQO alone and DC treated group 
that given DC 1000 mg/kg during (as in the chemopreventive study) or after secession 
(as in the chemotherapeutic study) of 4NQO administration. In addition, groups of 
Cisplatin and combination of DC 1000 mg/kg + Cisplatin were added to analysed the 
gene expression in the chemotherapeutic study. Gene expression analysis of the selected 
genes are shown in Table 4.27 for chemopreventive study and in Table 4.28 for 
chemotherapeutic study.  
The group of DC 1000 mg/kg showed statistically significant increase in expression 
of both Bax and Casp3 genes compared to Induced cancer group. Whereas Tp53, Bcl-2, 
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Cox-2, Cyclin D1 and EGFR genes were decreased when compared with the induced 
cancer group. The statistical significant difference (p < 0.05) was observed between the 
groups in all selected genes except in Cyclin D1 and EGFR for both chemopreventive 
and chemotherapeutic studies. Interestingly, the combination of DC 1000 mg/kg + 
Cisplatin group showed superior result than either DC 1000 mg/kg or Cisplatin alone.  
Table 4. 27: Gene expression analysis during oral carcinogenesis induced by 4NQO in 
rats for the chemopreventive study 
 
DC 1000 
mg/kg (2^-ΔCt) 
Induced 
cancer (2^-ΔCt) 
Fold 
Regulation 
P value 
Bax 0.042 0.014 2.98 0.010* 
Bcl-2 0.021 0.043 -2.06 0.035* 
Casp3 0.031 0.011 2.71 0.039* 
Tp53 0.016 0.040 -2.43 0.002* 
Ptgs2 0.184 0.437 -2.37 0.029* 
Ccnd1 0.054 0.120 -2.23 0.060 
EGFR 0.139 0.302 -2.17 0.119 
*p value less than 0.05, (p < 0.05) significant value. Red colure means overexpression 
and blue colure means under-expression.  
 
Table 4. 28: Gene expression analysis during oral carcinogenesis induced by 4NQO in 
rats for the chemotherapeutic study. 
 Bax Bcl-2 Casp3 Tp53 Ptgs2 Ccnd1 EGFR 
Induced cancer 
(2^-ΔCt) 
0.009 0.039 0.011 0.034 0.357 0.121 0.290 
DC 1000 mg/kg 
(2^-ΔCt) 
0.033 0.012 0.033 0.011 0.174 0.046 0.122 
Fold Regulation 3.57 -3.17 3.10 -3.14 -2.06 -2.62 -2.37 
P value 0.018* 0.040* 0.038* 0.008* 0.015* 0.087 0.123 
Cisplatin 
(2^-ΔCt) 
0.036 0.009 0.033 0.009 0.124 0.057 0.129 
Fold Regulation 3.85 -4.38 3.15 -3.80 -2.87 -2.12 -2.25 
P value 0.001* 0.027* 0.012* 0.005* 0.003* 0.111 0.117 
Cisplatin + DC 
1000 mg/kg 
(2^-ΔCt) 
0.048 0.008 0.047 0.007 0.111 0.039 0.111 
Fold Regulation 5.15 -4.68 4.41 -4.59 -3.20 -3.07 -2.61 
P value 0.000* 0.025* 0.033* 0.002* 0.004* 0.069 0.105 
*p value less than 0.05, (p < 0.05) significant value. Red colure means overexpression 
and blue colure means under-expression. 
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4.4 Discussion  
Head and neck SCC animal models have been achieved by using carcinogenic agents 
such as 7,12-dimethylbenz(a)anthracene or 4NQO. The induction of OSCC using 4NQO 
has been confirmed in several different rodent species, including mice, hamsters, and rats. 
This carcinogenic agent has been found to be superior on other agent for several reasons. 
First, the 4NQO induced tongue carcinogenesis model has been considered quite useful 
to investigate oral carcinogenesis and identify cancer chemopreventive agents because 
the most common site for oral carcinoma is the tongue and the administration of drinking 
water containing 4NQO is a straightforward and easy method (Tanaka et al., 2011). 
Second, 4NQO induced lesions that developed in the absence of nonspecific 
inflammatory changes. This is a very important because substances such as 7,12-
dimethylbenz(a)anthracene can be significant irritants, resulting in chronic inflammation, 
sloughing of tissue, necrosis, and the formation of organizing granulation tissue. These 
factors can produce lesions that are differ in the cytology and morphology from the 
dysplasia (Hasina et al., 2009). Finally, oral lesions produced by 4NQO are similar to 
human lesions because many ulcerated and endophytic or exophytic tongue tumours and 
dysplasia developed (Yoshida et al., 2005). In addition, the molecular alterations induced 
in rat tissue by 4NQO closely mimic the human disease. For example, altered expression 
of p53 as well as mutation of p53 have been shown in 4-NQO models are similar to 
humans (Takeuchi et al., 2000).  
4NQO is a water soluble quinoline derivative that produce DNA adducts and also can 
undergo redox cycling to produce reactive oxygen species that result in mutations and 
DNA strand breaks (Kanojia & Vaidya, 2006). A study that compared 4NQO painting of 
tongues and delivery of 4NQO in the drinking water in two mouse strains revealed that 
the latter method, resulted in a much higher incidence of oral cavity carcinogenesis (Tang 
et al., 2004).  
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 Several characteristics of oral cavity make it an attractive site for clinical efforts in 
cancer prevention. Key risk factors for OSCC are well-known, and can be used to identify 
high risk individuals who are most likely to benefit from a chemopreventive intervention 
(McCormick et al., 2015).  
Cisplatin is one of the main standard anticancer drugs, which still has an essential role 
in cancer chemotherapy (Ravindra et al., 2010). The common component of 
chemotherapy for the treatment of solid organ cancers was Cisplatin that was first 
described by Michele Peyrone as early as in 1845 (Kim et al., 2015). Cisplatin and other 
platinum drugs are the common drugs in the contemporary medical oncology, which 
considered to have a major impact in management of tumours of the ovary, testes, head 
and neck and other cancers (Kelland, 2007). However, the dose toxicities associated with 
platinum therapy has presented a serious concern where Cisplatin can affect organs such 
as nervous system and kidneys among the clinically established platinum compound 
(Hartmann et al., 1999; Hartmann & Lipp, 2003). For this reason, in the present study a 
combination of DC extract with Cisplatin has been evaluated. 
The present study was performed to evaluate the null hypothesis that carcinogenesis 
in the oral cavity cannot be inhibited or delayed by pharmacologic activation of medicinal 
plant. To address this null hypothesis, in vivo study was performed to determine the 
chemopreventive and chemotherapeutic activity of DC extract. In this study, 4NQO was 
used to induce oral cancer in rat, 4NQO is a potent chemical carcinogen. This material 
has been used in previous studies to induce oral cancer in rat tongues (Lee & Choi, 2011; 
McCormick et al., 2015; Patel & Damle, 2013; Ribeiro et al., 2007). Clinical and 
histopathologic studies have shown that squamous cell carcinoma due to 4NQO is 
considered equivalent to human SCC (Arima et al., 2006; Kitakawa et al., 2006). In many 
146
oral cancer chemoprevention studies, the 4NQO/rat models have been performed using 
F344 rats, however, the induction of OSCC in rats by 4NQO has also been studied in a 
variety of other rat strains. In a study involving seven strains of rats (Dark-Agouti, Long-
Evans, Sprague-Dawley, ACI/Ms, F344, Donryu, and Wistar/Furth), Kitano and 
colleagues reported considerable inter-strain differences in OSCC responses to 4NQO; 
Dark-Agouti rats were the most sensitive to the induction of oral carcinogenesis by 4-
NQO, while Wistar/Furth rats were the least sensitive (Kitano et al., 1992).  
4.4.1 Food Consumption and Body Weight Gain  
Regarding to the food consumption, it is important as proper intake of nutrients is 
essential to the physiological status of the animal and give a good impression on the 
proper response to the treatment (Sathish et al., 2012). Administration of 4NQO produced 
a significant body weight loss in animals due to the intra oral cancer development 
accompanying with malnutrition that caused by lack of appetite, unable to eat, increased 
metabolic rate (Thandavamoorthy et al., 2014).  
In the present study (chemopreventive study), 4NQO administration produced 
decreased food consumption in the induced cancer and vehicle groups from 12 through 
22 weeks which controlled and returned to nearly normal level in the groups that given 
DC resin methanol extract especially at doses of 500 and 1000 mg/kg except at the 21 
and 22 weeks compared to normal control group. In chemotherapeutic study, 4NQO 
administration and Cisplatin reduced food consumption which similarly controlled by DC 
resin methanol extract especially at doses of 500 and 1000 mg/kg throughout the 
experimental period except in the last three weeks for DC 500 mg/kg group and in the 
last two weeks for DC 500 mg/kg + Cisplatin and DC 1000 mg/kg with or without 
Cisplatin compared to normal control group. The effect of 4NQO on the food 
consumption reduction has been confirmed in several studies (Patel & Damle, 2013; 
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Sohrabi et al., 2009). Inversely, another study that used a mice as 4NQO animal model to 
study the chemopreventive effect of ABT-510 (a synthetic peptide) reported that there is 
no significant difference in food consumption between the control and treated groups 
when 4NQO administered in the drinking water for 8 weeks (Hasina et al., 2009).  
Patient with cancer cachexia usually suffer from body weight loss which contribute to 
patient morbidity and mortality (Fearon & Preston, 1990). In the current study, 4NQO 
produced a significant reduction of body weight among the induced cancer and vehicle 
groups which were controlled by treatment with DC extract with or without a combination 
of Cisplatin not with Cisplatin alone. Herein, the result based on the body weight gain 
revealed that the combination of DC extract (DC 500 mg/kg and DC 1000 mg/kg) with 
Cisplatin reduce the toxic effect of Cisplatin by gaining the body weight as nearly as that 
in normal control group. This result is in a like manner with study performed by Patel and 
Damle (2013), who demonstrated that loss of body weight caused by Cisplatin could be 
controlled by treatment with combination of telmisartan with Cisplatin.  
4.4.2 Haematological and Biochemical Parameters 
The administration of 4NQO in the drinking water in animals produces a significant 
alteration in the haematological and biochemical parameters. The dangerous effects of 
4NQO on liver and kidney are well identified and appear to be directly linked to 
increasing the concentration of hepatic and renal enzymes in the serum of experimental 
animals (Viswanadha et al., 2011). Furthermore, the observed changes in serum ALP, 
ALT, AST activity and bilirubin levels are good indicators of hepatic injury resulting 
from cellular leakage and the loss of functional integrity of the cell membrane in liver 
(Kadir et al., 2013). A study performed by Barcessat et al. (2014), who studied the 
systemic toxicity effect of 4NQO during oral carcinogenesis in rats, showed a significant 
reduction in WBC and monocyte counts as well as significant increase in serum ALT and 
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AST when 4NQO topically applied to the tongue of the rat (Barcessat et al., 2014). In the 
present study, a significant reduction in WBC, neutrophil and monocyte counts presented 
in the induced cancer and vehicle groups. This reduction could be attributed to the effect 
of 4NQO on the immune system. In this regard, a study performed by Gannot et al. (2004), 
who analysed the spleens in mice that developed OSCC, discussed the splenic alterations 
regarding cytokines released by the tumour cells affecting the immune system.  
Chemotherapy is one of the most important causes of anaemia in cancer patients, and 
the association between dose and duration of chemotherapy with anaemia is well known 
(Coiffier et al., 2001). The negative impact of anaemia on the cancer patient regarding 
survival and quality of life deserves attention, and this association has been established 
for almost all types of cancer studied (Caro et al., 2001; Spivak et al., 2009). In the 
previous study, when Cisplatin given to the rats twice a week at 2 mg/kg body weight, 
the lowest haemoglobin value recorded at week 4 after therapy was 5.9 g/dl. This 
progressive anaemia has been associated with a slight decline in total WBC and platelet 
counts. However, this reduction was within the normal range (Wood & Hrushesky, 1995).  
Cisplatin-induced renal dysfunction and the degree of therapy-induced anaemia is 
correlated with the amount of Cisplatin-induced renal damage (Wood & Hrushesky, 
1995). In the same manner, the Cisplatin-treated rats (Cisplatin group) in the 
chemotherapeutic study showed a significantly lower level of haemoglobin accompanied 
with lower WBC (with no significant difference) than that of normal control group. In a 
study performed by Wood and Hrushesky (1995), he found that during the administration 
of eight doses of Cisplatin over 25 days (total 16 mg/kg), rats developed a progressive 
decline in renal function measured by a three to fourfold rise in serum creatinine. Herein, 
in the groups of induced cancer, vehicle, Cisplatin and DC 100 mg/kg + Cisplatin, the 
serum creatinine showed significantly higher compared to normal control group. 
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However, the increase in serum creatinine was controlled when DC extract at doses of 
500 and 1000 mg/kg have been administered to the rats. 
Previous studies have shown that administration of 4NQO in drinking water for 8 
weeks significantly increased the level of liver and renal markers (ALP, AST, ALT, urea, 
creatinine and uric acid) which reflected a liver and renal toxicity (Viswanadha et al., 
2011). It is found that when the rats were given 4NQO in their drinking water, the level 
of liver markers (AST, ALT, ALP) and creatinine level were significantly increased, and 
conversely, albumin level was reduced. However, after the rats have been treated with 
Oroxylum indicum (L.) leaf extract, all changes brought back to near normal level (Mohan 
et al., 2016).  
According to previous studies performed by Palipoch and Punsawad (2013) and Yadav 
(2015), reported that Cisplatin administration in a single dose at 7.5, 10, 25 and 50 mg/kg 
induced significant increase in serum ALT, AST and ALP and significant decrease in 
serum albumin. These results were in agreement with the present study where the induced 
cancer, vehicle and Cisplatin groups presented with higher level of liver markers (AST, 
ALT, ALP) and creatinine, and low albumin level, however, Cisplatin 3 mg/kg was used 
in the present study. The ability of Cisplatin to cause alterations in the activity of these 
enzymes could be a secondary event following Cisplatin-induced liver damage with the 
consequent leakage from hepatocytes (Yadav, 2015).  
In the present study, a similar effect of 4NQO on rats was showed, i.e. an alteration in 
the level of the ALP, ALT, AST serum was evident in the groups of induced cancer, 
vehicle and Cisplatin. Treatment of the rats with DC extract at 100, 500 and 1000 mg/kg 
with or without the combination of Cisplatin restored the biochemical parameters (ALP, 
ALT and AST) towards normal. Decreased level of ALT, ALP and AST in blood serum 
of the rats could be attributed due to the antioxidant effect of DC and its ability to act as 
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a free radical scavenger (Machala et al., 2001; Yehia et al., 2013), thereby protecting 
membrane permeability after treatment with DC extract indicate hepatoprotective and 
curative effect. The homoisoflavonoids of DC exhibited a strong antioxidant activity 
comparable to that of the strongest flavonol antioxidant, quercetin (Machala et al., 2001). 
The DC extract returned the levels of haematological and biochemical parameters to 
nearly normal level compared to the normal control group in both chemopreventive and 
chemotherapeutic studies.  
4.4.3 Survival Rate and Tongue Tumour Volume  
The survival rates of the rats in both chemopreventive and chemotherapeutic studies 
that treated with DC extracts was 100% in both DC 500 and DC 1000 mg/kg groups and 
it was 85.7 in DC 100 mg/kg group, the survival rate seen to be dose-dependant. The rats 
that given 4NQO alone (induced cancer group) or with 10%DMSO (vehicle group) 
exhibited survival rates of 71.4%. The survival rate of 71.4% was showed in the Cisplatin 
as well as in the combination of DC 100 mg/kg + Cisplatin groups.  The administration 
of DC extract for 10 consecutive weeks especially at doses of DC 500 and 1000 mg/kg 
during or after the secession of 4NQO increased the survival rate. This result was in 
agreement with a study performed by McCormick et al. (2015), who reported that when 
the rats treated with rosiglitazone (800 mg/kg diet) after 10 weeks administration of 
4NQO, the survival rate increased from 73% to 90%. Inversely,  in a study performed by 
Droguett et al. (2015), who studied the efficacy of quercetin on 4NQO-mice model, they 
found that the survival rate was 65% in the animals that given 4NQO alone compared to 
that groups combined with quercetin at doses of 10 or 100 mg/kg where the survival rate 
presented were 60% and 45%, respectively. However, the significant difference was 
showed between the normal control and other groups. Quercetin does not improve 
survival rate in mice given 4‑NQO (Droguett et al., 2015).  
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The survival rate could be linked to the tumour volume and general health of the 
animals as the administration of 4NQO produced a significant body weight loss due to 
the intra oral cancer development accompanying with malnutrition that caused by lack of 
appetite, unable to eat, increased metabolic rate (Thandavamoorthy et al., 2014). 
Similarly, in the present study, the tumour volume was statistically increased in the 
induced cancer and vehicle groups compared to that groups treated with DC extract at all 
doses (100, 500 and 1000 mg/kg) during or after 4NQO administration. This was in 
agreement with a study performed by Wali et al. (2012), who reported that the 
administration of PEG-8000 for 14 weeks after the 14 weeks of 4NQO administration 
significantly developed smaller tumours volume than 4NQO group. Furthermore, the 
groups treated with Cisplatin alone or in combination with DC extract also showed 
smaller tumour volume compared to the induced cancer and vehicle groups. 
4.4.4 Histopathological Changes in the Tongue of the Rat 
4NQO produces histopathological changes in oral tongue from normal epithelium, 
hyperplasia, premalignant dysplasia, and carcinoma in situ to invasive squamous cell 
carcinoma similar to those in humans (Ribeiro et al., 2004). The results of the present 
study, showed that none of the normal control animals developed any visible tongue 
epithelia lesions and histopathological changes through the end of the study. In addition, 
4NQO at 20 ppm for 8 weeks induced typical precancerous signs and morphological 
alterations on the tongue epithelium after 22 weeks from the start of carcinogen 
administration. None of the induced cancer and vehicle groups showed with hyperplasia. 
There were sever epithelial dysplasia and SCC of well-differentiated type among the 
induced cancer and vehicle animals which were reduced with the treatment by DC extract 
especially at doses of DC 500 and DC 1000 mg/kg, in chemopreventive study. Similarly, 
in the chemotherapeutic study, the sever epithelial dysplasia and SCC controlled by DC 
extract especially at doses of DC 500 and DC 1000 mg/kg with or without Cisplatin and 
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with Cisplatin alone. However, combination of DC extract (DC 500 mg/kg and DC 1000 
mg/kg) with Cisplatin showed better improvement in histology of tongue. The 
combination of DC 1000 mg/kg + Cisplatin reduced the incidence of SCC to 0%. 
Similarly, in previous study, the combination of  telmisartan with Cisplatin reduced 
4NQO induced invasive SCC in the tongue (Patel & Damle, 2013). The histopathological 
grade was usually SCC of a well-differentiated type. The tumours spread into the 
submucosa and underlying muscle layer, forming small nests with typical keratin pearl 
formation (Zhao et al., 2014). In like manner, a study performed to evaluate the effects of 
a etodolac (Cox-2 inhibitor) on 4NQO-induced rat tongue carcinogenesis, showed that 
dysplasia, papilloma and SCC developed at incidences of 21.4, 7.2 and 100%, 
respectively, whereas hyperplasia was not detected. However, the 4NQO was 
administered in the drinking water for 8 weeks at 20-30 ppm and the experiment was 
completed at 28 weeks (Yamamoto et al., 2004).  
In another study, when the rats received 4NQO at 20 ppm in the drinking water for 10 
weeks, the incidence of invasive OSCC in the rat tongue was highly reproducible which 
was 83% and 75% in the two experiments demonstrated invasive oral cancers at 26 weeks 
after the start of 4NQO administration (Peng et al., 2015). Generally, 4NQO induced a 
variety of dysplastic and neoplastic lesions with morphological and molecular alterations 
in the oro-esophageal epithelium that mimic those occurring in human oral epithelial pre-
neoplastic and neoplastic lesions depend on the dose and duration of administration (Tang 
et al., 2004).  
4.4.5 Oral Cancer Metastasis  
Prognosis of cancer patients and success or failure of treatment is associated with the 
presence or absence of metastasis (Kawashiri et al., 2001). The effect of chemotherapy 
on the metastasis is expected when it achieved in combination with either surgery and/or 
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radiotherapy (local therapies).  However, there were few reports in which the inhibition 
of metastasis using chemotherapy was investigated, and the evaluations were not 
consistent (Kawashiri et al., 2009). Blocking metastatic spread measured as the greatest 
challenge of metastatic cancer that has proven additional worrying. Certainly, most of the 
current anticancer treatments have been developed to treat primary disease; they often fail 
in blocking metastasis (Desmet et al., 2013).  
Detection of metastatic foci, whether in lymph nodes or distant organs, can present a 
significant challenge. Classically, the presence of metastasis has been evaluated at 
necropsy in euthanised mice after completion of the experimental protocol. In OSCC, 
most investigators resect both the draining lymph node basins and the lungs for 
pathological evaluation (Milas et al., 2010). In other studies performed to investigate the 
effects of anticancer agents on cancer invasion and metastasis in mice, concluded that 
both Cisplatin and peplomycin are effectively inhibiting invasion and metastasis 
(Kawashiri et al., 2001; Kawashiri et al., 2009). Similarly, in the current 
chemotherapeutic study, metastatic tumour in the cervical lymph node was presented in 
two rats from the induced cancer and vehicle groups, while DC treated groups with or 
without Cisplatin as well as Cisplatin group inhibited cervical lymph node metastasis.  
4.4.6 Immunohistochemical Analysis   
Immunohistochemistry is a process of detecting targeted antigens (proteins) in tissue 
sections by the use of labelled antibodies through antigen-antibody interactions and is 
applied in paraffin embedded tissues (Van Eycke et al., 2017). Over the past decade, in 
clinical pathology diaminobenzidine (DAB) has been widely used as a (brown) 
chromogen for revealing protein expression using IHC together with haematoxylin for 
tissue counterstaining (Helps et al., 2012). Discrepancies in the decision of the accurate 
colour intensity turn out to be a problem and thus often leads to inter-observer variations. 
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Calculation of the stained area percentage has a varying (poor to good) rate of 
reproducibility, even if the data provided by the pathologist have good to excellent inter-
observer reproducibility (Jaraj et al., 2009). Because of the limitations mentioned above 
of visual IHC stained assessment, means of automated quantitation of IHC images may 
provide the necessary detailing to improve IHC data quality across the world. Recently, 
advanced digital image processing systems have been introduced to gather the high 
volume IHC analysis and scoring (Varghese et al., 2014).  
ImageJ released in 1997 and is public domain, Java-based image processing program, 
developed at National Institute of Mental Health, Bethesda, MD, USA (Schneider et al., 
2012). ImageJ with colour deconvolution and Immunoratio plugins, are freely available 
web-based applications, enabling their routine use for quantitative IHC analysis (Sysel et 
al., 2013). Another study used ImageJ with a plugin called IHC-toolbox as a method of 
automated digital image analysis for quantification of histological biomarkers, concluded 
that the ImageJ with IHC-toolbox plugin could generate a visual illustration of the 
statistical model and detect a specified colour automatically (Shu et al., 2016). Therefore, 
in the present study, ImageJ software with IHC-toolbox plugin was used to assess the 
quantification of tumour marker staining in tissue sections.  
Cyclin D1 considered as a key regulator of the cell-cycle progression and works as a 
transcriptional co-regulator. The overexpression of Cyclin D1 encourages transformation 
to a malignant phenotype, and it has been related to the development and progression of 
different types of cancer (Shan et al., 2009). Overexpression of cyclin D1 has a direct link 
to histopathological differentiation (Saawarn et al., 2012) and also functioned as an 
independent prognostic factor of oral cancers aggressiveness (Huang et al., 2012). In the 
present study, for both the chemopreventive and chemotherapeutic experiments, oral 
administration of DC 1000 mg/kg reduced the expression of Cyclin D1 that is usually 
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overexpressed in head and neck SCC (Perez-Ordonez et al., 2006), as shown in the 
induced cancer group of this study.  Administration of DC 1000 mg/kg also reduced the 
expression of Ki-67. This result is in agreement with a study performed by Wali et al. 
(2012), who demonstrated that the topical application of Polyethylene Glycol decreased 
proliferation (number of Ki-67 positive cells) and reduced expression of Cyclin D1 in the 
tongue mucosa of the 4NQO-rats group. Ki-67 protein is a reliable marker of proliferating 
cells because it can be detected during cell cycle especially in phases G1, S, G2, and M, 
however, cannot be detected in G0 phase. There was a direct connection between 
increasing Ki-67 labelling index and increasing Broders' grading of OSCC (Tumuluri et 
al., 2002). In a study that analysed the synergistic antitumor effect of Cisplatin with 
Andrographolide in human OSCC (CAL-27 cells in vitro and in vivo), the results 
demonstrated that this combination decreased Ki-67 expression in vivo and can be used 
as a potential therapeutic strategy for OSCC (Chen et al., 2017).  
In the present study (both chemopreventive and chemotherapeutic studies), a higher 
expression of Ki-67 was observed in the induced cancer group compared to the DC 1000 
mg/kg with or without Cisplatin. The combination of DC 1000 mg/kg + Cisplatin resulted 
in more reduction in the expression of Ki-67 than other groups. This result indicates that 
the DC 1000 mg/kg in combination with Cisplatin produced a synergistic anti-tumour 
growth activity against OSCC. In addition, this result indicated that DC 1000 mg/kg 
reduced the Ki-67 and Cyclin D1 expression, which in turn decreases the proliferation 
and the aggressiveness toward OSCC.  
The previous study presented that the expression of the antiapoptotic Bcl-2 protein 
closely correlated to the expression of p53 (Ravi et al., 1996). Furthermore, it is reported 
in North Indian patients, p53 was positivity expressed in 55% of oral dysplasia lesions, 
in 75% of oral carcinoma lesions and no positive staining was detected in normal oral 
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mucosa (Kaur et al., 1994). In another study, when the 4NQO topically applied on the rat 
tongue for 12 weeks, the expressions of Ki-67, Cyclin D1, p63, Bcl2 and p53 showed 
increased expression according to the grade of the dysplastic lesion in oral mucosal tissues 
of the rats (Scrobota et al., 2016). The result of the current study is in line with these 
findings where the Bcl-2 and p53 proteins expressed more in the induced cancer group 
that was given 4NQO alone for 8 weeks than the treated group that was given DC 1000 
mg/kg. Down-expression of Bcl-2 and high expression and activation of Bax, as well as 
caspase-3, were reported to enhance apoptotic effect (Kang et al., 2010).  
Overexpression of p53 mutant protein has been demonstrated in precancerous and 
cancerous lesions of the oral cavity and associated with poor clinical outcome (Chin et 
al., 2004). However, the present study indicated that DC 1000 mg/kg reduced the Bcl-2 
and p53 levels, successively enhanced the apoptotic effect during oral carcinogenesis. In 
head and neck SCC cell lines, high expression of endogenous Bcl-2 was linked to increase 
Cisplatin resistance, and experimental overexpression of Bcl-2 promoted Cisplatin 
resistance (Michaud et al., 2009). For this reason, during treatment of OSCC with 
Cisplatin, an adjunctive treatment that targeting Bcl-2 and its family members could be 
helpful. In the present study, in the chemotherapeutic experiment, the combination of DC 
1000 mg/kg with Cisplatin reduced the expression of Bcl-2 more than either DC 1000 
mg/kg or Cisplatin alone. This indicated that DC 1000 mg/kg augments the inhibitory 
effects of Cisplatin in vivo.  
β-catenin distribution is different in normal mucosal cells than in OSCC cells. In 
normal oral epithelium, β-catenin show mainly membranous staining (Pannone et al., 
1998), whereas in OSCC there is leaks of membrane-bound β-catenin and this results in 
a corresponding increase in cytoplasmic localisation and an irregular nuclear 
accumulation (Lo et al., 1999). β-catenin is a transcription factor in the Wnt pathway, 
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which promotes the transcription of genes involved in cellular proliferation and apoptosis 
inhibition (Van de Wetering et al., 1997). Overexpression in β-catenin protein level can 
lead to increased cell proliferation in human head and neck cancer cells (Song et al., 2010) 
and has been detected during human OSCC development (Pannone et al., 2010). Another 
study demonstrated that abnormal expression of β-catenin is expressively associated with 
invasion and poor prognosis (Mahomed et al., 2007).  
In a study performed by Osei-Sarfo et al. (2013), the level of β-catenin in the female 
mice tongue was increased by 2- to 3-fold after 4NQO treatment compared to untreated 
vehicle group. Hence, 4NQO treatment is associated with an increase in total β-catenin 
levels (Osei-Sarfo et al., 2013). Another study showed that β-catenin protein primarily 
presented in the basal layer of tongue epithelium in the normal control group samples, 
whereas 4NQO administration resulted in both an increase in the β-catenin level and an 
expansion of β-catenin staining to the suprabasal layers of the tongue epithelium and the 
tumour cells invading the underlying connective tissue. All 4NQO plus drug treatment 
groups (bexarotene, retinoid CD1530 and the combination of both of them) showed lower 
β-catenin protein levels in the tongue epithelium, primarily limited to the basal layer, even 
in the regions of the tumour (Tang et al., 2014).  
Correspondingly, in the present study, the expression of β-catenin in the induced 
cancer (4NQO alone) group showed an aberrant pattern with the leak of membrane-bound 
β-catenin and revealed a corresponding increase in cytoplasmic localisation of β-catenin 
as compared to that in the DC 1000 mg/kg group for both chemopreventive and 
chemotherapeutic studies. It has been suggested that the cytoplasmic expression pattern 
instead of membrane staining of β-Catenin is a common abnormal tumour-related 
alteration (Gao et al., 2005) rather than loss or reduction of expression, which has been 
described previously (Bankfalvi et al., 2002). In a study performed by Li et al. (2016), 
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who examined the role of β-catenin in the development of Cisplatin resistance in OSCC 
cell lines, found that the overexpression of β-catenin can result in Cisplatin resistance. In 
the present study, level of β-catenin in the Cisplatin group was higher than that in induced 
cancer group; however, the highest expression was presented in the combination of DC 
1000 mg/kg + Cisplatin group. This result indicates that DC 1000 mg/kg could restore 
the β-catenin level to the membranous layer and enhance role of Cisplatin in regulating 
level of β-catenin, which in turn decrease the cell proliferation in the cancer cells, and 
maintains normal epithelial polarity and inhibits invasion.   
E-cadherin is a calcium-dependent transmembrane glycoprotein, and it is expressed in 
most epithelial cells and is essential for the establishment of adherence junction between 
cells (Gall & Frampton, 2013). It has been reported that after topical application of 4NQO 
on the mouse tongue for 24 weeks, staining of E-cadherin was expressed strongly in the 
parabasal cell layer, but not on the surface of basal cells and after 40 weeks of 4NQO 
application, E-cadherin expression was lost in the invasive front, and a positive staining 
of tumour nests was noticed (Schoop et al., 2009).  
The expression of E-cadherin and β-catenin in OSCC depended on the degree of 
tumour differentiation as reported by Mahomed et al. (2007), where well-differentiated 
tumours showed significantly higher expression of E-cadherin and β-catenin compared 
with the moderate and poor differentiated tumours. Kudo et al. (2004) have linked this 
finding due to methylation of the E-cadherin gene promoter region and to degradation of 
the membranous β-catenin protein. However, a positive E-cadherin expression was 
observed in the cell membrane of the normal oral mucosa epithelial tissues, and it was 
also detected in poor- and moderate-differentiation OSCCs with the highest expression 
seen in well-differentiation OSCC (Zhou et al., 2015). In the present study, the expression 
of E-cadherin in the induced cancer group showed an aberrant pattern with leaks of 
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membrane-bound E-cadherin and revealed a corresponding increase in cytoplasmic 
localisation as opposed to that in the DC 1000 mg/kg group for both chemopreventive 
and chemotherapeutic experiments. The result of the present study is in agreement  with 
another study performed by Gao et al. (2005), who reported a mixture of cytoplasmic and 
membrane staining expression pattern of E-cadherin and β-catenin in the tumour cells. 
Therefore, the result of the present study indicated that DC 1000 mg/kg could restore the 
E-cadherin to the membranous layer, which in turn decreases the cell proliferation in the 
cancer cells and maintain normal epithelial polarity and inhibit invasion. 
Drug resistance considered the main problem associated with Cisplatin application as 
well as toxic side effects, which lead to termination or limited therapeutic efficacy. To 
overcome these problems, combination therapy with other agents is recommended (Jo et 
al., 2016). For this reason, DC 1000 mg/kg was used as an adjunctive agent with Cisplatin 
to treat OSCC in vivo.  
4.4.7 Gene Expression Analysis  
The findings of RT2 profiler PCR array in the present study showed a significant 
alteration in the genes; Bax, Bcl-2, Casp3, Tp53 and Cox-2, however, Cyclin D1 and 
EGFR genes showed an alteration but without significant difference between the induced 
cancer and DC 1000 mg/kg groups for both experiments (chemopreventive and 
chemotherapeutic). In addition, a significant difference showed in the induced cancer 
group compared to both Cisplatin and Cisplatin + DC 1000 mg/kg groups in the 
chemotherapeutic experiment.    
Apoptosis is a strongly regulated pathway of cell death not only during development 
but also in adult multicellular organisms, in which it partially controls cell numbers. 
Apoptosis is characterised by cell shrinkage, chromatin condensation, and nuclear and 
cell fragmentation. These features result in the formation of apoptotic bodies that are then 
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engulfed by adjacent phagocytic cells (Cotter, 2009). Severe DNA damage, such as that 
found in precancerous lesions can induce apoptosis via activation of the DNA damage 
checkpoint pathway which can serve to remove potentially harmful DNA-damaged cells 
and thereby block cancer development (Plati et al., 2011).  
The Bcl-2 proteins i.e. Anti-apoptotic proteins (such as Bcl-2 and Bcl-XL) and pro-
apoptotic (such as Bad, Bax or Bid) are a family of proteins involved in the response to 
apoptosis. The sensitivity of cells to apoptotic stimuli can depend on the balance of pro- 
and anti-apoptotic Bcl-2 proteins. When there is an excess of pro-apoptotic proteins, the 
cells are more sensitive to apoptosis, while an excess of anti-apoptotic proteins make the 
cells tend to be more resistant (Youle & Strasser, 2008). In the present study, the results 
revealed that the DC 1000 mg/kg induced apoptosis associated with a significant up-
regulation of Bax, activation of caspase 3, and the down-regulation of Bcl-2 in both 
chemopreventive and chemotherapeutic studies. This result is in agreement with a study 
conducted by Wang et al. (2014), who reported that the injection of Clotrimazole I.P at 
150 mg/kg per day for two weeks markedly reduced Bcl-2 expression and increased the 
protein level of Bax in tumour tissues of xenograft mice model. Anti-apoptotic Bcl-2 
family members function at least in part by inhibiting cytochrome c release from the 
mitochondria. They perform this task by preventing translocation and/or activation of 
Bax-like proteins on the mitochondria (Choi et al., 2005). This may explain the gene 
alterations of the present study where the induced cancer group showed with 
overexpression of Bcl-2 and down-expression of Bax genes.  
When the ratio of Bax to Bcl-2 increases, the mitochondrial permeability transition 
pore opens and in turn results in releasing apoptogenic mitochondrial proteins to activate 
caspases and induce cell apoptosis (Tait & Green, 2013). This could be the reason, in the 
present study, the caspase 3 was overexpressed in DC 1000 mg/kg group compared to the 
161
induced cancer group in both chemopreventive and chemotherapeutic studies. Recently, 
the effect of DC extract on H400 cells line was studied by Alabsi et al. (2016), and they 
found that the DC extract inhibited cells proliferation via apoptosis through activation of 
caspases 9 and 3/7 and demonstrated an up-regulation of Bax, Bad, and Bid as well as 
down-regulation of Bcl-2.  
Clinically, patients with high Bax expression had better disease specific survival 
compared with those who had low Bax expression, while high Bcl-2 expression resulted 
in poorer disease specific survival for patients (Xie et al., 1999). In the current study, the 
expression of Bax and Casps3 genes were overexpressed in Cisplatin group and were 
more in the combination group of DC 1000 mg/kg + Cisplatin, whereas Bcl-2 was down-
expressed with a greater reduction showed in the combination group. In another study 
that used combination therapy with Bax gene transfer and Cisplatin to increase the 
sensitivity of SCC to Cisplatin reported that a Bax gene administration to SCC by gene 
gun system has therapeutic applications for enhancing chemotherapy in SCC (Sugimoto 
et al., 1999). It has been reported that the combination of Ad‑ING4‑P53 and Cisplatin in 
an attempt to enhance chemosensitivity of hypopharyngeal cancer to Cisplatin, resulted 
in increased apoptosis induction through overexpression of Bax and down-expression of 
Bcl‑2 (Ren et al., 2016). This could be the reason that the DC 1000 mg/kg enhanced the 
effect of Cisplatin during chemotherapy treatment of oral cancer. 
The tumour suppressor gene p53 produced a p53 protein which functions in the G1-S 
phase of the cell cycle to allow repair of damaged DNA and to prevent the cell from 
entering S phase, or alternatively, in guiding the damaged cells to apoptosis (Patil et al., 
2016). In its wild-type form, p53 is a major tumour suppressor whose function is critical 
for protection against cancer (Mercer, 1992). Inversely, the mutant p53 protein loses its 
tumour suppressor function and becomes a tumour-promoting factor and promotes the 
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process of the tumour (Rivlin et al., 2011). Moreover, mutation of the p53 gene precedes 
the process of carcinogenesis (Osugi, 1996; Strano et al., 2007). Therefore, the level of 
p53 in 4NQO-treated mouse cells was dramatically increased compared with the 
untreated control (Maltzman & Czyzyk, 1984). From a clinical view, a high positivity 
p53 in patients with tumours make them tended to have a poor prognosis when compared 
with those who had tumours with positivity low p53 (Xie et al., 1999). Another study 
conducted to assess the effect of Zinc supplementation on 4NQO-induced rat oral 
carcinogenesis, found that Zinc supplementation can decrease the expression of the 
tumour markers like p53,  COX-2 and cyclin D1 compared to 4NQO-treated rats (Fong 
et al., 2011).  
In consistent with previous studies, the result of the current study demonstrated an 
overexpression of Tp53 in the induced cancer (4NQO-treated rats) compared to DC 1000 
mg/kg group in both chemopreventive and chemotherapeutic studies. Cisplatin also 
reduced the expression of Tp53, and this was further reduced when DC 1000 mg/kg used 
with the Cisplatin in DC 1000 mg/kg + Cisplatin combination group. It has been reported 
that in the xenograft mice model with p53 mutation a higher resistance to Cisplatin has 
been detected (Henriksson et al., 2006). So, from this point of view, the combination 
therapy with Cisplatin is necessary (Jo et al., 2016). 
Overexpression of the COX-2 gene is associated with oral cancer and oral 
premalignant lesions and appears to be greater in high-risk oral lesions (Wang, 2005). 
This concept was confirmed in a study performed by Ribeiro et al. (2009), who concluded 
that the expression of COX-2 showed abnormally in the initial stage of oral 
carcinogenesis and up-regulated with transformation to the oral malignant stage. In 
another study, the mean expression of COX-2 in OSCC was 15.9 ± 6.7-fold higher than 
that in adjacent phenotypically normal oral tissues harvested from the same animal 
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(McCormick et al., 2010). In the present study, the expression of COX-2 was decreased 
when the rats treated with DC extract compared to the induced cancer group in both 
studies (chemopreventive and chemotherapeutic). This result was in agreement with a 
study that conducted to evaluate the inhibitory effect of apple extract in which the groups 
that treated with apple extract showed decreased COX-2 expression when compared with 
the induced cancer (4NQO-treated) group (Ribeiro et al., 2014). For the chemotherapeutic 
study, the Cisplatin and combination of Cisplatin + DC 1000 mg/kg groups presented 
with down-expression of COX-2 and the highest inhibition exhibited in the combination 
group.  
Cyclin D1 (CCND1) located on chromosome 11q13 is a positive regulator of the cell 
cycle (Huang et al., 2012). Previous studies have approved the overexpression of cyclin 
D1 (CCND1) in OSCC and shortened overall survival (Kaminagakura et al., 2011; 
Michalides et al., 1995). In 2003, Yoshida and his colleagues investigated the inhibitory 
effect of troglitazone on 4NQO-rat tongue carcinogenesis and found that the 
supplementation of troglitazone in the diet reduced expression of CCND1 after 4NQO 
administration (Yoshida et al., 2003). Moreover, a study performed by Wilkey et al. 
(2009) reported that CCND1 overexpression increases susceptibility to 4NQO-induced 
oral tumorigenesis in mice.  
Similarly, Naoi et al. (2010) found that Nimesulide (a selective COX2 inhibitor) 
significantly reduced the expression of CCND1 and COX2 in 4NQO-induce tongue 
tumours of rats using RT-PCR analysis. In the same manner, the present studies 
(chemopreventive and chemotherapeutic) showed that the DC 1000 mg/kg reduced the 
expression of CCND1 compared to the induced cancer group, however, no significant 
difference was detected. The overexpression of cyclin D1 is usually associated with 
resistance to chemotherapy and radiotherapy in several types of cancer including SCC of 
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head and neck (Kothari & Mulherkar, 2012). This could explain the result of the present 
study where the expression of CCND1 in the Cisplatin group was a bit higher than that in 
both DC 1000 mg/kg and combination groups. Consequently, in another study, an attempt 
to increase the Cisplatin sensitivity by inhibition of Cyclin D1 via RNAi (shRNA) against 
cyclin D1 has been done, and this demonstrate the potential of combining vector-based 
cyclin D1 silencing with chemotherapy to achieve maximum tumour regression. (Kothari 
& Mulherkar, 2012). In the present study, the combination of DC 1000 mg/kg with 
Cisplatin resulted in a significant inhibition of cyclin D1 which may increase the 
sensitivity of the chemotherapy.  
Epidermal growth factor receptor (EGFR) is a critical early event in HNSCC and is 
overexpressed in > 80% of head and neck SCC (Benchekroun et al., 2010). It is a member 
of the ErbB family of receptors, and its overexpression has been associated with some 
cancers, including lung cancer, anal cancers and glioblastoma multiforme. A blockade of 
EGFR may lead the cancer cells to enter apoptosis (Khan et al., 2006). Therefore, 
inhibition of EGFR eliminates the invasive potential of the cancer cells (Singh et al., 
2011). Topical application of polyethylene glycol-8000 by painting the oral cavity of the 
rat using a sable brush (#4) for up to 3–4 minutes significantly lowered the intensity as 
well as the number of areas overexpressing EGFR in 4NQO-treated rats where baseline 
EGFR expression was much higher than the tongue/oral mucosa of healthy control rats 
(Wali et al., 2012). In the present study, the expression of EGFR was reduced in DC 1000 
mg/kg compared to the induced cancer groups in both chemopreventive and 
chemotherapeutic studies.  In the chemotherapeutic study, the Cisplatin group exhibited 
an inhibition rate but a bit higher than DC 1000 mg/kg and this could be attributed to the 
chemotherapy resistance. A study performed by (Hiraishi et al., 2008) suggested that the 
changes in EGFR expression play a significant role in controlling the drug-resistant 
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phenotype of cells in response to Cisplatin. It is therefore suggested that the DC 1000 
mg/kg could be used as an adjunctive agent with Cisplatin to treat OSCC.  
Generally, in the present study, the results suggest that DC 1000 mg/kg combined with 
Cisplatin treatment can indeed enhance chemotherapy in OSCC by regulation of various 
inflammatory and proliferative genes. 
4.5 Conclusion  
The present study reported that DC extract especially at doses of DC 500 mg/kg and 
DC 1000 mg/kg both confer statistically significant protection against carcinogenesis in 
a well-studied rat model for OSCC. Chemopreventive and chemotherapeutic efficacy 
were expressed as a significant increase in the food consumption, body weight gain, 
regulation the haematological and biochemical parameters, reduction in oral cancer-
related mortality and reduction in oral cancer incidence. The combination of DC extract 
and Cisplatin may be useful as a rational strategy for the treatment of patients with oral 
cancer.
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CHAPTER 5: CONCLUSION 
5.1 Introduction 
The current study provided an insight into the toxicity profile of DC resin methanol 
extract on the food consumption, water intake, body weight, organ weight, 
haematological parameters, biochemical parameters and histopathological of the vital 
organs (liver, kidney, heart, spleen and lung) in SD rats by using acute and subacute oral 
toxicity tests. In addition, the anticancer activity of DC resin methanol extract in the 
4NQO-induce oral tongue cancer animal model in both chemopreventive and 
chemotherapeutic studies by assessing food consumption, water intake, body weight, 
survival rate, tumour tongue volume and the incidence of OSCC in SD rats. Furthermore, 
the metastasis obstruction of DC resin methanol extract in the chemotherapeutic study by 
assessing the changed in regional cervical lymph node histopathologically.  
5.2 Summary of findings 
Results from the present study provided clear evidence into the following:  
1. DC resin methanol extract did not cause any lethality or produce any treatment-
related changes in haematological and serum biochemical parameters or important 
histopathological signs. 
2. DC resin methanol extract could be well tolerated up to the dose 2000 mg/kg body 
weight and could be classified as Category 5.  
3. DC resin methanol extract is well tolerated up to the dose of 1500 mg/kg body 
weight administered daily for up to 28 days.  
4. DC resin methanol extract increased water intake in SD rats compared to the 
control group. This result could be referred to the ability of DC to produce 
vasodilatation (hypotension) due to relaxation of smooth muscles of blood vessels 
which in turn stimulated thirst and increased water intake.  
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5. The present investigation demonstrates, at least in part, the safety of DC resin 
methanol extract suggesting its promising potential for pharmaceutical uses.   
6. DC resin methanol extract confer statistically significant protection against 
carcinogenesis in a well-studied rat model for OSCC as a marked increase in the 
food consumption, body weight gain, regulation the haematological and 
biochemical parameters, reduction in oral cancer-related mortality and reduction 
in oral cancer incidence especially at doses of DC 500 mg/kg and DC 1000 mg/kg.  
7. DC resin methanol extract at dose 1000 mg/kg reduced the incidence of OSCC 
into 0 % when used in combination with the commercially used anticancer drug 
(Cisplatin). 
8. DC 1000 mg/kg inhibited the proliferation of the cancer cells, maintained 
epithelial polarity and discouraged the aggressiveness toward OSCC by 
decreasing the expression of Cyclin D1, Ki-67, Bcl-2 and p53, and slightly 
increasing the expression of β-catenin and E-cadherin.  
9. DC 1000 mg/kg induced apoptosis by upregulation of Bax and Casp3 genes, and 
down-regulation of Tp53, Bcl-2, Cox-2, Cyclin D1 and EGFR genes compared to 
the induced cancer group. 
10. DC resin methanol extract can be used as an add-on therapy with Cisplatin for 
treatment of oral cancer and control Cisplatin toxicity, thus could increase the 
quality of life of cancer patients.  
Taken all together, the results highlighted that the Dracaena cinnabari is safe to be 
used systemically via oral administration and possesses anticarcinogenic potency on the 
oral carcinogenesis and has the potential to be developed as an anticancer agent for oral 
cancer. This makes Dracaena cinnabari a promising candidate for further investigation 
as a natural chemopreventive and/or chemotherapeutic agent. 
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5.3 Recommendation for future study 
Though oral administration of DC resin methanol extract may potentially represent a 
significant advance in chemopreventive and chemotherapy of OSCC, some questions 
remain to be answered. Future studies will need to assess the followings: 
1. Identification of pure compound(s) and chemical characterization of the 
cytotoxically active compounds of Dracaena cinnabari.  
2. We chose a maximum dose of DC resin methanol extract 1000 mg/kg orally 
administered for chemopreventive and chemotherapeutic studies based on data 
from acute and subacute oral toxicity tests. However, this will need to be increased 
to elucidate the most effective dose to treat OSCC.  
3. While our studies with 4NQO performed at initiation and post-initiation stages, 
studies of the therapeutic effect of Dracaena cinnabari with other models of 
OSCC (transgenic and orthotopic xenograft models) are helpful.  
4. It is useful to determine dosing and timing for introduction of Dracaena cinnabari 
treatment for achieving maximal effects depending on the stage of oral cancer. 
5. An animal model that can produce a high incidence of cancer metastasis is 
necessary to verify the metastasis obstruction effect of Dracaena cinnabari.  
6. Development a topically applied formulation of Dracaena cinnabari (via 
toothpaste, oral rinse, lozenge, chewing gum, etc.) may potentially represent a 
significant advance in oral cancer prevention strategy. 
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APPENDICES 
APPENDIX A – Food consumption of rats during 4NQO-induced oral carcinogenesis 
in the chemopreventive study. A one-way ANOVA test. 
 Groups Mean 
Standard 
Deviation 
P value 
Week 1 
Normal 86.27 2.99 
0.877 
Induced Cancer 85.17 3.77 
Vehicle 86.85 3.77 
DC 100 mg/kg 85.57 2.33 
DC 500 mg/kg 87.10 3.70 
DC 1000 mg/kg 85.90 3.09 
Week 2 
Normal 86.33 2.99 
0.810 
Induced Cancer 85.21 3.77 
Vehicle 87.32 3.77 
DC 100 mg/kg 85.62 2.33 
DC 500 mg/kg 87.15 3.70 
DC 1000 mg/kg 85.95 3.09 
Week 3 
Normal 87.32 2.71 
0.619 
Induced Cancer 86.04 3.43 
Vehicle 87.71 3.03 
DC 100 mg/kg 86.36 2.04 
DC 500 mg/kg 88.46 2.25 
DC 1000 mg/kg 86.90 3.09 
Week 4 
Normal 88.90 3.31 
0.954 
Induced Cancer 87.83 2.91 
Vehicle 88.74 2.44 
DC 100 mg/kg 88.23 2.35 
DC 500 mg/kg 89.17 2.95 
DC 1000 mg/kg 88.75 2.67 
Week 5 
Normal 89.32 3.49 
0.817 
Induced Cancer 89.11 2.05 
Vehicle 89.78 2.34 
DC 100 mg/kg 90.54 2.05 
DC 500 mg/kg 88.67 2.54 
DC 1000 mg/kg 89.57 2.48 
Week 6 
Normal 89.89 3.48 
0.852 
Induced Cancer 89.33 1.90 
Vehicle 90.62 2.27 
DC 100 mg/kg 90.86 2.21 
DC 500 mg/kg 89.69 2.75 
DC 1000 mg/kg 89.62 2.39 
Week 7 
Normal 92.26 2.74 
0.750 
Induced Cancer 91.57 1.44 
Vehicle 92.71 1.96 
DC 100 mg/kg 93.26 2.39 
DC 500 mg/kg 91.94 2.26 
DC 1000 mg/kg 92.69 2.21 
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Week 8 
Normal 94.01 2.45 
0.780 
Induced Cancer 92.47 0.99 
Vehicle 92.98 1.53 
DC 100 mg/kg 93.58 2.58 
DC 500 mg/kg 92.91 2.19 
DC 1000 mg/kg 93.49 2.33 
Week 9 
Normal 94.82 1.03 
0.315 
Induced Cancer 93.32 1.58 
Vehicle 92.75 1.37 
DC 100 mg/kg 94.25 2.16 
DC 500 mg/kg 93.63 2.44 
DC 1000 mg/kg 94.15 1.61 
Week 10 
Normal 95.04 1.66 
0.915 
Induced Cancer 93.86 2.63 
Vehicle 94.46 1.73 
DC 100 mg/kg 94.34 2.60 
DC 500 mg/kg 94.95 2.52 
DC 1000 mg/kg 95.00 2.54 
Week 11 
Normal 95.79 1.59 
0.385 
Induced Cancer 94.11 1.80 
Vehicle 94.85 1.35 
DC 100 mg/kg 95.28 2.22 
DC 500 mg/kg 96.13 1.77 
DC 1000 mg/kg 95.09 1.99 
Week 12 
Normal 98.24 1.59 
0.028 
Induced Cancer 95.31 1.85 
Vehicle 95.62 1.34 
DC 100 mg/kg 96.64 2.59 
DC 500 mg/kg 97.82 1.20 
DC 1000 mg/kg 97.23 2.11 
Week 13 
Normal 99.84 2.34 
0.001 
Induced Cancer 97.15 1.22 
Vehicle 96.31 1.36 
DC 100 mg/kg 98.71 1.37 
DC 500 mg/kg 99.08 0.90 
DC 1000 mg/kg 98.48 1.44 
Week 14 
Normal 101.71 2.21 
0.000 
Induced Cancer 97.96 1.20 
Vehicle 97.81 1.18 
DC 100 mg/kg 100.76 1.29 
DC 500 mg/kg 101.01 1.12 
DC 1000 mg/kg 101.20 0.79 
Week 15 
Normal 103.52 2.25 
0.000 
Induced Cancer 99.14 .85 
Vehicle 99.36 1.24 
DC 100 mg/kg 101.50 1.15 
DC 500 mg/kg 103.05 1.24 
DC 1000 mg/kg 103.29 1.46 
Week 16 
Normal 107.60 2.15 
0.000 
Induced Cancer 100.82 0.85 
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Vehicle 101.25 1.24 
DC 100 mg/kg 103.39 1.15 
DC 500 mg/kg 106.93 1.47 
DC 1000 mg/kg 107.04 2.08 
Week 17 
Normal 110.97 2.84 
0.000 
Induced Cancer 103.01 0.61 
Vehicle 103.93 1.60 
DC 100 mg/kg 105.51 0.89 
DC 500 mg/kg 109.83 1.33 
DC 1000 mg/kg 109.96 1.72 
Week 18 
Normal 115.85 3.39 
0.000 
Induced Cancer 103.51 1.42 
Vehicle 104.52 2.21 
DC 100 mg/kg 107.36 0.94 
DC 500 mg/kg 114.31 1.37 
DC 1000 mg/kg 114.88 2.04 
Week 19 
Normal 118.63 3.46 
0.000 
Induced Cancer 105.44 .75 
Vehicle 107.12 1.13 
DC 100 mg/kg 108.63 1.55 
DC 500 mg/kg 117.22 1.72 
DC 1000 mg/kg 117.28 1.49 
Week 20 
Normal 123.80 3.75 
0.000 
Induced Cancer 105.09 2.50 
Vehicle 108.41 1.76 
DC 100 mg/kg 111.29 1.04 
DC 500 mg/kg 121.82 1.56 
DC 1000 mg/kg 122.05 1.74 
Week 21 
Normal 129.74 3.11 
0.000 
Induced Cancer 106.91 2.05 
Vehicle 109.89 1.20 
DC 100 mg/kg 112.21 .94 
DC 500 mg/kg 123.96 2.09 
DC 1000 mg/kg 127.34 1.83 
Week 22 
Normal 135.15 1.26 
0.000 
Induced Cancer 110.07 .56 
Vehicle 111.11 1.20 
DC 100 mg/kg 113.53 .80 
DC 500 mg/kg 126.45 1.54 
DC 1000 mg/kg 129.93 1.28 
*p value less than 0.05, (p < 0.05) significant value. 
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APPENDIX B - Food consumption of rats during 4NQO-induced oral carcinogenesis in 
the chemotherapeutic study. A one-way ANOVA test. 
 Groups Mean 
Std. 
Deviation 
P value 
Week 1 
Normal 82.61 2.99 
0.973 
Induced cancer 81.51 3.77 
Vehicle 82.28 2.80 
Cisplatin 81.91 2.33 
DC 100 mg/kg 82.92 3.19 
DC 100 mg/kg + Cisplatin 81.54 2.28 
DC 500 mg/kg 81.71 2.74 
DC 500 mg/kg + Cisplatin 81.24 1.73 
DC 1000 mg/kg 81.13 4.11 
DC 1000 mg/kg + Cisplatin 82.38 2.54 
Week 2 
Normal 82.62 2.83 
0.714 
Induced cancer 81.88 1.58 
Vehicle 82.70 1.89 
Cisplatin 83.39 2.33 
DC 100 mg/kg 83.86 2.17 
DC 100 mg/kg + Cisplatin 83.18 1.49 
DC 500 mg/kg 82.12 2.11 
DC 500 mg/kg + Cisplatin 81.78 1.20 
DC 1000 mg/kg 82.55 3.40 
DC 1000 mg/kg + Cisplatin 83.00 1.14 
0.873 
Week 3 
Normal 84.71 2.57 
Induced cancer 83.09 1.84 
Vehicle 83.67 2.27 
Cisplatin 83.77 2.33 
DC 100 mg/kg 85.00 2.73 
DC 100 mg/kg + Cisplatin 83.40 2.28 
DC 500 mg/kg 83.57 2.74 
DC 500 mg/kg + Cisplatin 83.10 1.73 
DC 1000 mg/kg 82.99 4.11 
DC 1000 mg/kg + Cisplatin 83.96 2.05 
Week 4 
Normal 83.78 2.24 
0.392 
Induced cancer 82.62 1.30 
Vehicle 83.43 1.69 
Cisplatin 83.95 2.33 
DC 100 mg/kg 84.42 2.17 
DC 100 mg/kg + Cisplatin 83.74 1.49 
DC 500 mg/kg 82.15 1.10 
DC 500 mg/kg + Cisplatin 82.34 1.20 
DC 1000 mg/kg 83.40 3.05 
 
DC 1000 mg/kg + Cisplatin 83.56 1.14 
Week 5 
Normal 82.75 2.33 
0.385 
Induced cancer 82.55 1.58 
Vehicle 83.23 1.68 
Cisplatin 84.06 2.33 
DC 100 mg/kg 84.53 2.17 
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DC 100 mg/kg + Cisplatin 83.85 1.49 
DC 500 mg/kg 82.16 1.02 
DC 500 mg/kg + Cisplatin 82.45 1.20 
DC 1000 mg/kg 83.22 3.40 
DC 1000 mg/kg + Cisplatin 83.67 1.14 
Week 6 
Normal 85.85 2.57 
0.617 
 
 
 
 
Induced cancer 84.23 1.84 
Vehicle 84.81 2.27 
Cisplatin 84.91 2.33 
DC 100 mg/kg 85.83 2.71 
DC 100 mg/kg + Cisplatin 84.16 2.00 
DC 500 mg/kg 83.83 1.94 
DC 500 mg/kg + Cisplatin 84.01 1.37 
DC 1000 mg/kg 83.75 3.60 
DC 1000 mg/kg + Cisplatin 84.19 1.28 
Week 7 
Normal 84.04 2.36 
0.488 
Induced cancer 82.83 1.58 
Vehicle 83.65 1.89 
Cisplatin 84.34 2.33 
DC 100 mg/kg 84.81 2.17 
DC 100 mg/kg + Cisplatin 84.13 1.49 
DC 500 mg/kg 82.63 1.21 
DC 500 mg/kg + Cisplatin 82.73 1.20 
DC 1000 mg/kg 83.50 3.40 
DC 1000 mg/kg + Cisplatin 83.95 1.14 
Week 8 
Normal 85.58 2.20 
0.722 
Induced cancer 84.32 1.25 
Vehicle 84.81 1.94 
Cisplatin 85.37 2.33 
DC 100 mg/kg 86.29 2.71 
DC 100 mg/kg + Cisplatin 84.62 2.00 
DC 500 mg/kg 84.29 1.94 
DC 500 mg/kg + Cisplatin 84.47 1.37 
DC 1000 mg/kg 84.21 3.60 
DC 1000 mg/kg + Cisplatin 84.65 1.28 
Week 9 
Normal 86.08 2.02 
0.599 
Induced cancer 85.11 1.84 
Vehicle 85.69 2.27 
Cisplatin 85.55 2.00 
DC 100 mg/kg 87.02 2.23 
DC 100 mg/kg + Cisplatin 85.04 2.00 
DC 500 mg/kg 84.71 1.94 
DC 500 mg/kg + Cisplatin 84.89 1.37 
DC 1000 mg/kg 84.63 3.60 
DC 1000 mg/kg + Cisplatin 85.07 1.28 
Week 10 
Normal 86.98 2.07 
0.006 
Induced cancer 85.08 1.58 
Vehicle 85.22 1.05 
Cisplatin 83.00 2.32 
DC 100 mg/kg 86.38 1.49 
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DC 100 mg/kg + Cisplatin 83.82 1.56 
DC 500 mg/kg 84.88 1.21 
DC 500 mg/kg + Cisplatin 84.98 1.20 
DC 1000 mg/kg 85.75 3.40 
DC 1000 mg/kg + Cisplatin 86.20 1.14 
Week 11 
Normal 88.02 1.20 
0.200 
Induced cancer 86.61 1.24 
Vehicle 85.87 1.49 
Cisplatin 85.38 1.42 
DC 100 mg/kg 85.85 1.87 
DC 100 mg/kg + Cisplatin 87.40 2.00 
DC 500 mg/kg 87.07 1.94 
DC 500 mg/kg + Cisplatin 87.25 1.37 
DC 1000 mg/kg 86.99 3.60 
DC 1000 mg/kg + Cisplatin 87.43 1.28 
Week 12 
Normal 88.87 2.02 
0.000 
Induced cancer 83.67 1.41 
Vehicle 84.48 .92 
Cisplatin 86.79 2.29 
DC 100 mg/kg 88.07 2.00 
DC 100 mg/kg + Cisplatin 87.83 2.00 
DC 500 mg/kg 87.50 1.94 
DC 500 mg/kg + Cisplatin 87.68 1.37 
DC 1000 mg/kg 87.42 3.60 
DC 1000 mg/kg + Cisplatin 87.86 1.28 
Week 13 
Normal 90.34 2.02 
0.000 
Induced cancer 84.55 1.84 
Vehicle 85.42 1.53 
Cisplatin 89.32 1.77 
DC 100 mg/kg 89.86 1.86 
DC 100 mg/kg + Cisplatin 89.11 1.23 
DC 500 mg/kg 88.84 1.91 
DC 500 mg/kg + Cisplatin 89.02 1.11 
DC 1000 mg/kg 89.48 3.34 
DC 1000 mg/kg + Cisplatin 89.82 1.57 
Week 14 
Normal 92.73 1.67 
0.000 
Induced cancer 86.25 1.90 
Vehicle 86.41 1.71 
Cisplatin 88.26 1.62 
DC 100 mg/kg 91.03 1.76 
DC 100 mg/kg + Cisplatin 87.04 1.64 
DC 500 mg/kg 91.08 1.94 
DC 500 mg/kg + Cisplatin 91.26 1.37 
DC 1000 mg/kg 90.60 2.89 
DC 1000 mg/kg + Cisplatin 91.44 1.28 
Week 15 
Normal 94.73 2.02 
0.000 
Induced cancer 88.44 1.84 
Vehicle 89.04 1.53 
Cisplatin 91.02 2.29 
DC 100 mg/kg 91.22 2.00 
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DC 100 mg/kg + Cisplatin 90.89 2.00 
DC 500 mg/kg 92.62 1.94 
DC 500 mg/kg + Cisplatin 92.15 .99 
DC 1000 mg/kg 92.26 1.68 
DC 1000 mg/kg + Cisplatin 92.22 1.28 
Week 16 
Normal 96.02 2.02 
0.000 
Induced cancer 87.50 1.84 
Vehicle 88.54 1.53 
Cisplatin 91.57 1.77 
DC 100 mg/kg 92.42 1.86 
DC 100 mg/kg + Cisplatin 91.42 1.23 
DC 500 mg/kg 93.83 1.27 
DC 500 mg/kg + Cisplatin 93.72 1.41 
DC 1000 mg/kg 93.98 1.40 
DC 1000 mg/kg + Cisplatin 93.85 1.22 
Week 17 
Normal 97.43 1.12 
0.000 
Induced cancer 87.55 1.65 
Vehicle 88.64 1.80 
Cisplatin 90.70 .83 
DC 100 mg/kg 90.78 1.05 
DC 100 mg/kg + Cisplatin 90.62 1.17 
DC 500 mg/kg 95.98 1.09 
DC 500 mg/kg + Cisplatin 95.93 .95 
DC 1000 mg/kg 95.93 1.43 
DC 1000 mg/kg + Cisplatin 95.71 .46 
Week 18 
Normal 101.60 2.02 
0.000 
Induced cancer 91.05 1.01 
Vehicle 92.33 1.23 
Cisplatin 91.98 1.02 
DC 100 mg/kg 92.92 .79 
DC 100 mg/kg + Cisplatin 94.45 1.03 
DC 500 mg/kg 100.25 .93 
DC 500 mg/kg + Cisplatin 100.02 1.01 
DC 1000 mg/kg 100.48 .89 
DC 1000 mg/kg + Cisplatin 100.39 .74 
Week 19 
Normal 104.98 1.84 
0.000 
Induced cancer 93.56 1.57 
Vehicle 94.48 1.84 
Cisplatin 93.80 1.44 
DC 100 mg/kg 93.69 1.81 
DC 100 mg/kg + Cisplatin 96.13 1.22 
DC 500 mg/kg 102.86 .86 
DC 500 mg/kg + Cisplatin 102.89 1.77 
DC 1000 mg/kg 102.90 1.17 
DC 1000 mg/kg + Cisplatin 102.92 1.08 
Week 20 
Normal 109.72 2.02 
0.000 
Induced cancer 95.66 1.33 
Vehicle 97.25 2.02 
Cisplatin 99.20 1.27 
DC 100 mg/kg 99.54 1.25 
205
DC 100 mg/kg + Cisplatin 99.52 1.09 
DC 500 mg/kg 106.61 1.63 
DC 500 mg/kg + Cisplatin 108.15 1.04 
DC 1000 mg/kg 107.71 1.95 
DC 1000 mg/kg + Cisplatin 108.56 1.45 
Week 21 
Normal 114.56 1.84 
0.000 
Induced cancer 98.16 1.17 
Vehicle 99.25 1.78 
Cisplatin 99.92 1.58 
DC 100 mg/kg 101.86 1.44 
DC 100 mg/kg + Cisplatin 101.99 1.30 
DC 500 mg/kg 108.46 1.30 
DC 500 mg/kg + Cisplatin 108.79 1.06 
DC 1000 mg/kg 108.96 1.08 
DC 1000 mg/kg + Cisplatin 108.73 .74 
Week 22 
Normal 117.72 2.02 
0.000 
Induced cancer 99.44 1.43 
Vehicle 101.16 1.86 
Cisplatin 102.79 1.27 
DC 100 mg/kg 103.13 1.25 
DC 100 mg/kg + Cisplatin 103.11 1.09 
DC 500 mg/kg 111.20 1.94 
DC 500 mg/kg + Cisplatin 111.75 1.04 
DC 1000 mg/kg 111.63 1.15 
DC 1000 mg/kg + Cisplatin 112.15 1.45 
*p value less than 0.05, (p < 0.05) significant value.
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APPENDIX C - Water intake of rats during 4NQO-induced oral carcinogenesis in the 
chemopreventive study. A one-way ANOVA test. 
 
 Groups Mean Std. Deviation P value 
Week 1 
Normal 121.95 2.22 
0.059 
Induced Cancer 121.10 2.01 
Vehicle 120.72 1.71 
DC 100 mg/kg 122.27 2.08 
DC 500 mg/kg 123.47 1.83 
DC 1000 mg/kg 123.30 1.61 
Week 2 
Normal 125.46 2.07 
0.000* 
Induced Cancer 124.66 1.11 
Vehicle 124.71 1.26 
DC 100 mg/kg 127.69 1.43 
DC 500 mg/kg 127.72 1.79 
DC 1000 mg/kg 127.82 1.41 
Week 3 
Normal 130.83 1.20 
0.000* 
Induced Cancer 130.75 1.76 
Vehicle 130.46 1.87 
DC 100 mg/kg 133.10 1.23 
DC 500 mg/kg 133.39 1.31 
DC 1000 mg/kg 133.13 1.38 
Week 4 
Normal 135.44 1.56 
0.000* 
Induced Cancer 135.47 1.80 
Vehicle 135.16 2.49 
DC 100 mg/kg 138.62 1.21 
DC 500 mg/kg 138.48 1.61 
DC 1000 mg/kg 138.17 1.30 
Week 5 
Normal 138.02 1.56 
0.000* 
Induced Cancer 138.05 1.80 
Vehicle 137.74 2.49 
DC 100 mg/kg 141.20 1.21 
DC 500 mg/kg 141.06 1.61 
DC 1000 mg/kg 140.75 1.30 
Week 6 
Normal 140.72 1.16 
0.001* 
Induced Cancer 140.60 1.89 
Vehicle 140.54 2.27 
DC 100 mg/kg 143.20 1.21 
DC 500 mg/kg 143.03 1.65 
DC 1000 mg/kg 143.42 1.00 
Week 7 
Normal 142.31 1.17 
0.000* 
Induced Cancer 141.55 2.17 
Vehicle 142.88 1.88 
DC 100 mg/kg 144.48 1.56 
DC 500 mg/kg 145.19 0.99 
DC 1000 mg/kg 145.56 1.01 
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 Week 8 
Normal 146.85 1.34 
0.000* 
Induced Cancer 145.59 2.26 
Vehicle 147.53 1.56 
DC 100 mg/kg 149.57 1.48 
DC 500 mg/kg 150.06 1.27 
DC 1000 mg/kg 149.90 1.50 
Week 9 
Normal 150.40 1.23 
0.000* 
Induced Cancer 149.70 1.82 
Vehicle 150.17 1.34 
DC 100 mg/kg 152.20 1.11 
DC 500 mg/kg 152.38 1.08 
DC 1000 mg/kg 152.65 0.79 
Week 10 
Normal 152.32 1.21 
0.382 
Induced Cancer 152.28 1.89 
Vehicle 151.94 0.85 
DC 100 mg/kg 153.06 1.17 
DC 500 mg/kg 152.66 1.34 
DC 1000 mg/kg 153.22 0.63 
Week 11 
Normal 153.21 1.72 
0.206 
Induced Cancer 151.49 1.81 
Vehicle 152.20 1.67 
DC 100 mg/kg 153.12 1.58 
DC 500 mg/kg 153.15 1.25 
DC 1000 mg/kg 153.24 1.22 
Week 12 
Normal 156.75 1.27 
0.390 
Induced Cancer 156.20 1.76 
Vehicle 155.37 1.74 
DC 100 mg/kg 156.37 1.14 
DC 500 mg/kg 155.42 1.85 
DC 1000 mg/kg 155.36 1.38 
Week 13 
Normal 159.10 1.14 
0.000* 
Induced Cancer 156.74 0.66 
Vehicle 157.26 0.71 
DC 100 mg/kg 158.91 0.97 
DC 500 mg/kg 158.99 1.35 
DC 1000 mg/kg 159.00 1.43 
Week 14 
Normal 162.21 1.22 
0.000* 
Induced Cancer 158.43 0.37 
Vehicle 159.49 0.91 
DC 100 mg/kg 161.99 1.10 
DC 500 mg/kg 162.18 1.01 
DC 1000 mg/kg 162.20 1.03 
Week 15 
Normal 165.08 1.21 
0.000* 
Induced Cancer 159.51 1.03 
Vehicle 159.95 1.43 
DC 100 mg/kg 163.64 0.56 
DC 500 mg/kg 163.87 0.78 
DC 1000 mg/kg 164.15 0.92 
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*p value less than 0.05, (p < 0.05) significant value.
Week 16 
Normal 168.33 2.00 
0.000* 
Induced Cancer 162.25 0.34 
Vehicle 164.47 1.54 
DC 100 mg/kg 167.12 1.73 
DC 500 mg/kg 166.70 0.99 
DC 1000 mg/kg 167.05 1.00 
Week 17 
Normal 172.39 1.27 
0.000* 
Induced Cancer 165.49 1.69 
Vehicle 167.56 1.28 
DC 100 mg/kg 169.37 1.06 
DC 500 mg/kg 170.70 0.63 
DC 1000 mg/kg 171.29 1.50 
Week 18 
Normal 174.57 1.72 
0.001* 
Induced Cancer 171.04 2.31 
Vehicle 169.99 2.30 
DC 100 mg/kg 171.35 1.26 
DC 500 mg/kg 173.47 2.41 
DC 1000 mg/kg 173.61 1.76 
Week 19 
Normal 178.79 0.90 
0.000* 
Induced Cancer 169.73 2.72 
Vehicle 171.03 1.10 
DC 100 mg/kg 173.15 1.71 
DC 500 mg/kg 176.89 1.01 
DC 1000 mg/kg 177.64 1.21 
Week 20 
Normal 181.53 0.91 
0.000* 
Induced Cancer 171.67 2.12 
Vehicle 172.14 0.94 
DC 100 mg/kg 174.13 1.37 
DC 500 mg/kg 180.06 1.05 
DC 1000 mg/kg 180.27 1.53 
Week 21 
Normal 182.88 0.76 
0.000* 
Induced Cancer 171.84 1.36 
Vehicle 172.95 0.49 
DC 100 mg/kg 171.90 1.17 
DC 500 mg/kg 181.60 1.32 
DC 1000 mg/kg 181.76 0.77 
Week 22 
Normal 183.99 0.75 
0.000* 
Induced Cancer 172.21 1.38 
Vehicle 172.90 1.53 
DC 100 mg/kg 172.72 1.26 
DC 500 mg/kg 182.60 1.43 
DC 1000 mg/kg 182.68 0.88 
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APPENDIX D - Mean water intake of rats during 4NQO-induced oral carcinogenesis in 
the chemotherapeutic study. A one-way ANOVA test. 
 Groups Mean Std. Deviation P value 
Week 1 
Normal 120.33 1.76 
0.955 
Induced cancer 119.25 2.13 
Vehicle 119.87 2.12 
Cisplatin 119.15 1.80 
DC 100 mg/kg 118.88 2.24 
DC 100 mg/kg + Cisplatin 119.29 2.24 
DC 500 mg/kg 118.99 2.09 
DC 500 mg/kg + Cisplatin 119.35 2.09 
DC 1000 mg/kg 120.00 2.08 
DC 1000 mg/kg + Cisplatin 119.69 2.53 
Week 2 
Normal 121.05 1.87 
0.992 
Induced cancer 121.44 1.90 
Vehicle 121.60 1.68 
Cisplatin 120.51 2.11 
DC 100 mg/kg 120.57 2.26 
DC 100 mg/kg + Cisplatin 120.84 2.21 
DC 500 mg/kg 120.90 1.96 
DC 500 mg/kg + Cisplatin 120.80 2.04 
DC 1000 mg/kg 121.13 2.54 
DC 1000 mg/kg + Cisplatin 121.33 2.37 
0.830 
Week 3 
Normal 122.39 1.88 
Induced cancer 122.79 2.15 
Vehicle 121.87 1.24 
Cisplatin 121.27 2.21 
DC 100 mg/kg 121.61 2.33 
DC 100 mg/kg + Cisplatin 121.09 2.33 
DC 500 mg/kg 121.94 1.85 
DC 500 mg/kg + Cisplatin 121.58 2.09 
DC 1000 mg/kg 122.74 2.53 
DC 1000 mg/kg + Cisplatin 121.46 2.16 
Week 4 
Normal 124.56 1.59 
 
Induced cancer 124.08 1.29 
Vehicle 122.86 1.84 
Cisplatin 122.67 2.34 
DC 100 mg/kg 122.33 2.25 
DC 100 mg/kg + Cisplatin 123.09 1.99 
DC 500 mg/kg 123.28 2.10 
DC 500 mg/kg + Cisplatin 122.73 2.21 
DC 1000 mg/kg 123.63 2.51 
DC 1000 mg/kg + Cisplatin 123.13 2.37 
Week 5 
Normal 124.21 1.91 
 
Induced cancer 124.33 1.67 
Vehicle 123.24 2.10 
Cisplatin 123.37 2.31 
DC 100 mg/kg 123.20 2.09 
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DC 100 mg/kg + Cisplatin 123.68 1.94 
DC 500 mg/kg 123.99 2.20 
DC 500 mg/kg + Cisplatin 123.70 2.40 
DC 1000 mg/kg 123.80 2.38 
DC 1000 mg/kg + Cisplatin 123.87 2.54 
Week 6 
Normal 127.11 2.14 
0.934 
Induced cancer 126.52 1.30 
Vehicle 125.35 2.04 
Cisplatin 125.92 2.28 
DC 100 mg/kg 126.16 2.26 
DC 100 mg/kg + Cisplatin 126.22 2.00 
DC 500 mg/kg 125.75 2.24 
DC 500 mg/kg + Cisplatin 126.40 2.18 
DC 1000 mg/kg 126.80 2.42 
DC 1000 mg/kg + Cisplatin 126.66 2.92 
Week 7 
Normal 132.22 1.87 
0.284 
Induced cancer 129.48 1.80 
Vehicle 129.21 2.24 
Cisplatin 129.62 2.24 
DC 100 mg/kg 129.32 2.09 
DC 100 mg/kg + Cisplatin 129.68 2.09 
DC 500 mg/kg 130.33 2.08 
DC 500 mg/kg + Cisplatin 130.02 2.53 
DC 1000 mg/kg 129.53 2.09 
DC 1000 mg/kg + Cisplatin 130.82 2.50 
Week 8 
Normal 136.22 1.29 
0.873 
Induced cancer 135.00 1.84 
Vehicle 134.81 2.34 
Cisplatin 134.47 2.25 
DC 100 mg/kg 135.23 1.99 
DC 100 mg/kg + Cisplatin 135.42 2.10 
DC 500 mg/kg 134.87 2.21 
DC 500 mg/kg + Cisplatin 135.77 2.51 
DC 1000 mg/kg 135.27 2.37 
DC 1000 mg/kg + Cisplatin 136.07 2.17 
Week 9 
Normal 140.96 1.15 
0.299 
Induced cancer 138.58 2.11 
Vehicle 138.64 2.26 
Cisplatin 138.91 2.21 
DC 100 mg/kg 139.54 1.48 
DC 100 mg/kg + Cisplatin 138.87 2.04 
DC 500 mg/kg 140.20 1.64 
DC 500 mg/kg + Cisplatin 139.69 2.26 
DC 1000 mg/kg 140.05 1.42 
DC 1000 mg/kg + Cisplatin 140.15 2.04 
Week 10 
Normal 143.91 1.16 
0.067 
Induced cancer 141.87 1.93 
Vehicle 142.13 1.44 
Cisplatin 141.97 1.63 
DC 100 mg/kg 143.73 1.28 
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DC 100 mg/kg + Cisplatin 142.92 1.42 
DC 500 mg/kg 142.44 1.20 
DC 500 mg/kg + Cisplatin 142.29 1.24 
DC 1000 mg/kg 143.35 1.58 
DC 1000 mg/kg + Cisplatin 142.93 0.76 
Week 11 
Normal 145.82 1.41 
0.117 
Induced cancer 143.87 2.11 
Vehicle 143.93 2.26 
Cisplatin 143.85 2.05 
DC 100 mg/kg 145.61 1.24 
DC 100 mg/kg + Cisplatin 144.15 1.74 
DC 500 mg/kg 145.49 1.67 
DC 500 mg/kg + Cisplatin 144.53 1.56 
DC 1000 mg/kg 145.34 0.92 
DC 1000 mg/kg + Cisplatin 145.04 1.66 
Week 12 
Normal 150.17 1.19 
0.000* 
Induced cancer 147.35 2.10 
Vehicle 147.05 2.02 
Cisplatin 146.95 1.85 
DC 100 mg/kg 150.40 2.04 
DC 100 mg/kg + Cisplatin 149.48 1.39 
DC 500 mg/kg 150.31 2.78 
DC 500 mg/kg + Cisplatin 148.87 1.05 
DC 1000 mg/kg 151.47 2.03 
DC 1000 mg/kg + Cisplatin 149.12 1.23 
Week 13 
Normal 152.31 1.26 
0.000* 
Induced cancer 148.01 2.10 
Vehicle 148.14 2.31 
Cisplatin 147.61 1.85 
DC 100 mg/kg 151.68 1.75 
DC 100 mg/kg + Cisplatin 150.00 1.04 
DC 500 mg/kg 153.06 2.05 
DC 500 mg/kg + Cisplatin 150.62 1.51 
DC 1000 mg/kg 153.64 1.68 
DC 1000 mg/kg + Cisplatin 151.11 1.17 
Week 14 
Normal 154.55 1.19 
0.000* 
Induced cancer 149.41 1.06 
Vehicle 150.14 1.10 
Cisplatin 151.61 1.92 
DC 100 mg/kg 153.88 1.17 
DC 100 mg/kg + Cisplatin 153.13 1.14 
DC 500 mg/kg 154.57 1.84 
DC 500 mg/kg + Cisplatin 154.34 1.23 
DC 1000 mg/kg 155.15 1.04 
DC 1000 mg/kg + Cisplatin 154.00 1.12 
Week 15 
Normal 157.37 1.66 
0.000* 
Induced cancer 151.54 0.79 
Vehicle 151.76 0.89 
Cisplatin 152.44 1.92 
DC 100 mg/kg 155.54 2.27 
212
DC 100 mg/kg + Cisplatin 155.40 0.94 
DC 500 mg/kg 159.00 1.78 
DC 500 mg/kg + Cisplatin 156.65 1.65 
DC 1000 mg/kg 158.67 1.40 
DC 1000 mg/kg + Cisplatin 156.80 1.55 
Week 16 
Normal 161.80 0.78 
0.000* 
Induced cancer 156.10 0.85 
Vehicle 156.48 1.56 
Cisplatin 157.07 2.27 
DC 100 mg/kg 159.70 1.25 
DC 100 mg/kg + Cisplatin 159.45 1.26 
DC 500 mg/kg 160.94 1.21 
DC 500 mg/kg + Cisplatin 161.42 0.96 
DC 1000 mg/kg 162.73 1.04 
DC 1000 mg/kg + Cisplatin 160.92 1.07 
Week 17 
Normal 163.47 1.46 
0.000* 
Induced cancer 153.98 0.79 
Vehicle 154.47 1.10 
Cisplatin 155.84 2.76 
DC 100 mg/kg 159.26 1.10 
DC 100 mg/kg + Cisplatin 158.15 1.37 
DC 500 mg/kg 165.19 1.52 
DC 500 mg/kg + Cisplatin 162.97 1.53 
DC 1000 mg/kg 165.58 1.77 
DC 1000 mg/kg + Cisplatin 162.41 1.39 
Week 18 
Normal 167.15 1.24 
0.000* 
Induced cancer 156.43 0.82 
Vehicle 156.99 1.00 
Cisplatin 158.53 1.70 
DC 100 mg/kg 161.47 1.48 
DC 100 mg/kg + Cisplatin 161.11 1.35 
DC 500 mg/kg 168.33 2.24 
DC 500 mg/kg + Cisplatin 166.40 1.00 
DC 1000 mg/kg 168.96 1.92 
DC 1000 mg/kg + Cisplatin 165.37 1.71 
Week 19 
Normal 168.06 1.46 
0.000* 
Induced cancer 157.55 0.79 
Vehicle 158.04 1.10 
Cisplatin 159.41 2.76 
DC 100 mg/kg 162.83 1.10 
DC 100 mg/kg + Cisplatin 161.72 1.37 
DC 500 mg/kg 168.76 1.52 
DC 500 mg/kg + Cisplatin 166.54 1.53 
DC 1000 mg/kg 168.88 1.33 
DC 1000 mg/kg + Cisplatin 165.98 1.39 
Week 20 
Normal 174.16 1.00 
0.000* 
Induced cancer 159.65 1.84 
Vehicle 160.23 2.29 
Cisplatin 162.88 1.70 
DC 100 mg/kg 165.82 1.48 
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DC 100 mg/kg + Cisplatin 165.46 1.35 
DC 500 mg/kg 171.78 0.92 
DC 500 mg/kg + Cisplatin 170.75 1.00 
DC 1000 mg/kg 172.68 2.24 
DC 1000 mg/kg + Cisplatin 172.11 1.80 
Week 21 
Normal 173.73 0.82 
0.000* 
Induced cancer 158.15 1.06 
Vehicle 159.80 0.92 
Cisplatin 162.71 2.63 
DC 100 mg/kg 165.16 1.48 
DC 100 mg/kg + Cisplatin 165.45 2.65 
DC 500 mg/kg 170.80 2.24 
DC 500 mg/kg + Cisplatin 169.82 1.54 
DC 1000 mg/kg 172.91 2.77 
DC 1000 mg/kg + Cisplatin 172.67 0.78 
Week 22 
Normal 181.52 1.40 
0.000* 
Induced cancer 158.37 1.84 
Vehicle 159.47 2.29 
Cisplatin 162.30 1.70 
DC 100 mg/kg 165.24 1.48 
DC 100 mg/kg + Cisplatin 166.32 1.35 
DC 500 mg/kg 173.20 2.32 
DC 500 mg/kg + Cisplatin 172.32 1.00 
DC 1000 mg/kg 179.37 1.02 
DC 1000 mg/kg + Cisplatin 179.18 1.50 
*p value less than 0.05, (p < 0.05) significant value.
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APPENDIX E - Mean Body weights gain of rats during 4NQO-induced oral 
carcinogenesis in the chemopreventive study. A one-way ANOVA test. 
 
 Groups Mean Standard Deviation P value 
Week 1 
Normal 8.69 0.94 
0.612 
Induced Cancer 8.25 0.78 
Vehicle 8.16 0.85 
DC 100 mg/kg 8.71 0.71 
DC 500 mg/kg 8.13 0.95 
DC 1000 mg/kg 8.10 1.00 
Week 2 
Normal 15.52 1.19 
0.967 
Induced Cancer 15.07 0.94 
Vehicle 15.53 1.17 
DC 100 mg/kg 15.37 0.75 
DC 500 mg/kg 15.53 1.11 
DC 1000 mg/kg 15.34 1.39 
Week 3 
Normal 22.80 1.71 
0.579 
Induced Cancer 21.40 1.19 
Vehicle 21.91 1.26 
DC 100 mg/kg 21.88 1.42 
DC 500 mg/kg 21.63 1.28 
DC 1000 mg/kg 21.63 1.92 
Week 4 
Normal 31.94 3.28 
0.216 
Induced Cancer 28.93 1.91 
Vehicle 28.64 2.08 
DC 100 mg/kg 28.84 1.48 
DC 500 mg/kg 29.62 1.77 
DC 1000 mg/kg 29.91 4.27 
Week 5 
Normal 43.54 3.71 
0.536 
Induced Cancer 41.23 2.25 
Vehicle 41.36 1.53 
DC 100 mg/kg 42.43 1.66 
DC 500 mg/kg 42.59 1.29 
DC 1000 mg/kg 41.07 4.74 
Week 6 
Normal 60.02 4.17 
0.914 
Induced Cancer 59.01 2.16 
Vehicle 58.56 2.48 
DC 100 mg/kg 58.34 1.60 
DC 500 mg/kg 59.26 2.13 
DC 1000 mg/kg 59.41 4.16 
Week 7 
Normal 78.42 4.17 
0.810 
Induced Cancer 76.87 1.94 
Vehicle 76.42 1.66 
DC 100 mg/kg 76.49 2.01 
DC 500 mg/kg 77.40 2.05 
DC 1000 mg/kg 76.70 4.58 
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 Week 8 
Normal 94.32 4.17 
0.267 
Induced Cancer 90.75 1.77 
Vehicle 91.17 1.47 
DC 100 mg/kg 91.77 2.02 
DC 500 mg/kg 91.83 .89 
DC 1000 mg/kg 92.56 4.71 
Week 9 
Normal 111.78 4.17 
0.230 
Induced Cancer 109.07 2.23 
Vehicle 108.20 2.30 
DC 100 mg/kg 108.95 1.40 
DC 500 mg/kg 110.29 2.18 
DC 1000 mg/kg 110.16 3.52 
Week 10 
Normal 127.02 5.12 
0.161 
Induced Cancer 123.70 2.52 
Vehicle 123.02 1.57 
DC 100 mg/kg 123.97 1.99 
DC 500 mg/kg 125.07 1.83 
DC 1000 mg/kg 125.66 3.36 
Week 11 
Normal 142.32 4.38 
0.202 
Induced Cancer 138.79 2.70 
Vehicle 140.88 2.12 
DC 100 mg/kg 139.46 2.51 
DC 500 mg/kg 141.97 2.38 
DC 1000 mg/kg 141.59 3.48 
Week 12 
Normal 149.88 2.68 
0.001* 
Induced Cancer 144.99 1.76 
Vehicle 144.64 2.88 
DC 100 mg/kg 148.03 1.89 
DC 500 mg/kg 148.39 1.45 
DC 1000 mg/kg 148.31 2.74 
Week 13 
Normal 162.38 3.22 
0.000* 
Induced Cancer 155.70 2.55 
Vehicle 157.80 2.69 
DC 100 mg/kg 162.36 4.32 
DC 500 mg/kg 162.06 2.47 
DC 1000 mg/kg 162.91 1.52 
Week 14 
Normal 181.71 2.57 
0.000* 
Induced Cancer 173.72 3.30 
Vehicle 175.13 3.32 
DC 100 mg/kg 178.80 5.14 
DC 500 mg/kg 180.91 2.54 
DC 1000 mg/kg 180.46 2.87 
Week 15 
Normal 194.99 3.72 
0.000* 
Induced Cancer 186.57 3.98 
Vehicle 186.58 5.16 
DC 100 mg/kg 191.44 6.03 
DC 500 mg/kg 194.40 2.93 
DC 1000 mg/kg 194.66 1.07 
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*p value less than 0.05, (p < 0.05) significant value. 
 
 
Week 16 
Normal 216.57 6.22 
0.000* 
Induced Cancer 195.99 5.48 
Vehicle 195.00 6.48 
DC 100 mg/kg 200.00 7.44 
DC 500 mg/kg 209.46 4.85 
DC 1000 mg/kg 212.91 5.06 
Week 17 
Normal 234.38 6.10 
0.000* 
Induced Cancer 201.78 6.14 
Vehicle 199.32 6.69 
DC 100 mg/kg 203.75 7.25 
DC 500 mg/kg 226.13 5.67 
DC 1000 mg/kg 230.59 5.27 
Week 18 
Normal 251.65 6.71 
0.000* 
Induced Cancer 203.20 11.60 
Vehicle 200.20 6.58 
DC 100 mg/kg 208.13 6.65 
DC 500 mg/kg 241.43 5.33 
DC 1000 mg/kg 247.42 5.76 
Week 19 
Normal 262.06 6.84 
0.000* 
Induced Cancer 195.93 12.08 
Vehicle 187.75 17.89 
DC 100 mg/kg 205.84 10.80 
DC 500 mg/kg 252.84 3.74 
DC 1000 mg/kg 259.26 6.80 
Week 20 
Normal 274.95 8.43 
0.000* 
Induced Cancer 179.68 23.93 
Vehicle 180.69 23.69 
DC 100 mg/kg 200.89 24.00 
DC 500 mg/kg 265.45 2.82 
DC 1000 mg/kg 269.43 5.76 
Week 21 
Normal 287.98 7.39 
0.000* 
Induced Cancer 197.43 7.45 
Vehicle 193.25 7.67 
DC 100 mg/kg 213.87 3.60 
DC 500 mg/kg 276.87 5.06 
DC 1000 mg/kg 284.54 4.60 
Week 22 
Normal 294.44 6.05 
0.000* 
Induced Cancer 188.42 8.68 
Vehicle 184.64 8.04 
DC 100 mg/kg 205.92 3.95 
DC 500 mg/kg 280.38 3.46 
DC 1000 mg/kg 286.00 5.19 
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APPENDIX F - Mean body weights gain of rats during 4NQO-induced oral 
carcinogenesis in the chemotherapeutic study. A one-way ANOVA test. 
 Groups Mean Std. Deviation P value 
Week 1 
Normal 9.29 0.94 
0.528 
Induced cancer 9.06 0.44 
Vehicle 8.85 0.78 
Cisplatin 8.99 0.73 
DC 100 mg/kg 9.31 0.71 
DC 100 mg/kg + Cisplatin 9.59 0.35 
DC 500 mg/kg 8.73 0.95 
DC 500 mg/kg + Cisplatin 9.02 0.54 
DC 1000 mg/kg 8.99 0.55 
DC 1000 mg/kg + Cisplatin 9.13 0.62 
Week 2 
Normal 16.17 0.94 
0.920 
Induced cancer 15.59 0.89 
Vehicle 15.93 0.94 
Cisplatin 16.07 0.84 
DC 100 mg/kg 16.23 0.75 
DC 100 mg/kg + Cisplatin 15.95 0.75 
DC 500 mg/kg 16.39 1.11 
DC 500 mg/kg + Cisplatin 15.96 0.57 
DC 1000 mg/kg 16.20 1.39 
DC 1000 mg/kg + Cisplatin 15.89 0.71 
0.636 
Week 3 
Normal 24.70 1.71 
Induced cancer 23.40 1.59 
Vehicle 23.30 1.19 
Cisplatin 23.44 1.27 
DC 100 mg/kg 23.78 1.42 
DC 100 mg/kg + Cisplatin 24.21 1.33 
DC 500 mg/kg 23.53 1.28 
DC 500 mg/kg + Cisplatin 23.10 1.57 
DC 1000 mg/kg 23.53 1.92 
DC 1000 mg/kg + Cisplatin 23.10 1.65 
Week 4 
Normal 37.83 3.28 
0.213 
Induced cancer 36.67 2.74 
Vehicle 34.83 1.90 
Cisplatin 34.98 1.72 
DC 100 mg/kg 34.73 1.48 
DC 100 mg/kg + Cisplatin 34.31 2.21 
DC 500 mg/kg 35.51 1.77 
DC 500 mg/kg + Cisplatin 35.22 1.60 
DC 1000 mg/kg 35.80 4.27 
 
DC 1000 mg/kg + Cisplatin 34.24 2.65 
Week 5 
Normal 48.98 3.71 
0.719 
Induced cancer 47.83 4.29 
Vehicle 46.67 2.26 
Cisplatin 46.82 1.94 
DC 100 mg/kg 47.86 1.66 
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DC 100 mg/kg + Cisplatin 47.30 2.69 
DC 500 mg/kg 48.02 1.29 
DC 500 mg/kg + Cisplatin 47.73 0.93 
DC 1000 mg/kg 46.50 4.74 
DC 1000 mg/kg + Cisplatin 45.79 3.28 
Week 6 
Normal 64.26 4.17 
0.982 
Induced cancer 62.85 4.64 
Vehicle 63.25 2.16 
Cisplatin 63.53 1.99 
DC 100 mg/kg 62.58 1.60 
DC 100 mg/kg + Cisplatin 62.30 1.85 
DC 500 mg/kg 63.51 2.14 
DC 500 mg/kg + Cisplatin 63.09 2.28 
DC 1000 mg/kg 63.65 4.16 
DC 1000 mg/kg + Cisplatin 62.81 2.90 
Week 7 
Normal 79.65 4.17 
0.906 
Induced cancer 78.01 4.64 
Vehicle 78.10 1.94 
Cisplatin 77.67 2.82 
DC 100 mg/kg 77.72 2.01 
DC 100 mg/kg + Cisplatin 77.44 2.23 
DC 500 mg/kg 78.63 2.05 
DC 500 mg/kg + Cisplatin 78.35 1.95 
DC 1000 mg/kg 77.93 4.58 
DC 1000 mg/kg + Cisplatin 76.64 3.06 
Week 8 
Normal 92.34 4.17 
0.587 
Induced cancer 90.50 3.46 
Vehicle 89.63 2.96 
Cisplatin 88.63 1.92 
DC 100 mg/kg 89.79 2.02 
DC 100 mg/kg + Cisplatin 89.79 2.02 
DC 500 mg/kg 89.87 0.89 
DC 500 mg/kg + Cisplatin 89.72 1.05 
DC 1000 mg/kg 90.58 4.71 
DC 1000 mg/kg + Cisplatin 89.29 2.68 
Week 9 
Normal 108.92 4.17 
0.145 
Induced cancer 106.00 2.59 
Vehicle 106.18 3.18 
Cisplatin 105.12 2.07 
DC 100 mg/kg 105.21 2.68 
DC 100 mg/kg + Cisplatin 105.35 3.14 
DC 500 mg/kg 105.75 2.12 
DC 500 mg/kg + Cisplatin 105.60 1.79 
DC 1000 mg/kg 108.69 3.71 
DC 1000 mg/kg + Cisplatin 105.83 2.81 
Week 10 
Normal 127.97 5.12 
0.001* 
Induced cancer 123.58 3.29 
Vehicle 124.13 1.27 
Cisplatin 121.84 2.70 
DC 100 mg/kg 124.65 2.52 
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DC 100 mg/kg + Cisplatin 121.97 2.52 
DC 500 mg/kg 128.57 2.20 
DC 500 mg/kg + Cisplatin 123.97 2.56 
DC 1000 mg/kg 126.71 4.80 
DC 1000 mg/kg + Cisplatin 123.28 3.08 
Week 11 
Normal 141.09 4.38 
0.006* 
Induced cancer 136.96 4.22 
Vehicle 137.82 1.80 
Cisplatin 134.76 2.52 
DC 100 mg/kg 138.24 2.51 
DC 100 mg/kg + Cisplatin 135.47 1.81 
DC 500 mg/kg 139.54 2.69 
DC 500 mg/kg + Cisplatin 136.79 2.70 
DC 1000 mg/kg 140.92 5.49 
DC 1000 mg/kg + Cisplatin 136.79 2.95 
Week 12 
Normal 149.12 2.68 
0.018* 
Induced cancer 144.00 5.00 
Vehicle 144.03 3.71 
Cisplatin 148.35 2.02 
DC 100 mg/kg 147.27 1.89 
DC 100 mg/kg + Cisplatin 147.27 1.89 
DC 500 mg/kg 147.23 2.24 
DC 500 mg/kg + Cisplatin 147.24 2.24 
DC 1000 mg/kg 148.27 3.01 
DC 1000 mg/kg + Cisplatin 147.84 2.80 
Week 13 
Normal 165.13 3.22 
0.000* 
Induced cancer 156.96 4.27 
Vehicle 157.18 2.93 
Cisplatin 161.27 4.05 
DC 100 mg/kg 162.39 2.50 
DC 100 mg/kg + Cisplatin 161.60 3.67 
DC 500 mg/kg 163.97 4.09 
DC 500 mg/kg + Cisplatin 162.46 2.12 
DC 1000 mg/kg 164.37 2.50 
DC 1000 mg/kg + Cisplatin 162.66 2.17 
Week 14 
Normal 178.85 2.57 
0.000* 
Induced cancer 170.06 4.72 
Vehicle 169.88 2.58 
Cisplatin 175.70 3.38 
DC 100 mg/kg 173.65 3.23 
DC 100 mg/kg + Cisplatin 175.94 5.14 
DC 500 mg/kg 178.63 2.85 
DC 500 mg/kg + Cisplatin 178.63 2.85 
DC 1000 mg/kg 178.03 3.12 
DC 1000 mg/kg + Cisplatin 177.32 4.95 
Week 15 
Normal 196.28 4.21 
0.000* 
Induced cancer 185.23 5.39 
Vehicle 184.88 4.76 
Cisplatin 188.75 4.76 
DC 100 mg/kg 185.28 2.71 
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DC 100 mg/kg + Cisplatin 190.18 5.88 
DC 500 mg/kg 192.42 1.30 
DC 500 mg/kg + Cisplatin 191.59 2.49 
DC 1000 mg/kg 194.97 3.18 
DC 1000 mg/kg + Cisplatin 191.83 2.54 
Week 16 
Normal 210.48 4.21 
0.000* 
Induced cancer 195.02 6.26 
Vehicle 194.28 5.40 
Cisplatin 198.50 5.92 
DC 100 mg/kg 200.61 5.19 
DC 100 mg/kg + Cisplatin 199.47 5.88 
DC 500 mg/kg 205.01 1.30 
DC 500 mg/kg + Cisplatin 204.12 3.24 
DC 1000 mg/kg 208.03 3.00 
DC 1000 mg/kg + Cisplatin 202.24 3.40 
Week 17 
Normal 223.06 4.21 
0.000* 
Induced cancer 204.01 6.26 
Vehicle 203.27 5.40 
Cisplatin 207.49 5.92 
DC 100 mg/kg 209.60 5.19 
DC 100 mg/kg + Cisplatin 208.46 5.88 
DC 500 mg/kg 217.59 1.30 
DC 500 mg/kg + Cisplatin 216.70 3.24 
DC 1000 mg/kg 220.61 3.00 
DC 1000 mg/kg + Cisplatin 216.25 3.44 
Week 18 
Normal 237.92 3.84 
0.000* 
Induced cancer 213.07 8.08 
Vehicle 208.16 6.77 
Cisplatin 216.27 6.55 
DC 100 mg/kg 217.07 5.47 
DC 100 mg/kg + Cisplatin 220.36 5.94 
DC 500 mg/kg 231.53 5.85 
DC 500 mg/kg + Cisplatin 230.92 4.25 
DC 1000 mg/kg 231.38 2.72 
DC 1000 mg/kg + Cisplatin 231.71 4.31 
Week 19 
Normal 249.59 6.44 
0.000* 
Induced cancer 209.14 18.88 
Vehicle 205.44 18.87 
Cisplatin 225.47 6.78 
DC 100 mg/kg 226.14 5.40 
DC 100 mg/kg + Cisplatin 228.80 6.37 
DC 500 mg/kg 243.19 6.12 
DC 500 mg/kg + Cisplatin 242.78 3.37 
DC 1000 mg/kg 246.54 3.69 
DC 1000 mg/kg + Cisplatin 244.38 3.92 
Week 20 
Normal 262.25 3.94 
0.000* 
Induced cancer 206.04 22.16 
Vehicle 206.47 22.62 
Cisplatin 222.40 27.66 
DC 100 mg/kg 218.63 23.82 
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DC 100 mg/kg + Cisplatin 222.76 28.20 
DC 500 mg/kg 255.73 5.26 
DC 500 mg/kg + Cisplatin 247.84 5.27 
DC 1000 mg/kg 257.71 3.57 
DC 1000 mg/kg + Cisplatin 255.45 4.56 
Week 21 
Normal 270.60 6.18 
0.000* 
Induced cancer 216.61 6.04 
Vehicle 220.03 2.61 
Cisplatin 238.49 5.04 
DC 100 mg/kg 234.00 5.87 
DC 100 mg/kg + Cisplatin 237.32 6.45 
DC 500 mg/kg 266.90 4.49 
DC 500 mg/kg + Cisplatin 255.44 4.10 
DC 1000 mg/kg 267.97 2.54 
DC 1000 mg/kg + Cisplatin 263.43 3.81 
Week 22 
Normal 280.49 5.56 
0.000* 
Induced cancer 220.14 9.26 
Vehicle 223.07 2.01 
Cisplatin 245.47 5.53 
DC 100 mg/kg 236.22 3.84 
DC 100 mg/kg + Cisplatin 240.70 6.27 
DC 500 mg/kg 275.64 7.02 
DC 500 mg/kg + Cisplatin 260.46 5.07 
DC 1000 mg/kg 274.38 3.65 
DC 1000 mg/kg + Cisplatin 270.53 0.86 
*p value less than 0.05, (p < 0.05) significant value.
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APPENDIX G - Effect of DC extract on haematological parameters of the rats in the 
chemopreventive study. A one-way ANOVA test. 
Haematology Groups Mean SD P value 
HGB (g/l) 
Normal 147.29 4.68 
0.996 
Induced Cancer 146.00 5.15 
Vehicle 146.40 2.97 
DC 100 mg/kg 146.50 4.64 
DC 500 mg/kg 146.86 3.93 
DC 1000 mg/kg 147.00 3.32 
WBC (10^9/L) 
Normal 8.63 1.80 
0.003* 
Induced Cancer 5.04 0.71 
Vehicle 5.68 1.70 
DC 100 mg/kg 8.82 2.77 
DC 500 mg/kg 8.67 2.03 
DC 1000 mg/kg 8.49 1.30 
Neutrophil 
(10^9/L) 
Normal 1.04 0.21 
 
0.002* 
 
Induced Cancer 1.57 0.30 
Vehicle 1.54 0.37 
DC 100 mg/kg 1.13 0.26 
DC 500 mg/kg 1.14 0.21 
DC 1000 mg/kg 1.10 0.20 
Lymphocyte 
(10^9/L) 
Normal 9.12 0.84 
0.986 
Induced Cancer 9.37 0.76 
Vehicle 9.42 0.65 
DC 100 mg/kg 9.22 0.80 
DC 500 mg/kg 9.25 0.70 
DC 1000 mg/kg 9.21 0.69 
Monocyte 
(10^9/L) 
Normal 0.28 0.05 
0.000* 
Induced Cancer 0.11 0.02 
Vehicle 0.10 0.02 
DC 100 mg/kg 0.24 0.08 
DC 500 mg/kg 0.25 0.06 
DC 1000 mg/kg 0.25 0.07 
Eosinophil 
(10^9/L) 
Normal 0.13 0.02 
0.552 
Induced Cancer 0.11 0.03 
Vehicle 0.11 0.01 
DC 100 mg/kg 0.11 0.03 
DC 500 mg/kg 0.12 0.02 
DC 1000 mg/kg 0.11 0.03 
Basophil 
(10^9/L) 
Normal 0.03 0.02 
0.529 
Induced Cancer 0.02 0.01 
Vehicle 0.02 0.01 
DC 100 mg/kg 0.02 0.01 
DC 500 mg/kg 0.02 0.01 
DC 1000 mg/kg 0.02 0.01 
*p value less than 0.05, (p < 0.05) significant value. 
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APPENDIX H - Effect of DC extract on Haematological parameters of the rats in the 
chemotherapeutic study. A one-way ANOVA test.  
Haematological 
parameters 
Group Mean SD P value 
HGB 
Normal 146.57 7.79 
0.000 
Induced cancer 146.20 6.76 
Vehicle 144.00 5.70 
Cisplatin 122.00 13.27 
DC 100 mg/kg 145.50 4.42 
DC 100 mg/kg + Cisplatin 137.00 2.83 
DC 500 mg/kg 145.57 3.95 
DC 500 mg/kg + Cisplatin 142.00 6.22 
DC 1000 mg/kg 145.00 7.12 
DC 1000 mg/kg + Cisplatin 142.14 4.45 
WBC 
Normal 7.43 0.88 
0.000 
Induced cancer 4.13 1.13 
Vehicle 5.28 1.54 
Cisplatin 5.70 1.70 
DC 100 mg/kg 8.43 3.03 
DC 100 mg/kg + Cisplatin 9.13 1.45 
DC 500 mg/kg 7.90 1.09 
DC 500 mg/kg + Cisplatin 8.14 1.32 
DC 1000 mg/kg 9.31 2.61 
DC 1000 mg/kg + Cisplatin 8.17 1.75 
Neutrophil 
Normal 1.05 0.09 
0.000 
Induced cancer 1.58 0.09 
Vehicle 1.58 0.08 
Cisplatin 1.46 0.08 
DC 100 mg/kg 1.18 0.02 
DC 100 mg/kg + Cisplatin 1.35 0.08 
DC 500 mg/kg 1.14 0.04 
DC 500 mg/kg + Cisplatin 1.15 0.09 
DC 1000 mg/kg 1.13 0.03 
DC 1000 mg/kg + Cisplatin 1.15 0.09 
Lymphocyte 
Normal 9.12 0.48 
0.061 
Induced cancer 9.22 0.05 
Vehicle 9.20 0.35 
Cisplatin 8.84 0.31 
DC 100 mg/kg 9.21 0.40 
DC 100 mg/kg + Cisplatin 8.85 0.21 
DC 500 mg/kg 9.16 0.14 
DC 500 mg/kg + Cisplatin 8.84 0.41 
DC 1000 mg/kg 9.16 0.17 
DC 1000 mg/kg + Cisplatin 8.85 0.26 
Monocyte 
Normal 0.31 0.10 
0.003 
Induced cancer 0.19 0.04 
Vehicle 0.17 0.04 
Cisplatin 0.33 0.07 
DC 100 mg/kg 0.32 0.07 
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*p value less than 0.05, (p < 0.05) significant value.
DC 100 mg/kg + Cisplatin 0.29 0.04 
DC 500 mg/kg 0.31 0.08 
DC 500 mg/kg + Cisplatin 0.29 0.06 
DC 1000 mg/kg 0.30 0.08 
DC 1000 mg/kg + Cisplatin 0.28 0.06 
Eosinophil 
Normal 0.14 0.02 
0.004 
Induced cancer 0.16 0.06 
Vehicle 0.16 0.02 
Cisplatin 0.07 0.04 
DC 100 mg/kg 0.15 0.03 
DC 100 mg/kg + Cisplatin 0.12 0.04 
DC 500 mg/kg 0.15 0.03 
DC 500 mg/kg + Cisplatin 0.12 0.03 
DC 1000 mg/kg 0.14 0.03 
DC 1000 mg/kg + Cisplatin 0.12 0.04 
Basophil 
Normal 0.02 0.01 
0.484 
Induced cancer 0.02 0.01 
Vehicle 0.02 0.01 
Cisplatin 0.03 0.01 
DC 100 mg/kg 0.02 0.01 
DC 100 mg/kg + Cisplatin 0.03 0.01 
DC 500 mg/kg 0.02 0.01 
DC 500 mg/kg + Cisplatin 0.03 0.02 
DC 1000 mg/kg 0.02 0.01 
DC 1000 mg/kg + Cisplatin 0.03 0.01 
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APPENDIX I - Biochemical parameters of the rats in the chemopreventive study. A 
one-way ANOVA test.  
*p value less than 0.05, (p < 0.05) significant value.
Biochemical 
parameters 
Groups Mean 
Standard 
Deviation 
P value 
Urea (mmol/L) 
Normal 5.86 0.70 
.000* 
Induced Cancer 9.76 1.79 
Vehicle 8.60 2.49 
DC 100 mg/kg 7.12 0.71 
DC 500 mg/kg 6.93 0.91 
DC 1000 mg/kg 6.50 1.31 
Creatinine 
(umol/L) 
Normal 38.00 3.21 
0.000* 
Induced Cancer 69.00 6.44 
Vehicle 69.20 9.42 
DC 100 mg/kg 45.33 5.05 
DC 500 mg/kg 41.29 2.43 
DC 1000 mg/kg 41.00 2.58 
Albumin (g/L) 
Normal 33.86 1.86 
0.124 
Induced Cancer 31.00 2.00 
Vehicle 30.40 1.67 
DC 100 mg/kg 32.67 3.33 
DC 500 mg/kg 34.29 3.68 
DC 1000 mg/kg 34.14 3.18 
Total bilirubin 
(umol/L) 
Normal 2.00 0.00 
.273 
Induced Cancer 2.20 0.45 
Vehicle 2.00 0.00 
DC 100 mg/kg 2.00 0.00 
DC 500 mg/kg 2.00 0.00 
DC 1000 mg/kg 2.00 0.00 
ALP (U/L) 
Normal 140.00 27.17 
.004* 
Induced Cancer 186.20 26.36 
Vehicle 195.20 31.73 
DC 100 mg/kg 148.33 20.50 
DC 500 mg/kg 151.71 23.96 
DC 1000 mg/kg 147.57 24.90 
ALT (U/L) 
Normal 35.29 2.36 
0.000* 
Induced Cancer 52.20 9.91 
Vehicle 53.60 8.17 
DC 100 mg/kg 37.50 4.64 
DC 500 mg/kg 37.71 4.79 
DC 1000 mg/kg 38.29 3.59 
AST (U/L) 
Normal 97.86 12.39 
0.000* 
Induced Cancer 165.80 37.49 
Vehicle 171.00 34.98 
DC 100 mg/kg 103.83 13.48 
DC 500 mg/kg 100.43 14.93 
DC 1000 mg/kg 101.86 18.53 
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APPENDIX J - Biochemical parameters of the rats in the chemotherapeutic study. A 
one-way ANOVA test. 
Biochemical 
parameters 
Groups Mean 
Standard 
Deviation 
P value 
Urea (mmol/L) 
Normal 7.49 0.72 
0.000 
Induced cancer 9.68 2.23 
Vehicle 9.30 2.90 
Cisplatin 14.70 2.21 
DC 100 mg/kg 9.67 1.52 
DC 100 mg/kg + Cisplatin 10.88 3.18 
DC 500 mg/kg 8.16 1.23 
DC 500 mg/kg + Cisplatin 10.10 2.37 
DC 1000 mg/kg 8.16 2.18 
DC 1000 mg/kg + Cisplatin 9.54 2.56 
Creatinine 
(umol/L) 
Normal 29.57 4.79 
0.000 
Induced cancer 51.20 7.79 
Vehicle 52.40 6.27 
Cisplatin 74.50 10.31 
DC 100 mg/kg 32.33 5.79 
DC 100 mg/kg + Cisplatin 46.83 13.59 
DC 500 mg/kg 32.00 4.32 
DC 500 mg/kg + Cisplatin 38.00 4.86 
DC 1000 mg/kg 32.57 4.96 
DC 1000 mg/kg + Cisplatin 38.71 4.35 
Albumin (g/L) 
Normal 34.71 2.69 
0.036 
Induced cancer 31.40 1.67 
Vehicle 30.40 3.36 
Cisplatin 26.67 3.93 
DC 100 mg/kg 32.33 4.23 
DC 100 mg/kg + Cisplatin 30.00 4.00 
DC 500 mg/kg 32.57 2.70 
DC 500 mg/kg + Cisplatin 31.71 4.23 
DC 1000 mg/kg 34.29 2.87 
DC 1000 mg/kg + Cisplatin 32.00 6.40 
Total bilirubin 
(umol/L) 
Normal 2.00 0.00 
- 
Induced cancer 2.00 0.00 
Vehicle 2.00 0.00 
Cisplatin 2.00 0.00 
DC 100 mg/kg 2.00 0.00 
DC 100 mg/kg + Cisplatin 2.00 0.00 
DC 500 mg/kg 2.00 0.00 
DC 500 mg/kg + Cisplatin 2.00 0.00 
DC 1000 mg/kg 2.00 0.00 
DC 1000 mg/kg + Cisplatin 2.00 0.00 
ALP (U/L) 
Normal 126.71 16.15 
0.001 
Induced cancer 186.60 37.78 
Vehicle 182.80 22.79 
Cisplatin 176.83 34.03 
DC 100 mg/kg 140.83 6.18 
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DC 100 mg/kg + Cisplatin 145.83 12.40 
DC 500 mg/kg 137.57 16.64 
DC 500 mg/kg + Cisplatin 144.57 25.46 
DC 1000 mg/kg 133.29 8.65 
DC 1000 mg/kg + Cisplatin 142.00 8.72 
ALT (U/L) 
Normal 32.86 3.58 
0.000 
Induced cancer 57.40 5.55 
Vehicle 58.40 6.99 
Cisplatin 54.33 3.33 
DC 100 mg/kg 38.83 3.43 
DC 100 mg/kg + Cisplatin 39.17 6.11 
DC 500 mg/kg 38.57 2.57 
DC 500 mg/kg + Cisplatin 38.14 4.06 
DC 1000 mg/kg 38.47 4.10 
DC 1000 mg/kg + Cisplatin 38.00 4.32 
AST (U/L) 
Normal 95.57 8.26 
0.000 
Induced cancer 170.00 13.69 
Vehicle 170.80 14.96 
Cisplatin 151.50 13.90 
DC 100 mg/kg 108.17 14.85 
DC 100 mg/kg + Cisplatin 117.33 5.57 
DC 500 mg/kg 107.71 15.29 
DC 500 mg/kg + Cisplatin 113.57 8.62 
DC 1000 mg/kg 103.43 25.68 
DC 1000 mg/kg + Cisplatin 107.29 14.45 
*p value less than 0.05, (p < 0.05) significant value. 
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